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ABSTRACT 
 
The serotonin (5-HT) system has been implicated in both depression and reward and 
punishment processing. This thesis presents data from four studies designed to better 
understand the role of serotonin in decision-making and mood. Following the general 
introduction and description of the main experimental methods, the first experimental chapter 
presents a study that examined the relationship between naturally-varying 5-HT1A receptor 
availability, measured using positron emission tomography, and decision-making in healthy 
volunteers. This study identified correlations between 5-HT1A receptor availability in the 
hippocampal complex and both impulsivity and sensitivity to the probability of an outcome 
during decision-making. The second experimental chapter examined decision-making in 
healthy volunteers 3 days following MDMA (3,4-methylenedioxymethamphetamine) 
administration, when serotonin transmission is thought to be reduced. A specific type of 
decision-making process, “pruning” (the reflexive avoidance of aversive outcomes when 
searching through a tree of potential decisions), was significantly attenuated 3 days following 
MDMA administration. However, the expected positive relationship between the attenuation 
in this decision-making process and low mood was not observed. The third experimental 
chapter attempted to extend this finding using the acute tryptophan depletion method, which 
removes tryptophan (the precursor to serotonin) from the diet and is thought to reduce 
serotonin synthesis. Performance on three decision making tasks (pruning, gambling and 
impulsivity) was examined in healthy volunteers following tryptophan depletion. Results 
revealed that treatment decreased participants’ choosing of high probability gambles. The 
final chapter examined pruning in unmedicated depressed patients, and found that they 
behaved very similarly to healthy volunteers when evaluating aversive outcomes in the 
context of a tree of potential decisions, despite the hypothesised disruption to the serotonin 
system in this disorder. These experiments provide a more complete understanding of the 
relationship between serotonin, decision-making and mood, and are discussed in relation to 
theories of depression that pose a central role for disrupted decision-making. 
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1) GENERAL INTRODUCTION  
 
Major depressive disorder (MDD; also known as unipolar depression) is the most common 
psychiatric disorder, globally affecting more than 350 million people. It is a leading cause of 
disability worldwide, and in Western societies affects roughly 10% of men and 20% of 
women at some point during their lifetime. Further, Greenberg and Birnbaum (2005) reported 
that in the year 2000 MDD was the second leading cause (behind HIV/AIDS) of lost years of 
healthy life in adults aged 15-44, with a risk of suicide between 2% and 9% depending on the 
severity of the illness (Bostwick and Pankratz, 2000). As such, the economic burden of this 
disorder is huge: Chisholm et al (2001) reported that in the UK alone, depression is 
associated with direct costs of over £400 million per year for the diagnosis, treatment and 
rehabilitation of patients. In the US, this figure rises to $2 billion.  
 
A major focus of research has aimed to understand the mechanisms involved in MDD, 
particularly to better understand dysfunction in monoamine systems, such as dopamine (DA), 
noradrenaline (NA) and serotonin (5-HT). These transmitter systems have been suggested to 
be involved in some of the most important symptoms of the disorder such as dysphoria and 
anhedonia. However, depression has also been associated with dysfunctions in cognitive 
domains such as memory, attention and executive function (in particular decision-making, 
which together with attention is one of the core symptoms in standard diagnostic criteria; 
Elliot et al, 1996). Further, pharmacological treatments that act upon the monoamine systems 
can have selective effects upon both mood and cognition that in some cases mimic the profile 
observed in MDD (Harmer and Cowen, 2013). This latter point provides indirect support for 
the notion of monoamine involvement in the aetiology of the disorder (McLean et al, 2004b).  
 
The focus of this thesis is the link between 5-HT and decision-making, and whether 
dysfunctions in 5-HT may lead to aberrant decision-making behaviours that are often 
observed in MDD. This introduction will provide a review of the clinical, cognitive and 
biological features of MDD. We will review evidence for how 5-HT dysfunction has been 
implicated in abnormalities in decision-making. In particular, we will evaluate a theoretical 
account (Dayan and Huys, 2008) of how this relationship might lead to low mood and risk for 
MDD, in which they posit that low levels of 5-HT result in a decrease in the ‘pruning’ of 
aversive options from a tree of potential decisions, which in turn leads to low mood. Finally, 
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this introduction will consider the major research questions of this thesis before giving a brief 
summary of each experimental chapter, including the hypotheses examined in each. 
 
1.1 Clinical characteristics of depression 
 
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) guidelines, 
in order to be diagnosed with a major depressive episode, an individual must display not only 
low mood or anhedonia (loss of interest in, or the inability to experience pleasure from, 
activities that are usually found to be enjoyable, such as social interaction, work or hobbies) 
for a two week period or longer, but must also experience 4 or more symptoms (out of 7) in 
the same period of time. These symptoms include feelings of worthlessness and/or guilt, 
significantly altered sleeping patterns, talking or moving more slowly/quickly, fatigue or loss 
of energy, increased/decreased weight and/or appetite, difficulty in concentrating and making 
decisions, and suicidal ideation or suicide attempts (American Psychiatric Association, 2013). 
Furthermore, in order to gain a diagnosis of unipolar depression an individual must not have 
any symptoms of feeling ‘up’ or ‘high’ or hyper’ (bipolar) nor psychosis. Several other non-
diagnostic characteristics of unipolar depression exist, such as pessimism, rumination 
(particularly on negative events) decreased sociability, expectation of punishment and 
helplessness and a decrease in libido.  
 
1.2 Cognitive impairments in depression 
 
Abnormal performance on a wide range of neuropsychological tests by patients suffering 
from depression has been described in the literature (Beats et al, 1996, Elliot et al, 1996). 
Brown et al (1994) report that even depressed patients who display unimpaired normal, 
everyday functioning still display cognitive deficits such as language function, memory (both 
recall and recognition) and attention. Furthermore, Pizzagalli (2005) reported that both 
depressed patients and healthy volunteers with high scores on the Beck Depression Inventory 
(BDI) display deficits in decision-making. Such deficits are important as they may affect 
patients’ abilities to function efficiently on a daily basis, which in turn may affect their daily 
experiences and thus mood, and also their ability to respond to various treatments, both 
behavioural and pharmacological. Research has produced evidence of deficits in memory, 
executive functioning, emotional processing, and decision-making in depression. This 
introduction will now consider each of these domains in turn. 
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1.2.1 Memory deficits 
 
A very consistent finding in the literature is that depressed patients suffer from impairments 
on tests of episodic memory, both in recognition (e.g. Miller and Lewis, 1977, Beats et al, 
1996, Elliot et al, 1996) and recall (e.g. Breslow et al, 1980, Austin et al, 1992, O’Carroll et 
al, 1997, Fossati et al, 2004). Roediger and McDermott (1992) however report that implicit 
memory deficits are not normally observed in depression. This has led to the hypothesis that 
depressed patients are impaired on tasks that require effortful processes, rather than automatic 
ones. One hypothesis that attempts to support this account is the resource-allocation 
hypothesis (Ellis and Ashbrook, 1998), which postulates that depressed individuals’ general 
cognitive capacity is reduced, and as such they have deficits in remembering and engaging in 
other effortful cognitive processes. Other hypotheses have been put forward as to why this 
may be the case, from reduced motivation (e.g. Miller, 1975), and reduced cognitive 
initiative, which leaves the patient less able to effectively recruit and control cognitive 
resources (Hertel and Hardin, 1990). Indeed, studies have indicated that depression is 
associated with lesser memory impairments in contexts in which attention is constrained by 
the task: Hertel and Rude (1991) were able to eliminate depression-related memory deficits 
by providing instructions that focussed participants on the task and decreased the probability 
that task irrelevant thoughts could occur, meaning participants were more able to control their 
cognitive resources (see Hartlage et al, 1993 for a review). Gotlib and Joorman (2010) argue 
that these results suggest that depressed people may have the ability to perform at the same 
level as non-depressed people in constrained, structured situations, but that the opportunity to 
ruminate during more unconstrained situations leads to the above deficits in memory 
performances. As such, it could be argued that depressed patients find it difficult to control 
their cognitive resources, meaning that their cognitive deficits lie in the domain of executive 
functioning, rather than memory processes.  
 
1.2.2 Executive function deficits  
 
Executive functions can be considered to be a set of higher-order cognitive processes that 
optimise behaviour involved in complex tasks. They are often associated with a number of 
behavioural tasks on which performance is dependent on frontal lobe functioning, such as the 
Tower of Hanoi (planning: Shallice, 1982), the Wisconsin Card Sorting Test (cognitive 
flexibility; Nelson, 1976), the Stop Signal Task (response inhibition; Logan et al, 1984) and 
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the N-Back Test (working memory, cognitive flexibility, speeded response; Gevins and 
Cutillo, 1993).  
 
Depressed patients have been shown to be impaired on a number of tasks that are thought to 
tap into executive functioning. For example, Rose and Ebmeier (2006) reported that patients 
were both slower and less accurate than healthy controls on an N-back test. Furthermore, 
Harvey et al (2004) reported that the severity of this deficit in performance on the N-back test 
was correlated with the number of hospitalisations due to depressive episodes. However, the 
authors here did not report poorer performance by these patients on any other tasks of 
working memory, including a digit span task. Consistent with this, Engelend et al (2003) 
argue that reduced performance on working memory tasks is due not to deficits in executive 
functioning, but to decreased speed and motivation (the latter of which often characterizes 
depressed patients; Scheurich et al, 2008).  
 
In addition to the above deficits, depressed patients have also been shown to display poorer 
performance on tasks of verbal fluency (indicating difficulties in cognitive flexibility; Fossati 
et al, 2003), on the Tower of Hanoi (Watts et al 1988) and the computerized version, the 
Tower of London test (Owen et al, 1990), indicating impairments in planning. Beats et al 
(1996) reported impaired performance on this task in an elderly depressed sample, whilst 
Elliot et al (1996) showed the same in a middle-aged sample. However, Purcell et al (1997) 
failed to show the same in a younger sample. Studies have been able to show that patients 
display ‘perseverative’ impairments (responding to a previous rule following a rule change) 
on the Wisconsin Card Sorting Test (Lockwood et al, 2002, Moritz et al, 2002, Merriam et al, 
1999). Performance on this task relies on the ability to form, maintain and shift an attentional 
set, and in order to assess each of these individually, the Cambridge Automated 
Neuropsychological Test Assessment Battery (CANTAB) Intra-dimensional/Extra-
dimensional Attentional Set-Shifting test (ID/ED): Roberts et al, 1998 and Downes et al, 
1989 was designed. Purcell et al (1997) report that a younger sample of patients displayed 
difficulties only in shifting attentional sets, whereas Beats et al (1996) reported that an elderly 
sample had difficulty in both forming and shifting attentional sets.  
 
In sum, evidence is conflicting as to the specific cognitive deficits inherent in depression, and 
it is not clear whether there indeed exists a specific neuropsychological profile in the 
disorder. One of the reasons for this may be the lack of homogeneity between depressed 
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samples: the above results highlight the differences between samples of different ages 
(particularly in older patients, who may have more frontal lobe impairments), and a recent 
review (Castaneda et al, 2008) concluded that certain deficits in executive control and 
attentional deficits characterise depression in general, but that the evidence for learning and 
memory deficits is more mixed. Indeed, the authors argue that studies report deficits to be 
most prominent in those who are severely depressed. 
 
1.2.3 Biased emotional processing and processing of feedback in depression 
 
Depression is also associated with biased emotional processing and impaired emotional 
regulation. In line with this, early research characterised depression as a disorder associated 
with negative self-schemata (Beck, 1967, 1976): studies have shown depressed patients to 
attribute more negative adjectives to themselves in a self-referential encoding task (e.g. 
Clifford and Hemsley, 1987). However, there is also strong evidence for biased processing of 
emotional information that does not pertain to the self in depression. For example, studies 
have reported preferential recall of negative compared to positive memories (Mathews and 
MacLeod, 2005, Lloyd and Lishman, 1975, Williams et al, 1997) which in Lloyd and 
Lishman’s (1975) study correlated positively with the severity of depression. Further, Matt et 
al (1992) in a review report that studies show depressed patients to remember 10% more 
negative words than positive, whilst 20 out of 25 studies report healthy controls to exhibit a 
memory bias for positive information. Some studies have also found evidence for a bias in 
the interpretation of events in depressed patients: Butler and Mathews (1983) report that 
depressed patients showed a bias towards interpreting information about ambiguous scenarios 
in a negative manner. Whilst some studies have failed to find such an effect (e.g. Lawson and 
MacLeod, 1999 and Bisson and Sears, 2007), Lawson et al (2002) argue that this is due to 
such studies using response latencies as the dependent variable. Further, Dearing and Gotlib 
(2009) reported a negative interpretation bias in never-depressed daughters of depressed 
mothers, indicating that these biases may be involved in an increased risk for the onset of 
depression. Finally, attentional biases in depressed patients have been reported, such as 
interferences in the Stroop colour-naming task using emotional words (Nunn et al, 1997), 
biases towards sad faces (Gotlib et al, 2004) and increased response times to happy words in 
a go/no-go task (Murphy et al, 1999).  
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Studies have also shown that depressed patients may display abnormal responses to negative 
feedback, performing poorly on trials immediately following negative feedback (Elliot et al, 
1996). Shah et al (1999) did report a negative result however. Despite this, Holmes and 
Pizzagalli (2007) showed that healthy volunteers with high BDI scores adjusted their 
responses significantly less after errors on the Simon (Simon, 1969) and Stroop tasks (Stroop, 
1935) than those with low BDI scores. Murphy et al (2003) report that a group of depressed 
patients displayed difficulties in maintaining a response in the face of misleading information 
on a probabilistic reversal learning paradigm. This is consistent with the results of Teasdale 
and Barnard (1993), which suggest that tests with feedback contain both informational 
components (which demand ‘cold’ processing of information) and emotional components 
(which demand ‘hot’ processing of information). The authors of the latter study suggest that 
depressed patients may have difficulty in thinking about the past failures (on previous trials) 
without generating a negative state of mood (e.g. without processing ‘hot’ information), such 
that if they feel they are performing poorly (potentially even in the absence of feedback) their 
resultant negative mood may interfere with their future performance.  
 
In summary, studies have highlighted biased emotional processing and impaired emotional 
regulation in depression. Depressed patients have been shown to display a bias towards 
processing more negative information and a bias towards interpreting events in an overly 
negative manner. Further, it has been shown that patients display abnormal responses to 
negative feedback, both in the form of exhibiting difficulties in thinking about previous 
failures and responding appropriately following a failure, which has been argued to be due to 
difficulties in regulating ‘hot’ processing during such performance.  
 
1.2.4 Decision-making deficits in depression 
 
Just as with the link between depression and other forms of cognition, much research has 
been conducted into the deficient decision-making processes seen in depression (see Eshel 
and Roiser (2010) for a review). Studies have examined depressed patients’ abilities to 
process information pertaining to rewards and punishments, along with their performance on 
tests of impulsive responding, and this section will discuss the findings of these experiments.  
 
Much research has been conducted into depressed patients’ processing of rewards and 
punishments, and how such processing affects the decisions that they make. In a recent 
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review Eshel and Roiser (2010) argue that two major conclusions arise from the literature: 
that depressed patients display hyposensitive responses to rewards and positive feedback, and 
that they show maladaptive responses to punishment.  
 
The fact that depressed patients exhibit hyposenstivity to rewards has been identified in many 
studies. For example McFarland and Klein (2009) reported that depressed patients who were 
asked to rate their mood prior to performing a task in which correct responses were rewarded 
and incorrect responses were punished, displayed significantly decreased enjoyment when 
anticipating reward than controls, despite no difference in anxiety when anticipating 
punishments. Pizzagalli et al (2005, 2009) administered a task in which correct responses to 
one target were three times more likely to be rewarded than correct responses to another. 
Whilst healthy controls gained a preference for the former target, experiencing more reward, 
both participants with high BDI scores and participants with MDD did not. However, Huys et 
al (2013) argue that these deficits in depression are not due to an inability to learn from prior 
rewards or reinforcements (e.g. a reduction in sensitivity to prediction errors for rewards that 
determine reward-related learning), but are simply due to a specific reduction in reward 
sensitivity. Further, as discussed in 1.2.3 above, depressed patients also show maladaptive 
responses to punishments and display abnormal responses to negative feedback (Elliot et al 
(1996).  
 
Studies using gambling tasks have also shown deficits in the processing of rewards in 
depressed patients; for example Smoski et al (2008) reported increased risk aversion for 
rewarding stimuli on the Iowa Gambling Task (IGT; Bechara et al, 1994), and Murphy 
(2001) reported that depressed patients display slower deliberation times and suboptimal 
betting strategies on the Cambridge gamble task (CGT; Rogers et al, 1999). In addition Clark 
et al (2011) administered this CGT to depressed patients who had a history of suicide 
attempts, a group of depressed patients with active suicidal ideation but without attempts, a 
group of depressed patients without a history of suicide attempts, and a group of healthy 
controls. The authors discovered that suicide attempters displayed poorer ability to choose the 
more likely rewarding outcome compared to non-suicide attempters, with older suicide 
attempters seeming to neglect outcome probability significantly more than younger suicide 
attempters. Studies using the CGT have also provided evidence for dysfunctional reward 
processing influencing early vulnerability for depression. As parental depression is the most 
robust risk factor for adolescents in developing depression (Rice et al, 2002), Rawal et al 
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(2013) examined 197 such adolescents in a 1-year longitudinal study. The authors examined 
participants’ reward seeking behaviours on the CGT both at baseline and at 1-year, and 
discovered that low reward seeking on this task predicted depressive symptoms and new-
onset depression at 1-year in those participants who were depression-free at baseline. 
Furthermore, those participants who currently exhibited depressive symptoms also displayed 
reduced reward seeking compared to those who were free of depressive symptomatology. 
The results of this study indicate that diminished reward processing may be a risk factor for 
those who are at risk for developing depression.  
 
Finally, few studies have been conducted into impulsive responding in depression. However, 
Takahashi et al (2008) administered a temporal discounting paradigm that contained both 
rewards and losses to both depressed and control participants. This temporal discounting 
paradigm posed scenarios to participants in which they had to choose between a smaller, 
sooner reward, or a larger, later reward (or the opposite in the loss condition), enabling the 
authors to examine participants’ discount factor (which describes the notion that a reward 
loses intrinsic value based upon its temporal delay) and the consistency with which either the 
sooner or later options were chosen. The results revealed that depressed patients were both 
more impulsive (as shown by them displaying increased discounting) and more inconsistent 
in their choices.  
 
In summary, studies have found it difficult to fully characterise the cognitive profile of 
depression, potentially due to the heterogeneous nature of the disorder. It appears that 
depressed individuals may have more difficulty with controlling their cognitive resources and 
executive functioning such as working memory, planning and cognitive flexibility, but that 
these difficulties may be more apparent in older and more severely depressed patient 
populations. However, studies examining cognition in depression have provided more 
concrete evidence for decision-making deficiencies in the disorder.  
 
1.3 Neuroimaging findings in depression  
 
In order to understand the origins of the symptomatology and cognitive deficits and biases of 
MDD it may be important to utilise neuroimaging techniques, as many pharmacological 
treatments may lead to differences in brain structure/function (see Harmer and Cowen, 2013). 
Differences between depressed patients and healthy volunteers have been reported with
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respect to structure, ‘resting-state’ neural blood flow and metabolism and task-related 
responses measured using blood-oxygenated-level-dependent functional magnetic resonance 
imaging (BOLD fMRI). Whilst not all results are consistent, a clearer picture of neural 
abnormalities in depression has emerged, with structures such as the amygdala, striatum, 
hippocampus and other limbic regions along with more cortical areas, particularly the 
prefrontal cortex (PFC) being implicated in the pathogenesis of this disorder.  
 
1.3.1 Structural and resting-state functional studies implicate the amygdala, hippocampus 
and medial PFC in MDD 
 
Many subcortical limbic structures have been implicated in depression, with one of the most 
consistent findings being that the amygdala displays abnormal functioning in MDD patients. 
For example, Drevets et al (2002a) have shown that this structure is overactive in 
melancholic depression, bipolar depression, and those at familial risk of MDD. However, 
such amygdala abnormalities are not always apparent in patients who meet a diagnosis for 
unipolar depression (see Drevets et al, 2003 for a review).  
 
Abnormalities in the hippocampus have also been implicated in depression: MDD is 
recognised as a highly stress-sensitive illness (Kessler, 1997), whilst the hippocampus is a 
highly stress-sensitive brain-region (Thomas et al, 2007), and studies have argued that 
antidepressant treatments may ameliorate stress-associated changes in the hippocampus by 
inducing neurogenesis in this brain region (Duman et al, 2001, Santarelli et al, 2003). Many 
structural imaging studies have reported the hippocampus to be reduced in size in depressed 
patients, and a meta-analysis by Videbech and Ravnkilde (2004) reported a weighted average 
of an 8% and 10% reduction in left and right hippocampal volume, respectively. MacQueen 
and Frodl (2011) report that hyperactivity of the hypothalamus-pituitary-adrenal (HPA) axis 
(and the resultant increase in glucocorticoid levels) in the brain to be the cause of dendritic 
remodelling in the CA1 and CA3 hippocampal subfields and even decreased neurogenesis 
within the hippocampus. This, coupled with the fact that the hippocampus has been shown to 
provide negative modulation to the HPA stress hormone axis, means that dysregulation of the 
hippocampus can lead to sustained dysregulation of the stress hormone, which can lead to 
increased vulnerability of neuronal death in the CA3 field.  
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Studies have also shown abnormalities in the medial PFC in depression, with research 
showing that total PFC and anterior cingulate cortex (ACC; within the PFC) volume are 
decreased in depression (Drevets et al, 1997, 1998, 1998b). Results of George et al (1995) 
and Mayberg et al (1997) show that negative mood induction in healthy controls increases 
ACC activation, and results of Mayberg et al (1999) show that resting state ACC blood flow 
activity decreases following remission from a depressive episode. These results have led to 
the interpretation that once the amount of reduction in total PFC and ACC volume is 
accounted for, depressed individuals show a relative increase in ACC activity (Drevets et al, 
1999), which Drevets (2001) argued could be the result of adaptation to the increased 
amygdala activity discussed above.  
 
1.3.2 Other regions implicated in depression 
 
A number of other areas have also been identified as displaying abnormal structure or 
function in depressed individuals, such as the lateral PFC, anterior thalamus, caudate and 
orbitofrontal cortex (OFC; see Drevets (2000) for a review). However, findings for these 
regions have not been as consistent as for the amygdala or medial PFC. In a meta-analysis of 
143 fMRI and x-ray computed tomography studies, Kempton et al (2011) report that 
depressed patients display decreased caudate, putamen, globus pallidus, thalamus and OFC 
volume. Hamilton et al (2012) in a meta-analysis of 24 fMRI studies reported that, relative to 
healthy controls, depressed patients exhibited greater responses in the amygdala, insula and 
ACC, and decreased responses in the dorsal striatum and dorsolateral PFC when viewing 
negative stimuli.  
 
1.3.3 Neural correlates of reward and punishment processing deficits in depression 
 
Studies using neuroimaging techniques have provided a better understanding of the neural 
mechanisms underlying abnormal reward and punishment processing. For example, Elliot et 
al (1998) showed blunted responses in patients’ medial caudate and OFC to both positive and 
negative feedback on the CGT. Steele et al (2007) report that patients displayed both reduced 
behavioural responses to both positive (win) and negative (lose) feedback on a novel 
gambling task (from Steele et al, 2004), and attenuated responses in the ACC and ventral 
striatum. In support of these results, Pizzagalli et al (2009) report both reduced behavioural 
responses and attenuated BOLD responses in the ventral striatum during reward feedback on 
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a monetary incentive delay task in medicated depressed patients, which in Steele’s results 
correlated negatively with anhedonia. Further, Knutson et al (2008) reported increased dorsal 
ACC activity (but no differences in the striatum) to anticipated increasing gains using the 
same monetary incentive delay task in unmedicated depressed patients compared to controls. 
Finally, McCabe et al (2009) reported that remitted depressed patients displayed decreased 
responses to positive stimuli in the ventral striatum, and enhanced responses in the caudate 
and blunted responses in the lateral OFC to aversive stimuli. These differences in neural 
responsivity between groups were observed despite the fact that these patients displayed no 
clinical symptoms or differences in subjective ratings of the stimuli compared to controls. 
However, it must be noted that antidepressant use can have an effect upon neural responses in 
depression: McCabe et al (2010) administered 20mg of citalopram daily for 7 days to healthy 
volunteers, and discovered a reduction in the resting state connectivity between the dorsal 
nexus and the left hippocampus after such treatment. Connectivity between these two regions 
has been shown to be increased in depression (e.g. Frodl et al, 2010) and as such, it must be 
noted that some of the results of the above studies could be affected by antidepressant use; 
e.g. Steele et al (2007) administered their task to medicated MDD patients.  
 
Few studies have examined the neural correlates of impulsive responding in MDD. However, 
Dombrovski et al (2013) recently examined the link between impulsivity, reward learning, 
depression and suicidality by administering a probabilistic reversal learning task to both 
elderly depressed individuals who had and had not attempted suicide, and healthy volunteers 
during fMRI. Measures of impulsivity were obtained from subscales of the Barratt 
impulsiveness scale, as well as the number of bets against the odds on the CGT, both of 
which the authors demonstrate to be linked to suicidality. The results of this study revealed 
that impulsivity and a history of suicide attempts were associated with a weakened expected 
reward signal on a probabilistic reversal learning task in the paralimbic cortex, and that 
severity of depression was associated with disrupted corticostriatothalamic encoding of 
unpredicted rewards in depression. As such, studies using neuroimaging techniques have 
been able to support the results of behavioural studies, highlighting deficient processing of 
rewards and punishments in medicated, unmedicated and even remitted depressed patients at 
the neural level. 
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1.4. Serotonin hypothesis of depression 
 
Whilst the above imaging studies have helped to shed light on the neural circuits implicated 
in depression, theories of the neurochemical basis of this disorder have come from studies of 
the monoamine systems, which have long been thought to be important in the aetiology and 
particularly the treatment of depression (Baumeister et al, 2003). This emphasis on the 
monoamine systems began from the discovery that reserpine, a drug that was initially used in 
order to treat hypertension, induced depressive symptoms by depleting monoamine 
neurotransmitters in a small number of patients (Freis, 1954). There are relatively few 
neurons of the 5-HT, DA and NA systems in comparison to other neurotransmitter systems 
(e.g. the glutamatergic system) but the fact that they each have diffuse projections throughout 
the cortex means that they can greatly influence cognition and mood. Pharmacological 
treatments that block the re-uptake of one or more of these monoamines (e.g. selective 
serotonin reuptake inhibitors; SSRIs) are effective at alleviating the symptoms of depression 
(e.g. Anderson, 2000, Steffens et al, 1997). This led to the ‘monoamine hypothesis’ of 
depression, which posits that the disorder is caused by low monoamine levels (Everett and 
Toman, 1959). There is in fact good evidence that depleting the monoamines through 
pharmacological and dietary treatments can induce specific cognitive and mood effects seen 
in depression in both experimental animals and humans (e.g. Booij et al, 2003, McLean et al, 
2004b, Riedel 2004). An overview of the current literature on the involvement of 5-HT in 
depression will be presented below, along with the effects of depleting 5-HT in both animals 
and humans. Whilst there is research indicating that DA and NA are involved in depression 
(e.g. Blier et al, 2003), these studies will not be discussed, as the focus of this thesis is the 
role of 5-HT in decision-making and mood.  
 
1.4.1 Animal studies of 5-HT’s role in depression 
 
Animal models largely provide support for the notion that 5-HT is involved in depression, 
although not all results are consistent with this hypothesis. For example, the most widely used 
model of depression in rodents, the learned helplessness (LH) model (which is induced by 
exposing the rodent to inescapable and chronic stressors) has been shown to reduce 5-HT 
release within the PFC (e.g. Petty et al, 1994). Adell et al (1997) also report that acute 
exposure to a stressor can lead to increased firing in the dorsal raphe nucleus (DRN; the 
origin of the 5-HT system in the brain), resulting in 5-HT release in downstream projection 
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targets of the DRN, including the hippocampus (Amat et al, 1998) and the PFC (Yoshioka et 
al, 1995). Furthermore, both pre-treatment with an SSRI (Petty et al, 1996) or the selective 5-
HT1A receptor (an inhibitory receptor) agonist 8-OH-DPAT directly into the DRN (Remy et 
al, 1996, Hogg et al, 1994) can inhibit the development of LH. However, Perona et al (2008) 
report that 5-HT-transporter (5-HTT) knockout-mice performed no differently to wildtype 
(control) mice on tests of the forced swim test (to measure helplessness), tail suspension test 
(to measure behavioural despair) and sucrose consumption (to measure anhedonia), whilst 
differences in depressive-like behaviours were observed between DAT (dopamine 
transporter) knockout-mice and wildtype mice. The results of this study indicate that 
dopamine, not 5-HT, may play a more important role in animal models of depression. 
 
As such, not all animal research supports a role for 5-HT in animal models of depression. 
However, it could be argued that animal models of psychiatric disorders are poor replicates of 
such disorders in humans: for example, the fact that administration of almost all 
antidepressants immediately reverses behaviours interpreted to replicate depression contrasts 
with the fact that antidepressants restore mood in humans only after many weeks of 
administration (Krishnan and Nestler, 2011). Further, it could be argued that decreased 
mobility on the forced swim test represents the animal learning that it cannot escape and that 
the best strategy is to conserve energy until it is rescued, rather than increased helplessness 
(e.g. Krishnan and Nestler, 2011). As such, it may be difficult to draw conclusions about 
depression in humans from animal models.  
 
However, an important hypothesis regarding the involvement of 5-HT in depression stems 
from such animal research findings (Deakin and Graeff, 1991, Graeff et al, 1996). This 
hypothesis posits that there are two main 5-HT systems within the brain; one that projects 
from the DRN to the amygdala, and one that projects from the median raphe nucleus (MRN) 
to the hippocampus, with the former mediating adaptive responses to dangerous life events 
via 5-HT2C receptors (influencing anxiety), and the latter mediating responses to life events in 
which loss is experienced, via 5-HT1A receptors (influencing resilience to aversive events and 
thereby depression). Graeff et al (1996) provide empirical support for this hypothesis, by 
showing that decreasing DRN firing by injection of 8-OH-DPAT decreased conditioned fear 
(as shown by decreasing avoidance on the elevated T-maze test), whilst increasing DRN 
firing did the opposite. Furthermore, drug-induced increases in 5-HT within the extracellular 
space in the hippocampus attenuated the decrease in exploratory behaviours that occurs 24 
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hours after induction of a stressor, interpreted as reflecting resilience. Interestingly, this 
attenuation was also decreased by administration of the 5-HT1A receptor antagonist WAY-
100135; Graeff et al (1996). Taken together, the above studies provide some evidence to 
suggest that 5-HT is implicated in animal models of depression and provide convergent 
evidence supporting an important role for the hippocampus in the disorder.  
 
1.4.2 Human studies of 5-HT’s role in depression 
 
The strongest evidence that 5-HT is involved in depression comes from studies using human 
participants, including studies showing the anti-depressant effects of drugs that increase 
extracellular 5-HT, the effects of acute tryptophan depletion (ATD) upon the mood of 
recovering depressed patients, measurements of 5-HT metabolites and tryptophan in the 
cerebrospinal fluid (CSF) and plasma of depressed patients, and post-mortem studies 
examining the expression and distribution of 5-HT receptors throughout the brain of suicide 
victims.  
 
The fact that the most successful pharmacological treatments increase levels of extracellular 
5-HT suggests that this neurotransmitter may be involved in the aetiology of depression. The 
most commonly prescribed antidepressants are the selective serotonin reuptake inhibitors 
(SSRIs), which have a high affinity for the 5-HTT, greatly reducing the extent to which this 
transporter can re-uptake 5-HT back inside the cell. These drugs have been shown to have a 
reliable antidepressant effects (e.g. Anderson et al, 2000), alleviating many symptoms of 
depression in some patients. However, it must be noted that the results of an extensive 
examination of the efficacy of many antidepressants showed that administration of citalopram 
(an SSRI) over a 12-14 week period led to roughly one third of depressed patients reaching 
remission, with a further 10-15% of patients exhibiting decreased symptoms without actually 
reaching remission. Further, it took roughly 6 weeks of daily administration for citalopram to 
reduce symptoms, with remission only being achieved at 7 weeks (Insel, 2006, Hierholzer, 
2006). Roughly one third of the non-responders were then administered sertraline (another 
SSRI), following which one third of these patients became symptom free (Nelson, 2006). The 
results of this study therefore show that whilst administration of SSRIs improves mood in 
many patients, a substantial proportion of patients (30-40%) show no such improvement, 
indicating that 5-HT may not be the only neurotransmitter involved in this disorder.  
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As discussed above, there is a delay in the alleviation of depressive symptoms of anywhere 
between 2-6 weeks (Blier et al, 2003). This has traditionally been attributed to the 5-HT1A 
inhibitory autoreceptors within the DRN; the autoreceptor hypothesis posits that after SSRI 
administration these inhibitory receptors experience increased binding by 5-HT which 
initially decreases DRN output. However, over time these receptors are hypothesized to 
become desensitized to the increased levels of 5-HT and thus cease inhibiting firing from this 
region, leading to increased 5-HT levels throughout the cortex. Selvaraj et al (2012) provide 
some support for this hypothesis by reporting that a single 10mg dose of citalopram leads to a 
decrease in 5-HT release throughout the cortex. However, Harmer et al (2009) recently 
reviewed behavioural and neuroimaging studies that have examined the effect of 
antidepressants, and argue that the effects of antidepressants upon patients’ neural and 
cognitive processing of emotional and social stimuli in a more positive manner are apparent 
within only a couple of hours, but that mood takes longer to improve due to a resultant 
gradual change in social reinforcement that over time increases mood. As such, there are 
differing accounts of the true mechanism of antidepressant action, however the consensus is 
that these pharmacological treatments further indicate a role for dysfunctional 5-HT in 
depression. 
  
Studies examining 3,4 methylenedioxymethamphetamine (MDMA) users have also indicated 
a role for 5-HT in mood. MDMA is a psychoactive stimulant that has been shown to affect 
the 5-HT system (Fitzgerald and Reid, 1990) by binding the 5-HT transporter (5-HTT) and 
reversing its function, leading to increased levels of extracellular 5-HT (Rudnick and Wall, 
1992). Neuroimaging studies have shown this stimulant to affect the 5-HT system also: Kish 
et al (2000) report that MDMA exposure leads to decreased levels of 5-HT within the 
striatum, and Kish et al (2010) show decreases in 5-HTT binding throughout the cortex in 
chronic MDMA users (which Mcann et al (1998) showed is inversely related to the number 
of previous MDMA exposures). Curran and Verheyden (2003) reported that ecstasy users 
scored slightly less than 3 points more on the BDI than poly-drug users. However, it must be 
noted that neither MDMA-users nor poly-drug users scored within the clinical range for 
depression in this study, and Gerra et al 1998 report that MDMA-users score significantly 
higher on the Hamilton Rating Scale for Depression than non-drug users. Curran and Travill 
(1997) examined recreational MDMA users’ self-reported mood levels both acutely and sub-
acutely, and discovered that participants’ rated their mood as elevated immediately after 
taking MDMA, but that their mood became progressively lower over the next 4 days, with 
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some participants recording mood within the range for clinical depression. The authors 
attribute this subsequent low mood to reflect MDMA-dependent 5-HT depletion that may 
occur days after administration.  
 
Whilst not specifically related to depression, some related studies have examined levels of the 
5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA) within the CSF and plasma of 
depressed patients, and have suggested a role for 5-HT dysfunction in suicide. For instance, 
5-HIAA has been shown to predict suicide (Asberg et al, 1976) and suicidal intentions 
(Nordstrom et al, 1994, Samuelsson et al, 2006). Further, Jokinen et al (2007) report that 5-
HIAA levels were correlated with scores on the Suicide Intent Scale (SIS) but not scores of 
depression or anhedonia. Further, Cremniter et al (1999) report that CSF 5-HIAA levels are 
lower in suicide attempters compared to healthy controls, with this effect being driven 
entirely by the impulsive suicide attempters. Roggenbach et al (2002) in a review of several 
often quoted reports of associations between aggression and levels of CSF 5-HIAA, argue 
that these reports perceive such a link due to an interpretation of suicide as an ‘autoagressive 
behaviour’, and that this is wrong due to the fact that aggresivity is insufficiently defined. 
Although, Stanley et al (2000) showed that 5-HIAA levels did correlate with self-reports of 
aggressive behaviour on a 6-item history of aggression scale, there was no relationship with 
aggressive feelings or thoughts. Consistent with the notion that self-control (impulsivity), and 
not aggression per se, mediates this effect, results linking 5-HIAA levels with suicidality, 
impulsivity and aggression are complicated by the fact that successful alleviation of 
depressive symptoms through the administration of SSRIs leads to a reduction in 5-HIAA 
(Backman et al, 2000). As such, levels of 5-HIAA within the CSF may be linked to some 
depressive symptoms, particularly suicide, but the exact nature of this relationship is not fully 
understood.  
 
Finally, post-mortem studies of 5-HT receptor density suggest a role for altered 5-HT 
functioning in depression. For example, Owens and Nemeroff (1994) found reduced 5-HTT 
density in depressed patients, although Hrdina et al (1993) did not find such a result. 
However, the same study (along with McKeith et al, 1987) did find increased 5-HT2 receptors 
in the post-mortem brains of depressed patients. Further, Shelton et al (2009) report that there 
are increased levels of 5-HT2A (but not 5-HT1A, or 5-HT2C) receptors in the post-mortem 
prefrontal cortex tissue of patients with MDD, and that increased levels of 5-HT2A receptors 
in their depressed sample was correlated negatively with levels of protein kinase A (PKA). 
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The results of this latter study suggest a mechanism by which depressed patients may exhibit 
altered levels of such receptors.  
 
In summary, the above studies administering SSRIs to both animal and human subjects 
implicate a role for 5-HT in depression; and studies administrating various 
agonists/antagonists and post-mortem studies have provided further evidence for an 
involvement of specific 5-HT receptor subtypes in the aetiology of depression. 
  
1.4.3 Mood and cognitive effects of ATD in patients recovered from depression and healthy 
volunteers 
 
Many studies have attempted to link 5-HT and depression by examining the effect of ATD on 
both mood (see Ruhe et al (2007) for a review) and cognition (see Mendelsohn et al (2009) 
for a review). With regards to the mood effects, this dietary technique has been shown to 
have little or no effect on mood in healthy volunteers (e.g. Carpenter et al, 1998, Nishizawa et 
al, 1997, Riedel et al, 1999, Rogers et al, 1999a). Some studies however have suggested that 
ATD may decrease mood in individuals vulnerable to depression (e.g. those with a family 
history; e.g. Ellenbogen et al, 1999, Stewart et al, 2002), or may reinstate depressive 
symptoms in patients recovered from depression (Delgado et al, 1990; see Booij et al, 2002 
for a review). Other studies report that patients considered to have a more severe form of 
depression (such as those who required the help of SSRIs to recover from a depressive 
episode, or those who have suffered from multiple episodes) are at higher risk of relapse 
following ATD (Booij et al, 2002, Delgado et al, 1999). However, O’Reardon et al (2004) 
found that ATD only produces this transient increase in symptoms in roughly 50-60% of 
patients who have recovered using SSRI treatment, and that those patients who have 
recovered by other means (e.g. cognitive-behavioural therapy) rarely experience any change 
in mood under ATD.  
 
With regards to the cognitive effects of ATD, studies have shown differing effects upon 
different cognitive measures. For example, ATD has been shown to impair performance on 
verbal learning tasks of episodic memory (e.g. Riedel et al, 1999, Schmitt et al, 2000, 
Sambeth et al, 2009), and McAllister-Williams (2002) showed that ATD affected 
participants’ episodic source memory on a word learning task. However, studies of the effect 
of ATD upon spatial memory, a specific type of episodic memory, have found conflicting 
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results, with Mendelsohn et al (2009) in a review concluding that sufficient evidence does not 
exist to claim ATD has an effect upon spatial memory. Further, ATD has been found to not 
affect declarative memory (Park et al, 1994, Porter et al, 2000, 2005) or semantic memory 
(Allen et al, 2006, Amin et al, 2006, Gallagher et al, 2003). However, taken together, the 
results of these studies indicate that ATD treatment in healthy volunteers leads to cognitive 
deficits that are similar to those observed in depressed patients, and as such provide 
convergent evidence for the serotonin hypothesis of depression. 
 
ATD has been found to have effects on emotional processing and decision-making. For 
example, Murphy et al (2002) report that participants who had undergone ATD treatment 
displayed increased response times for happy but not sad targets. Further, Roiser at al (2008) 
report that ATD attenuated the bias towards positive words, and that this was accompanied 
by increased hemodynamic responses during the processing of these words in cortical 
structures including the striatum and ACC. Feder et al (2011) have also shown that relative to 
healthy controls who were at low familial risk for depression, those at high risk made a 
higher number of inappropriate responses to sad distractors on an affective go/no-go task 
following ATD. Munafo et al (2006) administered ATD to previously SSRI-medicated and 
unmedicated recovered depressed patients, along with healthy controls. The results of this 
study revealed that the previously medicated patients demonstrated an increase in selective 
processing of social threat cues on an emotional Stroop task after ATD compared to the 
control condition. With regards to decision-making, Rogers et al (2003) report that ATD led 
to reduced discrimination between magnitudes of expected gains on a gambling task, 
Crockett et al (2012) administered ATD to healthy controls and report a decrease in the 
sampling of costly information on the information sampling task, and Schweighofer et al 
(2008) report that ATD leads to an increase in the discounting of future rewards based upon 
their temporal delay; see 1.4.5 5-HT in decision-making, below).  
 
However, studies using tasks that tap ‘executive functions’ such as working memory, 
attention, response inhibition, planning and cognitive flexibility have generally found no 
effect of ATD upon performance. For example, Luciana et al (2001) found no effect of ATD 
upon digit span or spatial span using the Sternberg Memory Scanning task (which measures 
working memory), Schmitt et al (2000) and Murphy (2002) discovered that ATD did not 
affect efficiency of planning (supported by Mendelsohn et al’s (2009) claim that studies have 
not found effects of ATD upon performance on the Tower of London task).  
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Similarly, studies examining effects of ATD upon attention report largely null results: 
Luciana et al (2001) report such null results during two types of letter cancellation tasks 
(although they do report that acute tryptophan loading (to increase levels of tryptophan; ATL) 
did decrease the number of omission errors on this task), and Harrison et al (2004) and Park 
et al (1994) report that ATD did not affect performance on a continuous performance task. 
Gallagher et al (2003) showing that ATD does not affect performance on a Stroop task, but 
Booij et al (2005), Schmitt et al (2000) and Scholes et al (2007) all reported that ATD 
improved focussed attention. However, Sobczak et al (2002) report no such improvement on 
the same task, which the authors claim is due to the testing of participants with a wider age-
range. Therefore it seems unlikely that executive function deficits commonly reported in 
depression are directly related to altered 5-HT transmission.  
 
In sum, studies administering ATD have provided support for the theory for a role of 
abnormal 5-HT functioning in the aetiology of depression. Both mood and cognitive effects 
have been observed in healthy controls, those at risk for depression and patients who have 
recovered from depression after administration of this dietary technique, and importantly in 
some cases these mimic the pattern observed in currently depressed patients, though not with 
respect to executive function. ATD has been shown to transiently lower mood in a proportion 
of patients vulnerable to the disorder, and also to lead to a temporary recurrence of some 
depressive symptoms in those patients who recovered using SSRI treatments, further 
indicating a role for 5-HT in the aetiology of depression.  
 
1.4.4 Neuroimaging studies of 5-HT’s role in depression 
 
There have been many studies examining the role of 5-HT in depression using neuroimaging 
techniques. Commonly, studies have used positron emission tomography (PET) or single-
photon emission computerised tomography (SPECT) in order to examine 5-HT receptor 
binding in depressed patients, whilst other studies have used fMRI or PET combined with a 
manipulation of participants’ 5-HT levels in order to examine metabolism or haemodynamic 
responses in brain regions hypothesised to be involved in depression.  
 
Studies using SPECT ligand 123I-2 beta carbomethoxy-3 beta-(4-iodophenyl) tropane (123I-β-
CIT) have generally reported decreased 5-HTT binding potential in depressed patients (e.g. 
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Malison et al, 1998). However, Dahlstrom et al (2000) reported increased binding in 
depressed adolescents and children. Furthermore, a study examining patients recovered from 
depression revealed that these patients had a greater increase in binding than those who did 
not recover over a 6 month period (Laasonen-balk et al, 2004). Ruhe et al (2009) reported 
differences in 5-HTT binding potential between depressed and non-depressed males, but no 
such difference with regards to females, and intriguingly an effect of season upon 5-HTT 
binding potential within the midbrain. This latter result is consistent with the finding of 
Willeit et al (2000) who reported decreased 5-HTT binding potential in seasonal affective 
disorder (SAD) patients, and also the results of Neumeister et al (2000), in which it was 
reported that patients who were tested in the winter displayed reduced binding potential 
compared to those patients tested in the summer. The results of the above studies indicate that 
decreased 5-HTT binding potential is associated with depression, however, the results of 
Dahlstrom et al (2000) indicate otherwise. An interpretation of this could be that the patients 
studied in the latter experiment were children and adolescents, who would have experienced 
both fewer depressive episodes and fewer administrations of antidepressants. This could be 
an indication of a depression-related change in 5-HTT binding potential throughout 
adolescence. However, in order to better understand the results of Dahlstrom et al (2000), 
more research needs to be conducted. Finally, Selvaraj et al (2011), using the ligand 
[11C]DASB in conjunction with PET, did observe decreases in the binding of this transporter 
in several brain regions, including the brain stem, thalamus, striatum, ACC and PFC, 
supporting the above SPECT studies.  
 
Studies using PET to observe 5-HT1A receptor binding in depression have provided some 
evidence for its dysfunction in the disorder, although relatively few studies exist. Using the 
ligand 11C-WAY100635, Drevets et al (1999) (replicated by Drevets et al, 2007) and Sargent 
et al (2000) have reported reduced binding in both the raphe and cortex in depressed patients, 
and Bhagwagar et al (2004) and Moses-Kolko et al (2003) report (using the same ligand) 
reduced 5-HT1A receptor binding potential throughout the cortex in recovered depressed 
patients. Moses-Kolko et al (2007) shed light on the effect of SSRI treatment upon 5-HT1A 
receptor binding potential in MDD; here the authors discovered that out of 22 depressed 
patients who were administered an SSRI for 9 weeks, the treatment non-responders had 
higher baseline 5-HT1A receptor binding potential in the OFC bilaterally than treatment 
responders. Further, the authors discovered that the antidepressant drug treatment did not 
significantly change cerebral 5-HT1A receptor binding potential in treatment responders, 
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which they argue supports findings that alterations in 5-HT functioning after SSRI treatment 
do not involve changes in 5-HT1A receptor density. However, Shrestha et al (2012) report in a 
recent review that that not all studies support these results, highlighting the fact that Parsey et 
al (2006, 2010) reported an increase in 5-HT1A receptor binding potential in MDD patients 
compared to healthy controls. However, Shrestha et al argue that these discrepant results 
were observed due to both heterogeneity between patient samples, and differences in 
methodology between studies, with those studies reporting an increase in MDD 5-HT1A 
binding potential (Parsey et al, 2006, 2010) using the cerebellum as a reference regions, 
whereas the others above used radioactivity concentration in the plasma. As such, whilst the 
above studies indicate a role for decreased 5-HT1A receptor binding potential in MDD (with 
such decreased levels in the OFC also being related to increased potential for treatment 
response), the methodological differences between studies need to be rectified in order to 
gain a better understanding of the role of this receptor in MDD.  
 
Studies attempting to observe 5-HT2 receptor binding in depression have provided less 
consistent results however, potentially due to the fact that more than one ligand has been 
deployed in these studies (only one receptor ligand was used to look at 5-HT1A receptors – 
11C-WAY-100635 – as this was the only one that was available until relatively recently). 
Some studies have reported decreased 5-HT2 receptor binding in depressed patients compared 
to controls (e.g. Attar-Levy et al, 1999, Messa et al, 2003, Larisch et al 2001), whilst others 
report no difference (Meltzer et al, 1999, Meyer et al, 1999). Meyer et al (2003) were able to 
show that 5-HT2 binding was positively correlated with negative dysfunctional attitudes in a 
depressed sample, which is supported by results of Meyer et al (2001) that show decreased 5-
HT2 binding following recovery from depression (though results of this latter study are 
contrary to results of Massou et al, 1997 and Zanardi et al, 2001). As such, results regarding 
5-HT2 receptors in depression are conflicting. 
 
Lastly, studies using PET and fMRI have also attempted to image the neural correlates of the 
relapse in patients recovered from depression observed after ATD. Firstly, Bremner et al 
(1997) reported that ATD both induced symptom increases in these patients and was linked to 
decreased glucose metabolism within regions of the dorsolateral and ventrolateral PFC, OFC, 
ACC and the thalamus, with the levels of metabolism correlating negatively with increased 
mood scores. This is supported in part by Smith et al (1999) who, using H215O-PET, reported 
that increasing levels of depression after ATD were correlated with diminished blood flow in 
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ACC, OFC and caudate nucleus in patients recovering from depression. However, 
Neumeister et al (2004) report on a sample of depressed patients who were free from 
antidepressants (unlike the studies above), and report increased glucose metabolism in the 
OFC, posterior cingulate cortex, thalamus and right putamen following ATD treatment, 
which is the opposite to findings found in the above studies that used patients who were being 
administered antidepressants. Finally, Roiser et al (2009), using fMRI, discovered a 
differential effect of ATD upon BOLD responses in the dorsal ACC to emotional relative to 
neutral words in remitted depressed patients compared to healthy volunteers, despite no 
difference in mood between the groups following ATD.  
 
As such, these studies provide further results that implicate 5-HT in depression, and show 
that a rather consistent set of neural circuits underlies mood changes following ATD 
treatment, through the precise direction of changes observed does appear to depend on 
medication status. Importantly, many of these brain regions within this circuitry have been 
implicated in depression from neuroimaging studies using fMRI (see 1.3 Neuroimaging  
findings in depression, above).  
 
1.5 Serotonin in Decision-Making 
 
Much research has been conducted into the role of 5-HT in decision-making (e.g. Dayan and 
Huys, 2008), but it must be noted that decision-making includes many facets including 
reward and punishment processing (e.g. Rogers et al, 1999b, 2003, Eshel and Roiser, 2010) 
and impulsivity (e.g. Schweighofer et al, 2008, Pine et al, 2009, Dalley and Roiser, 2012). 
Studies have implicated 5-HT in each of these areas of decision-making, and this section will 
discuss each in turn. 
 
1.5.1 Serotonin and reward and punishment processing  
 
1.5.1.1 Animal studies of serotonin in reward and punishment processing 
 
Decision-making has been defined as computing predictions of future consequences of 
possible actions, and selecting a behaviourally appropriate response based upon those 
predictions (Dayan and Huys, 2008). A rich animal literature has measured reward-related 
behaviour in rodents using three main paradigms: place conditioning, intracranial self-
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stimulation (ICC) and drug self-administration. The results of these studies have reported the 
processing of reward-related information to be regulated by the action of 5-HT at a range of 
receptors.  
 
For example, Ahn et al (2005) report on the dose-dependent effects of the 5-HT1A receptor 
agonist 8-OHDPAT in reward responding, by showing that injection of a low dose into the 
rodent raphe nucleus (which decreases 5-HT neuron firing) led to increased responding to 
rewards on a conditioned place preference (CPP) task, but that injection of a high dose into 
the same brain region led to a decrease in responding. This is supported by results reported by 
Harrison and Markou (2001), but Markou et al (2005) and Budygin et al (2004) found that 5-
HT1A receptor antagonists have no effect. Studies have also shown dose-dependent effects of 
5-HT1A receptor agonists upon drug self-administration, with Peltier and Schenk (1993) 
showing high doses to inhibit the rewarding effects of cocaine self-administration in rats.  
 
In general, stimulation of 5-HT1B receptors has been shown to decrease the rewarding effects 
of rewards such as intracranial self-stimulation, cocaine, ethanol and amphetamine (e.g. 
Hayes et al, 2009b, Harrison et al, 1999, Fletcher et al, 2002a). However, Hoplight et al 
(2006) report an increase in the rewarding effects of ethanol following increased 5-HT1B 
receptor expression in the ventral tegmental area (VTA) of rodents, though this result may 
reflect effects on the dopamine system.   
 
Results regarding 5-HT2 receptors are less consistent, with administration of 5-HT2A receptor 
antagonists having no effect on the rewarding effects of intracranial self-stimulation or 
cocaine self-administration (Moser et al, 1996), but having an attenuating effect of self-
administration of MDMA (Fantegrossi et al, 2002) and ethanol (Ding et al, 2009) when 
injected directly into the VTA. However, Hayes and Greenshaw (2011) argue that this may 
be due to the fact that 5-HT2A receptors in the VTA increase dopamine release. No effects of 
5-HT2B or 5-HT3 receptor stimulation upon reward processing have as of yet been published 
(Hayes and Greenshaw, 2011).  
 
Early animal studies focussed more on the role of 5-HT in punishment processing (see 
Soubrie (1986) for a review). Studies that have administered both 5-HT receptor antagonists 
and manipulations known to decrease 5-HT release in terminal areas, as well as lesion studies 
(using 5, 7 dihydroxytryptamine), have shown that decreased 5-HT release results in 
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attenuation of punishment-induced inhibition (e.g. Thiebot et al, 1982, Tye et al, 1977, Tye et 
al, 1979, Wise et al, 1970), whilst Wise et al (1973) report that these effects can be reversed 
by direct injections of 5-HT or 5-HT agonists. Further, studies have shown that lesions of the 
raphe nuclei or administration of para-chloropheylalanine (pCPA) to deplete 5-HT can cause 
a deficit in passive avoidance of footshocks, and that the effect of pCPA is attenuated by 5-
HT administration (Thornton and Goudie, 1978).  
 
In summary, animal studies have provided some evidence for a role for 5-HT in reward and 
punishment processing, with numerous findings that 5-HT depletion disinhibits punishment 
processing. However, different receptors have been shown to have different effects upon 
responding to rewards and punishments: 5-HT1A receptor agonists have been reported to have 
a dose dependent increase upon the processing of the rewarding aspects of drug self-
administration, and stimulation of 5-HT1B receptors has been shown to decrease the 
rewarding effects of stimuli. However, less is understood about the role of specific 5-HT 
receptors in punishment processing.  
 
1.5.1.2 Human studies of serotonin in reward and punishment processing 
 
Studies using human participants have also implicated 5-HT in the processing of rewards and 
punishments. For example, Anderson et al (2003) administered a novel gambling task in 
which participants who had undergone ATD treatment could choose between option ‘A’ 
which provided a smaller but nearly certain win, and option ‘B’ which provided a win 2.5 
times that of ‘A’ but with a varying probability of occurring. The results of this study 
revealed that those who had undergone ATD treatment were more likely to take a risk for 
smaller rewards, but that ATD treatment did not modulate probabilistic choice overall. 
Rogers et al (1999b) administered the CGT to participants who had undergone ATD 
treatment, and found that treatment increased the number of sub-optimal decisions made, and 
increased deliberation times before making a decision. Further, Talbot et al (2006) discovered 
that ATD treatment had no effect on set shifting or reversal learning on the ID/ED set-
shifting task of the CANTAB, and even risk taking (contrary to the results of Anderson et al, 
2003 above, which used a different task). However, the authors here did report increased 
choosing of the more probable outcomes after ATD compared to sham depletion. Rogers et al 
(1999a) report that healthy volunteers who had undergone ATD treatment exhibited a deficit 
in the ability to learn changed stimulus-reward associations. Further, Rogers et al (2003) 
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administered a decision-making task that allowed the authors to examine the amount healthy 
volunteers (who had undergone ATD) used information pertaining to wins, losses and the 
probability of which they would win or lose in making their decisions. The results of this 
study showed that ATD attenuated participants’ sensitivity to wins (rewards), but not losses 
(punishments) or probabilities. By contrast, Robinson et al (2012) report that ATD improved 
healthy controls’ ability to predict upcoming punishments (but not rewards) on a reversal 
learning task, which supported the results of Cools et al (2008), who reported that ATD 
abolished the bias towards prediction errors (the difference between expected and actual 
outcomes) for punishing stimuli compared to rewarding stimuli. Crockett et al (2009) showed 
that ATD abolished punishment-induced behavioural inhibition on a go/no-go task without 
affecting overall motor response inhibition. Furthermore, Crockett et al (2012) report that 
ATD removed the suppressive effects of small local costs on information sampling in healthy 
volunteers on an information sampling task. In summary, behavioural studies using ATD 
suggest that there may be some role for 5-HT in both reward and punishment processing in 
humans, though many discrepant findings have been reported, and it is difficult to draw firm 
conclusions from the extant literature due to the large range of tasks employed.  
 
Neuroimaging studies in humans have also shown reward and punishment processing to be 
linked to 5-HT. Seymour et al (2012) administered a four-arm bandit task to healthy 
volunteers who had undergone ATD that allowed the authors to simultaneously examine 
participants’ responses to both rewards and punishments, and found that ATD altered the 
exchange rate by which rewards and punishments were compared, decreasing the subjective 
value of rewards, which was related to an increase in striatal and PFC responses. Few studies 
using fMRI have examined the role of specific receptor subtypes in this form of decision-
making however, although one recent study has done so: Macoveanu et al (2013) reported on 
the effects of the 5-HT2A receptor in risky decision-making. The authors administered a 
probabilistic gambling task to participants who were either administered the 5-HT2A receptor 
antagonist ketanserin or a placebo. The results of this study showed that blockade of the 5-
HT2A receptor made participants more risk-averse and selectively reduced the neural response 
of the PFC to negative outcomes that occurred on low risk trials. Furthermore, the ventral 
striatum displayed a stronger response to low-risk negative outcomes at baseline in risk-
taking compared to risk-averse individuals, which was abolished after administration of 
ketanserin. 
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1.5.2 Serotonin and impulsive responding and the processing of delayed rewards 
 
1.5.2.1 Animals studies of serotonin and impulsive responding and the processing of delayed 
rewards 
 
Research into impulsive responding to rewards and punishments using animals has shown 
that rats who have undergone 5, 7-dihydroxytryptamine (5, 7 DHT) administration (to deplete 
5-HT globally) exhibit increased premature responding on the 5-choice serial reaction time 
task (5-CSRTT; Harrison et al, 1997). In support of this, Masaki et al (2006) report that 
depleting 5-HT via administration of parachloroamphetamine (pCA) leads to impairments on 
a go/no-go paradigm. However, Eagle et al (2008) show that modulating 5-HT functioning 
only affects ‘action restraint’ in rodents, and does not affect performance on the stop-signal 
reaction time task (SSRT) or temporal discounting tasks (supported by Eagle et al, 2009, Bari 
et al, 2009). However, the role of 5-HT in delayed rewards is controversial. Initially Bizot et 
al (1988) showed that rats on a range of antidepressants chose delayed but larger rewards 
(e.g. decreased discounting). However, Winstanley et al (2003, 2004) reported no effect of 5-
HT lesions in performance on a temporal discounting paradigm, which may be due to 
differences in experimental procedures (Winstanley et al, 2006a, Dalley and Roiser, 2012).  
 
Further insights have come from studies examining the effects of 5-HT receptor 
stimulation/blockade on impulsive responding: Blokland et al (2005) and Evenden and Ryan 
(1999) found that administration of the 5-HT2A/2C receptor agonist DOI (1-(2, 5-dimethoxy-4-
iodophenyl)-2-aminopropan) increases impulsivity on both reaction time and temporal 
discounting tasks, an effect that can be reversed by administration of 5-HT2A/2C receptor 
antagonists, and Winstanley et al (2004) reported an effect of DOI on performance on the 5-
CSRTT. However, Talpos et al (2006) found no such effect by administering the 5-HT2A/2C 
receptor antagonist SER082, and Blokland et al (2005) showed that systemic administration 
of the 5-HT1A receptor agonist 8-OH-DPAT decreased impulsivity on a choice reaction time 
task but increased temporal discounting. This latter result highlights the fact that impulsivity 
is not a unitary construct and that different tasks of impulsivity do not tap into the exact same 
decision-making processes (Dalley and Roiser, 2012).  
 
 
36	  
	  
1.5.2.2 Human studies of serotonin and impulsive responding and the processing of delayed 
rewards 
 
Whilst research into impulsive responding in humans does not have the range of 
pharmacological interventions, there nonetheless exists a consistent body of work that 
implicates 5-HT in this form of decision-making. The dietary technique ATD has often been 
used in order to examine 5-HT’s role in impulsive decision-making: with regards to response 
inhibition, several studies report no effect of ATD: Clark et al, (2005), and Evers et al 
(2006b), Rubia et al (2005) and LeMarquand et al (1998, 1999) found no change in error 
rates on a go/no-go task after ATD treatment. The results of studies using the SSRT have 
been very consistent with those using animals, finding no effect of ATD on behaviour (e.g. 
Cools et al, 2005a, Clark et al, 2005). However, Walderhaug et al (2002) did report 
disinhibited behaviour following ATD in healthy controls, and Crean et al (2002) found that 
ATD increased stop reaction times in participants who had a family history of alcoholism. 
With regards to temporal discounting, results using human participants have been much more 
consistent than those using animals: Tanaka et al (2007) report that ATD increased healthy 
volunteers’ rate of discounting, and Schweighofer et al (2008) tested healthy volunteers who 
had undergone both ATD and ATL on a ‘dynamic’ delayed discounting paradigm that 
required a continuous update of reward value estimates. The results of this latter study 
showed an increase in the rate of discounting delayed rewards in the low tryptophan group 
compared to baseline and high tryptophan groups. However, it should be noted that Crean et 
al (2002) reported no effect of ATD upon temporal discounting in a sample of men both with 
and without a family history of alcoholism. 
 
Studies using other methods have also provided support for a role of 5-HT in this form of 
decision-making. For instance, Lindstrom et al (2004) and Ryding et al (2006) report reduced 
5-HTT levels as shown by PET in impulsive compared to non-impulsive suicide attempters, 
which the authors claim could be due to reduced density of 5-HT terminals. Further, Frankle 
et al (2005) report similarly reduced levels of 5-HTT in impulsive compared to non-
impulsive aggressive individuals. 
 
The psychoactive drug MDMA has been shown to affect the 5-HT system (e.g. Rudnick and 
Wall, 1992, Kish et al, 2000, 2010), and studies examining decision-making in human 
MDMA users have provided some, although often conflicting, evidence for the role of 5-HT 
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in the processing of delayed rewards and impulsive responding. For example, Quednow et al 
(2007) reported on the decision-making and impulsive responses of chronic but recently-
abstinent MDMA users by comparing them with both chronic but recently-abstinent cannabis 
users and controls. The results of this study revealed MDMA users to display higher levels of 
impulsivity on the Matching Familiar Figures Test (MFFT; Kagan et al, 1966) and poorer 
performance on the IGT. These findings are supported by Morgan et al (2002) and Bickel and 
Marsch (2001), who were able to show that regular ecstasy users display increased impulsive 
responding compared to both poly-drug users and drug-naïve controls on the MFFT and a 
temporal discounting paradigm, respectively. However, Clark et al (2009) reported that a 
cohort of previous ecstasy users and current ecstasy users did not display disrupted reflection 
impulsivity compared to drug-naïve controls on an information sampling task, despite the 
previous and current ecstasy users scoring significantly higher on the impulsivity subscale of 
the self-report Eysenck Impulsivness-Venturesomeness-Empathy questionnaire (interestingly 
the previous users scored (numerically) higher on this subscale than current users). However, 
it should be noted that there are limitations of studies of MDMA users, specifically that these 
participants often ingest various other drugs that can confound results, and that such cross-
sectional studies cannot exclude the possibility that any differences observed were pre-
existing. This makes any attempt to draw conclusions regarding links between MDMA use, 
5-HT and task performance difficult.   
 
Relatively few neuroimaging studies have studied the neural correlates of 5-HT’s influence 
on impulsive responding. However Tanaka et al (2007) were able to show a role of 5-HT in 
temporal discounting using fMRI: here they discovered that BOLD responses within the 
ventral striatum were correlated with reward prediction at shorter time scales, which was 
stronger at lower levels of 5-HT. Further, BOLD responses within the dorsal portion of the 
striatum were correlated with reward prediction at longer time scales, which was stronger at 
higher levels of 5-HT. Whilst the results of this study support a role for 5-HT in temporal 
discounting by altering striatal responding, more research needs to be conducted in order to 
gain a more complete understanding of the neural circuitry involved in the link between 5-HT 
and impulsive responding. 
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1.6 Computational models of decision-making and the theory of altered pruning in 
depression 
 
The behavioural, psychopharmacological and imaging studies reported above all utilised 
descriptive approaches to their analyses of the data, using ‘raw score summary statistics’ that 
simply average over trials at the subject level in order to produce the outcome measures of 
interest, such as average reaction times or proportion of choices made. An alternative 
approach to understanding participants’ performances is computational modelling. Such an 
approach involves building a mathematical algorithm that putatively describes how 
participants perform a task (often explaining changes in behaviour over time - e.g. learning) 
and summarises performance according to a set of parameters that have been estimated on the 
basis of participants’ behaviour (Montague, 1995).  
 
This approach has allowed recent studies to provide novel insights into decision-making 
differences between depressed and non-depressed individuals. Applying models that attempt 
to explain performance in this way may help researchers understand more about why 
participants made particular choices: if an extra parameter is added to a model, for example, a 
parameter that influences reward sensitivity (which indexes the subjective value placed upon 
a reward that was administered) and this parameter increases the likelihood that this new 
model will be able to predict participants choices, then the inference can be made that 
participants are indeed using reward sensitivity information to guide their choices. 
Additionally, parameter estimates from models that accurately explain participants’ 
behaviour (e.g. provide a good fit to the data) can be compared between groups, allowing a 
computationally and theoretically precise analysis of specific cognitive processes. Thus 
computational models can be informative over and above traditional statistical models which 
can help researchers to understand why certain behaviours on certain tasks are observed. In 
this thesis, such a computational approach was utilised in two of the chapters to characterise 
decision-making on a ‘pruning’ task (see below). 
 
Whilst the advent of such models was rather recent, meaning that a large body of work does 
not yet exist, computational theories of decision-making in depression have been proposed, 
and a particularly relevant theory for this thesis is the theory of altered ‘pruning’ in 
depression which is discussed below (Dayan and Huys, 2008, Huys et al, 2012). 
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Early behavioural studies using the computational modelling approach did not apply such 
methods to study depression. However, Huys and Dayan (2009) were able to show that 
certain computations are linked to specific depressive symptoms. Administering a range of 
decision-making tasks, the authors were able to compute measures of reward sensitivity (how 
much a previous reward affected future choices) and controllability (the participants’ belief 
that their action will lead to a particular set of outcomes – the opposite of ‘helplessness’).  
The results showed that reward sensitivity and controllability were negatively correlated with 
self-reported anhedonia and self-reported helplessness, respectively. Furthermore, Chase et al 
(2010) tested both MDD subjects and controls on a probabilistic learning paradigm, and 
found that learning rates (the extent to which stimulus value estimates are updated following 
feedback) were negatively correlated with self-reported anhedonia in both groups, although 
the groups did not differ overall. Thus, studies using computational modelling of decision-
making behaviour are beginning to provide insight into the specific decision-making 
processes in depression. 
 
1.6.1 Theory of altered pruning in depression 
 
Dayan and Huys (2008) posit a theory based upon computational work that is important to 
the studies and hypotheses set out in the chapters below. This work highlights how 
computational modelling may be able to aid our understanding of the role of 
neurotransmitters in psychiatric conditions, and is based upon early work in rodents that 
implicates 5-HT in both the prediction of aversive events (e.g. Deakin, 1983) and behavioural 
inhibition (Soubrie, 1986; see section 1.5.1.1 above). This theory posits that 5-HT is involved 
in the prevention of ongoing actions or thoughts in light of aversive events. Dayan and Huys 
(2008?) argue that many of the decisions made on an everyday basis are not single-step 
decisions, but rather require evaluation of rewards and punishments at many stages. Beyond a 
few steps, these kinds of planning problems cannot be solved by evaluating all potential 
sequences one by one, since too many alternatives would need to be evaluated: instead 
strategies, or heuristics, must be employed that allow one to eliminate sequences in order to 
lessen the computational load. As such, possible alternative action sequences are ‘pruned’ 
away from a ‘tree’ of potential decisions, and 5-HT is posited to be involved in such pruning 
for such sequences that include highly aversive outcomes. For example, when deciding upon 
a holiday destination, one may prune based on a number of heuristics; one may wish to prune 
away regions that are too expensive to travel to (e.g. Australasia), or those that one has 
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already travelled to (e.g. North America), or which are currently experiencing social unrest 
and thus could be unsafe (e.g. the middle east). Once a decision has been made (e.g. Asia), 
countries within that continent that are less attractive to the holiday-maker may be pruned 
away, until a decision is made. To consider all of the hotels, in all the towns, in all the world 
would be computationally ruinous, and pruning away large portions of the tree of decisions 
lessens this load.  
 
Dayan and Huys et al (2008) and Huys et al (2012) argue that 5-HT is involved in pruning 
this tree of decisions in light of potentially aversive events, and that a decrease in levels of 5-
HT could result in a decrease in behavioural inhibition, leading to decreased pruning. This is 
then hypothesised to lead to an increase in large negative prediction errors as more 
unexpected, negative consequences are encountered, leading to a more pessimistic evaluation 
of the world, and a decrease in mood. However, healthy controls (with normal levels of 5-
HT) should reflexively prune away choices with aversive expected outcomes, and would thus 
underexplore negative environments leading to the experiencing of (and thinking about) 
fewer negative experiences and a more optimistic view of the world. The authors thus argue 
that it would be important to test this theory in MDD patients and subjects with high scores 
on depression scales in order to better understanding the link between decision-making, 5-HT 
and low mood.  
 
The specific heuristics that humans deploy when pruning are difficult to ascertain. However 
Huys et al (2012) administered to healthy controls a sequential decision making task that was 
designed to reveal such specific pruning strategies based on aversive outcomes. On this task, 
healthy participants had to devise a sequence of moves of pre-specified length, with each 
move being deterministically associated with either a large or small financial win or loss. 
Three separate conditions were performed in a between subjects design, with group specific 
large losses of either £1.40, £1.00, or 70p. Due to the financial rewards and punishment 
associated with the other 3 move types (win of £1.40, win of 20p, loss of 20p), it was 
increasingly financially disadvantageous to cut the ever expanding decision tree down to a 
manageable size by pruning sub-trees that begun with a large loss in each condition (e.g. 
most disadvantageous in the 70p loss condition). However, participants pruned such sub-trees 
equally in all 3 conditions, extensively reducing their search space by failing to consider 
sequences of moves that began with a large loss.  
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Computational modelling of participants’ choices was applied to the data to confirm that they 
were indeed employing a heuristic in which planning to transition through large losses was 
avoided (even when this strategy was financially disadvantageous). The fact that participants 
continued with this pruning behaviour, even when it was highly disadvantageous (e.g. in the 
70p loss condition) indicated that it was reflexive, elicited in response to large losses in a 
Pavlovian manner that is non-adaptive and inflexible to task demands. Further, the authors 
also discovered a correlation between sub-clinical depression scores on the BDI and pruning 
behaviours. This correlation was, however, in opposition to the direction predicted by Dayan 
and Huys (2008), with a higher depression score being correlated with a higher pruning 
score. As such, whilst the employment of computational models in this study allowed for a 
better understanding of the link between pruning, 5-HT and mood, more work needs to be 
performed, with Huys et al (2012) pointing out that future studies should examine pruning in 
clinically depressed patients.  
 
1.7. Major questions and aims of this thesis 
 
The main aim of this thesis is to examine the link between 5-HT, decision-making and mood. 
Due to the putative disruption of 5-HT functioning in depression, it will examine how 
dysfunctional 5-HT is linked to the altered processing of information pertaining to rewards 
and punishments that may lead to the observed dysfunctional decision-making in depression. 
 
This thesis will present data from 4 experiments in which tasks tapping different aspects of 
reward and punishment processing were administered. The main task of focus is the pruning 
task used in Huys et al (2012) which was administered in every study. From this there 
followed 2 main aims: firstly, to replicate findings from Huys et al (2012) in which it was 
discovered that healthy controls make computationally complex, multi-step decisions by 
curtailing the search of a tree of potential decisions in light of potentially aversive events 
(pruning): secondly to test Dayan and Huys’ (2008) hypotheses that 5-HT is involved in this 
pruning process, and that impaired pruning behaviours are linked to low mood. This was 
tested by examining the pruning behaviours of both healthy controls who have undergone 
administration of MDMA (chapter 4) and ATD (chapter 5), and unmedicated unipolar 
depressed patients (chapter 6). This thesis also presents data from a study that attempted to 
examine whether such pruning behaviours were related to the availability of a specific 
serotonin receptor, the 5-HT1A receptor (chapter 3).  
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This thesis will also present data from two other tasks of reward and punishment processing; 
a gambling task described in Rogers et al (2003) and a temporal discounting paradigm 
described in Pine et al (2009). The first aim with regards to these studies was to confirm that 
performance on these tasks is dependent upon 5-HT functioning by replicating findings 
(chapter 5) from previous studies which, using ATD, have shown decreased levels of 
tryptophan to lead to a decrease in sensitivity to rewards (Rogers et al, 2003) and to increased 
discounting of rewards based upon their temporal delay (Schweighofer et al, 2008). The 
second aim was to extend these findings by showing a link between performance on these 
two tasks and availability of the 5-HT1A receptor (chapter 3). 
 
1.8 Summary of thesis chapters 
 
Chapter 2 details the various techniques used in the experiments described in chapters 3-6. 
This chapter is set out into 3 sections, with the first detailing the psychometric questionnaires 
and interviews administered, the second describing the behavioural tasks that were 
administered, and the third detailing the experimental techniques used to examine the impact 
of 5-HT on behaviour - one imaging technique (PET) which allowed the observation of 5-
HT1A receptor binding and putative 5-HT release, and two 5-HT manipulation techniques,  
MDMA and acute tryptophan depletion administration. 
 
Chapter 3 details the results of a study in which participants were given 2 PET scans in order 
to observe both availability of the 5-HT1A receptor and SSRI-induced 5-HT release in healthy 
controls, which were then correlated with performance on 3 decision-making tasks from a 
separate testing session. These behavioural tasks allowed the examination of pruning 
behaviours (using a sequential decision-making task), risky decision-making (using a risky 
decision-making task) and delay aversion (using a temporal discounting paradigm). It was 
hypothesised that performance on the above tasks would be correlated with both baseline 5-
HT1A receptor availability, and 5-HT release due to infusion of the SSRI citalopram in both 
the striatum and hippocampus. 
 
Chapter 4 details the results of a study in which participants were administered an acute dose 
of MDMA, and then 3 days later completed both self-report mood questionnaires and the 
pruning task. This was performed in order to examine the subacute effects of MDMA 
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administration (and the putative decrease in 5-HT thought to occur at this time) upon 
performance on this task. It was hypothesized that compared to placebo, participants would 
display decreased pruning behaviours due to the decrease in 5-HT, and that this would be 
linked to decreases in mood.  
 
Chapter 5 details the results of a study in which participants underwent ATD (which is 
hypothesized to lead to decreased levels of 5-HT in the brain) and performed 3 decision-
making tasks (the pruning task, and the risky decision making and delay aversion tasks 
administered in chapter 3). It was hypothesized that participants who had undergone ATD 
treatment would decrease pruning behaviours, decrease discrimination between magnitudes 
of wins on the gambling task, and increase participants’ discounting of future rewards on the 
temporal discounting paradigm. It was also hypothesised that ATD treatment would not alter 
mood.  
 
Chapter 6 details the results of a study in which the pruning task was administered to both 
depressed patients and healthy controls. It was hypothesized that depressed patients would 
display decreased pruning behaviours compared to controls, and that this would be more 
marked in more severely depressed patients.  
 
Chapter 7  provides a summary of the major findings of each experimental chapter, in 
particular focussing on the relationship between decision-making, 5-HT and mood. It 
compares the effects of the 5-HT manipulations, variation in 5-HT1A receptors, and effects of 
MDD upon performance on the above 3 decision-making tasks. Finally, it considers 
limitations of these studies and directions for future research. 
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2) EXPERIMENTAL METHODS  
 
This chapter details the various techniques used to collect the data that are reported in 
chapters 3-6. It will first outline the various mood and personality rating questionnaires and 
that were employed, before describing the computerized cognitive tasks that were 
administered and the chapters in which they appear. The method of positron emission 
tomography used in chapter 3 will be described, after which the method of administering 
MDMA in order to manipulate the 5-HT system (as in chapter 4) will be outlined, as will the 
technique of acute tryptophan depletion (ATD), which is thought to selectively lower levels 
of 5-HT synthesis, that was used in chapter 5. In all studies participants were compensated 
for their time and provided written informed consent to participate. Studies were approved 
either by the UCL Ethics Committee or the London Queen Square NHS Ethics Committee.  
 
2.1. Mini-International Neuropsychiatric Interview (MINI) – Sheehan et al (1998); 
Chapters 3, 5 and 6 
 
The MINI is a short, structured clinically diagnostic interview developed for the DSM-IV and 
ICD-10. Each section asks the participant about different psychiatric conditions; the 
interviewer asked questions from sections on unipolar depression, bipolar depression, panic 
disorder, agoraphobia, obsessive-compulsive disorder, post-traumatic stress disorder, alcohol 
and substance abuse/dependence, psychotic symptoms, anorexia nervosa, bulimia nervosa 
and generalized anxiety disorder. Each section began with a simple question (i.e. for unipolar 
depression: ‘Have you been consistently depressed or down most of the day, nearly every day 
for the past two weeks?’). If the participant responded yes to any of these first questions, 
follow-up questions, according to the specific criteria, were asked in order to assess whether 
they met criteria for the relevant condition. Kotwicki and Harvey (2013) report that the MINI 
substantially improves upon the stability of diagnoses compared to unstructured procedures 
relying on clinician diagnoses. Further, the authors report that the differences in rates of 
changes in diagnoses between the Structured Clinical Interview for DSM disorders are non-
significant (chi2(1)=2.01, P=.16). 
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2.2 Mood/Personality Questionnaires 
 
2.2.1 Hamilton Rating Scale for Depression (HAM-D) – Hamilton (1960); Murphy et al 
(2002); Chapters 5 and 6 
 
The HAM-D is conducted in a structured interview and provides a measure of the severity of 
depressive symptoms. The interviewer asks the participant questions and then rates their 
answers, from 0-3,4 or 5, depending on the question. There were 17 questions on this 
questionnaire, with a maximum score of 49. A score of 0-7 is considered normal; 8-13 means 
mild depression, 14-18 moderate depression, 19-22 severe depression, and 23+ very severe 
depression. This was administered to measure severity of mood disturbance. A sample 
question was ‘Depressed Mood’, with the possible answers being 0 (Absent), 1 (Sadness etc), 
2 (Occasional weeping), 3 (Frequent weeping), 4 (Extreme Symptoms). Kobak et al (1999) 
report that this measure has an internal consistency of .90, and a test-retest reliability of .74. 
 
2.2.2 Profile of Mood States (POMS) – Biehl and Landhauer (1975); Chapter 6 
 
The POMS is a self-rating scale in which participants must rate themselves as either ‘not at 
all’, ‘ a little’, ‘moderately’, ‘quite a bit’ or ‘extremely’ similar to each of the 65 adjectives 
presented to them. The items load onto 6 factors; ‘tension-anxiety’, ‘depression-dejection’, 
‘anger-hostility’, ‘fatigue-inertia’, ‘vigour-activity’ and ‘confusion-bewilderment’, with 
participants having to score between 1 (not at all) and 5 (extremely). Wywrich and Yu (2011) 
report that the internal consistency of this measure is .84, and the test-retest reliability is 0.78. 
 
2.2.3 Beck Depression Inventory (BDI) – Beck et al (1961); Chapters 3, 4, 5 and 6 
 
The BDI is a 21-question self-rating scale used to determine depressive symptomatology. For 
each item the participant is asked to choose one of four statements that best suits their mood 
over the previous two weeks. This scale was modified for administration in chapter 4 to 
examine participants’ mood over the past 3 days. Statements for each item are given a score, 
from 0-3, depending on their severity. The maximum score is thus 63, but the BDI manual 
(Beck and Steer, 1987) recommends the following classifications; 0-9 normal mood, 10-16 
mild mood disturbance, 17-20 borderline clinical depression, 21-30 moderate depression, 31-
40 severe depression, and 41+ extreme depression. A sample question from this measure was 
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to rate either 0 (I do not feel sad), 1 (I feel sad), 2 (I am sad all of the time and cannot snap 
out of it) and 3 (I am so sad or unhappy I cannot stand it). Storch et al (2004) report the 
internal consistency of this measure to be 0.90.  
 
2.2.4 Neuroticism/Extraversion/Openness Scale (NEO) – Costa and McCrae (1985) 
Chapters 3, 5 and 6 
 
The NEO is a 60-item, self-rating personality measure, measuring the five personality traits 
of Extraversion, Agreeableness, Conscientiousness, Neuroticism and Openness. Participants 
are presented with the 60 statements, and must decide whether they ‘strongly disagree’, 
‘disagree’, are ‘neutral’ towards, ‘agree’ or strongly agree’ with each. A sample question 
would be ‘I am not a worrier’ and I rarely feel alone or blue’. McCrae et al (2011) report that 
the internal consistency for the neuroticism scale is 0.55, for the extraversion scale is 0.64, 
for the openness scale is 0.59, for the agreeableness scale is 0.58 and for the 
conscientiousness scale is 0.50. 
 
2.2.5 State/Trait Anxiety Inventory (STAI) – Spielberger et al (1983); Chapters 3, 5 and 6 
The STAI is a 40-item, self-rating anxiety measure, with the first 20 items identifying the 
participants’ state anxiety, and the second 20 identifying the participants’ trait anxiety. 
Participants are presented with the 40 statements and must give a score of either 1 (‘do not 
agree at all’), 2 (‘agree somewhat’), 3 (‘agree moderately’) or 4 (‘very much agree’). A 
sample question would be ‘I feel calm’, or ‘I feel upset’. These scores are then summed to 
give their state and trait anxiety scores. Spielberger et al (1983) report the internal 
consistency of the state measure to be 0.83, and 0.89 for the trait measure.  
 
2.3. Psychometric Measures 
 
2.3.1 Digit-Span; Chapters 3, 5 and 6 
 
In order to test working memory, participants were asked to listen carefully to a sequence of 
numbers, and then repeat them back to the researcher. Once the participant had given their 
answer, the next sequence was given. Sequences were presented in ‘levels’ depending on 
their length (3-8), with each level containing two same-length sequences. If a participant 
failed both sequences at any level, the task stopped. Once this section was completed, 
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participants performed the same digit-span task, but had to repeat the sequences backwards 
(length 2-7).  
 
2.3.2 Wechsler Test for Adult Reading (WTAR) – Wechsler (2001) – Chapters 3, 5 and 6 
 
Participants were given a list of 50 words, which they had to, in their own time, read out loud. 
Each volunteer was instructed to read each word out loud, regardless of whether or not they 
recognised the word. A point was given for each correct pronunciation, and none for an 
incorrect pronunciation. From this a verbal IQ score was calculated following conversion to 
standardised scores.  
 
2.4 Computerised Cognitive Tasks 
 
2.4.1 Pruning Tasks – Huys et al (2012) – Chapters 3, 4, 5 and 6 
 
This task was administered in every experiment throughout the thesis, with two versions of 
this task being used: in chapters 3 and 6 an un-timed version was administered, and in 
chapters 4 and 5 a timed version was used. First, the general task will be described as it was 
used in chapters 3 and 6 and then the modifications made to the task due to time constraints 
in chapters 5 and 6 will be explained.  
 
2.4.1.1 Pruning Task used in Chapters 3 and 6  
 
First, participants learned how to move around the matrix during ‘transition training’. This 
matrix contained 6 boxes, and participants could move between these boxes by pressing 
either the U or the I key on a keyboard. From each box it was possible to move to two other 
boxes, depending on which key was pressed. Participants had a schematic of the transition 
matrix (figure 2.1, left) in front of them so that they could learn the moves, which they could 
look at as much as necessary. Neither the order of these transitions, nor the keys that moved 
from box to box ever changed. Participants were instructed that they were the white box, and 
had to reach a green target box within a set number of moves (1-4 moves; figure 2.1, right). If 
they failed on a trial, they simply tried again without incurring a penalty. Once they had 
reached the end of this training, they were then given a test, whereby they had to reach the 
green box in a specific number of moves on at least 9 of the next 10 trials on their first 
48	  
	  
attempt, without the schematic to help them. All subjects completed this test within two 
attempts.  
 
 
                
 
Figure	   2.1.	   Left:	   Schematic	   of	   transition	   matrix	   presented	   to	   participants	   in	   order	   to	   aid	   the	  
learning	  process.	  Right:	  Transition	  matrix	  as	  seen	  during	  the	  training	  phase	  –	  participants	  had	  to	  
move	  the	  white	  box	  into	  the	  green	  box	  by	  using	  every	  move	  (precise	  number	  specified	  at	  the	  top	  
of	  the	  screen	  on	  each	  trial)	  
 
Once this training was complete, participants began the task proper. This task began with a 
short further training phase. This instructed participants that each transition was associated 
with a deterministic financial outcome (£1.40 or 20p gain £1.40 or 20p loss; Figure 2.2). 
Participants were not told how much each transition would reward or punish, but instead 
would have to learn by themselves, by trial and error. Subjects completed 48 trials of varying 
length (2-8 moves). The first 24 trials were considered part of the reward transition matrix 
training and were discarded. Thus only the latter 24 trials were analysed. At the beginning of 
each episode subjects began in a random state, and had to make a sequence of transitions of a 
certain length in order to maximize financial gain. Relevant ‘+’ or ‘-’ signs were displayed 
beneath each box throughout the entire task to denote the deterministic rewards and 
punishments that would occur by leaving that box. The relevant deterministic rewards or 
punishments were displayed in the centre of the screen after each transition was made. On 
half of the trials, unless instructed otherwise, participants’ decisions were displayed after each 
button press. However, on half of the trials participants were asked to plan ahead the 
remaining (2-4) moves. This involved subjects planning out their desired sequence, 
completing it, and only after the final button press was made would the sequence be played 
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out on the screen (figure 2.2, left). The reward matrix, denoting the financial rewards and 
punishments, can be seen in figure 2.2, right.     
 
     
 
Figure	   2.2.	   Left:	   Task	   as	   seen	  during	  performance:	   on	   this	   example	  participants	   have	   to	   enter	   4	  
moves	  without	  immediate	  feedback,	  and	  Right:	  Reward	  matrix	  denoting	  the	  financial	  rewards	  and	  
punishments	  for	  each	  transition.	  Participants	  never	  actually	  saw	  this	  schematic,	  but	  rather	  had	  to	  
learn	  the	  value	  of	  each	  transition	  by	  trial	  and	  error	  
 
Participants were paid according to their earnings on the task, in order to motivate them to 
perform accurately, and were also financially compensated for their time. In chapter 3, this 
task was always administered first in the battery, with the order of the remaining tasks being 
switched so as to avoid any possible effects of fatigue due to a long testing session. 
 
A set of increasingly complex computational models was fit to the data from this version of 
the task (chapters 3 and 6) using Bayesian model comparison approach by our collaborator, 
Dr Quentin Huys (senior research fellow, translational neuromodelling unit, ETZ Zurich and 
University of Zurich). Each successive model had extra parameters in order to explain the 
data, and was assessed according to its Bayesian information criterion (BICint), which is 
based on the likelihood function (the likelihood that the model can explain the data) but 
penalizes a model for extra complexity, so as to avoid model overfitting. The first model here 
was a simple ‘look ahead’ model that assumed subjects evaluated the entire decision tree. The 
second included a ‘discount’ factor parameter (termed γG), which represents the probability 
that participants will choose to continue to evaluate the next step of the sequence at any given 
point, and can also be termed the ‘continuing probability’. The third, termed the ‘pruning’ 
model, is central to this study’s hypothesis, and splits this ‘discount’ factor parameter into 
‘general’ (γG) and ‘specific’ pruning parameter (γS), with the former describing discounting as 
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it is described above, and the latter being applied to transitions that immediately followed a 
large negative result. Both general and specific pruning denote continuing probabilities, and 
as such a higher score here reflects a lower occurrence of curtailment of the tree search. The 
final model included a learned Pavlovian component, which accounted for the 
attraction/repulsion to/from specific states after cumulative exposures. An additional set of 
parameters, ‘rho’, was assigned in order to capture sensitivity to each of the four transition 
types. A loss of a given amount may be more aversive than a win of that same amount is 
appetitive (loss aversion), and to test whether this was the case here the weights that each 
subject gave to each of the four possible reinforcements were inferred within this component 
‘rho’.  
 
2.4.1.2 Pruning Task used in Chapters 4 and 5 
 
A slightly different version of the pruning task was employed in chapters 4 and 5. The main 
differences were that the large negative transition resulted in a loss of 70 pence rather than 
140 pence, the pre-specified sequence lengths were wither 3, 4 or 5 moves long, and 
participants had to plan their sequence of moves in a 9 second period, and then enter all of 
their moves in under 2.5 seconds. Furthermore, the experiments within chapters 4 and 5 were 
carried out using a within-subjects design, meaning that the training was slightly shorter in 
the second week as participants needed less training.  
 
The initial ‘transition matrix’ training (including the end of training ‘test’) of week 1 was still 
the same as that used in chapters 3 and 6. However, this training phase was removed and 
replaced with the ‘end of training test’ in week two. In both weeks there was a second 
training session which was identical across weeks. This ‘reward matrix’ training involved 
participants having to learn that each move in the matrix was worth a win or loss of money. 
With each move, they could win £1.40 or 20p, or lose 70p or 20p, depending which move 
they made. Once again volunteers saw pluses or minuses at each box throughout the training 
and task (see figure 2.2, above), denoting the amount that could be won or lost by leaving that 
box. During training participants completed 10 of these trials without a time limit, and then 
completed 10 more which had time constraints. On the latter trials participants had 9 seconds 
to both look at the matrix and identify a sequence of moves of the length specified (3, 4 or 5 
moves), and then 2.5 seconds to enter their moves. If they were too slow here, they would 
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lose £2. This latter point ensured that participants always attempted to enter moves and 
enough data was acquired. This training remained the same from week 1 to week 2. 
 
Once the training was complete, participants played the game for real, which was exactly as 
the time-constrained training had been. The task included 90 trials: 30 of which the optimal 
sequence of transitions did not include a large punishment (termed non-large loss optimal 
(NLLO) trials), and the remaining 60 of which the optimal sequence of transitions did include 
a large punishment (termed large loss optimal (LLO) trials). From this, participants’ pruning 
behaviours were estimated using two variables: the difference between the proportion of trials 
on each trial type in which participants made the optimal sequence of moves, denoted as the 
‘difference estimate’; and the proportion of trials of type LLO in which participants did not 
make the optimal sequence of moves because it contained a large negative, and instead took 
the next best sequence of moves because it did not contain a large negative, termed the 
‘proportion best remaining’ score. Other variables of interest include the proportion optimal 
on each trial type, and at each depth, reaction times on each trial type, the number of trials 
missed (due to being to slow under time constraints) and the amount of money won 
(participants could win up to £20 at each session as compensation for their time which was 
added to the compensation for their time). Importantly participants were excluded from any 
analyses if they obtained a proportion optimal score of less than 40% on the NLLO trials, as 
this would indicate an inability to perform the task adequately. 
 
Unlike in chapters 3 and 6 (described above) no computational models were applied to the 
data for the task administered in either chapters 4 or 5 due to the fact that these models were 
not fully developed and as such could not yet adequately explain the data. Given more time 
our collaborators would have been able to complete these models, but due to time constraints 
they could not be applied to the data in chapters 4 or 5. 
 
2.4.2 Choice x Risk (CxR) – Rogers et al (2003), Chapters 3 and 5 
 
Participants completed 80 trials, each of which required them to make a choice between two 
gambles. They were paid according to their winnings, with each point won being converted to 
1 penny. Each gamble was represented as a histogram, the height of which conveyed the 
probability (0%, 25%, 50%, 75% or 100%) of winning or losing a number of points, the 
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amount of which was displayed at the top (in green) and bottom (in red) of the histogram, 
respectively (figure 2.3). 
 
 
	  
Figure	  2.3.	  Example	  trials	  from	  the	  CxR	  task	  showing	  the	  ‘control’	  gamble	  (left)	  consisting	  of	  a	  50%	  
chance	  of	  winning	  or	  losing	  10	  points,	  and	  the	  ‘experimental’	  gamble	  (right).	  Possible	  wins	  are	  in	  
green,	  and	  possible	  losses	  are	  in	  red	  
 
On each trial participants had to choose between the ‘control’ gamble, which consisted of a 
50% chance of winning or losing 10 points, and an ‘experimental’ gamble, which varied in 
terms of probability, high (75%) or low (25%) potential gains (80 or 20 points) and potential 
losses (80 or 20 points), resulting in eight trial types. These two gamble types appeared 
randomly on either the right or left hand side of the screen. The dependent measure here is 
the proportion of choices of the ‘experimental’ gamble over the control gamble. Within these 
8 trial types there are three main measures, specifically the proportion of choices of the 
experimental gamble over the control gamble as a function of 1) probability, 2) the size of 
expected gains and 3) the size of expected losses. These measures were calculated by 
measuring the difference between the proportion of experimental alternatives chosen when 
each of these three values were high, with the proportion of same choices when these values 
were low.  
 
2.4.3 Temporal Discounting – Pine et al (2009); Chapters 3 and 5 
 
Participants completed 220 trials, making hypothetical choices between options that varied in 
terms of the amount of money that could be gained and the delay associated with it. In 200 of 
these trials subjects were presented with 2 scenarios, one in which they would receive a 
smaller amount of money to be presented in the more immediate future, and one in which 
they would receive a larger amount of money in the more distant future (figure 2.4). The 
remaining 20 trials were ‘catch’ trials, and consisted of one scenario in which subjects could 
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receive a smaller amount of money presented in the more distant future, and one in which 
they would receive a larger amount in the more immediate future. These trials were 
administered to ensure that participants were engaged with the task. The choices ranged in 
magnitude (from £1 to £100) and delay (from 1 week to 1 year). Participants had to decide 
which of these scenarios they would rather experience, and were told to press left on a 
computer keyboard for the choice on the left, and right for the choice on the right.  
 
 
 
Figure	  2.4.	  Subjects	  had	  to	  choose	  between	  a	  smaller,	  more	   immediate	  reward	  (left	  side	  of	  blue	  
bar)	   and	   a	   larger	   but	   more	   delayed	   reward	   (right	   side).	   The	   amounts	   of	   money	   differed	   in	  
magnitude	  (£1	  to	  £100)	  and	  in	  delay	  (1	  week	  to	  1	  year).	  Subjects	  completed	  220	  trials,	  giving	  them	  
different	  scenarios	  each	  time	  
 
Critical to subjects’ choices in this task is the steepness of the discounting of expected reward 
values according to delay, denoted by V = D * U. Here, V is the subjective value (discounted 
utility) placed upon an expected, delayed reward; D is a reciprocal function of the delay of 
the reward, with each participant’s ‘temporal discount’ factor, k, ranging from 0 to 1; and U 
is a negative exponential function of the magnitude of the reward, incorporating a 
‘diminishing marginal utility’ parameter, r, that describes the concavity of the subject’s utility 
function. This latter function examines the extent to which participants differ on how much 
value they place upon an amount (i.e. £1) in a total (i.e. £100), with the assumption that £1 is 
worth more in a £2 total than it is in a £100 total.. A steep rate of temporal discounting 
(higher k) results in more choices for the smaller, more immediate option being made, while a 
more shallow rate would result in the opposite, to the point that a ‘flat’ discounting rate (k=0) 
would result in no discounting at all, leading subjects to always choose the larger, more 
delayed reward, no matter how long the wait or how small the increase in magnitude. As 
such, subjects’ choices were assessed in order to reveal the extent of discounting for both 
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magnitude and delay, and the best fitting parameter estimates for the discount rate (k) and 
utility concavity (r) were calculated. It is important to note that this modeling was performed 
by Dr Alex Pine (Weizmann Institute, Israel).  
 
2.5. Positron Emission Tomography; Chapter 3 
 
PET is a nuclear imaging technique which utilizes a radioactive compound (a molecule of 
interest bound to a radioactive tracer) that is introduced into the bloodstream in order to 
determine where it is taken up by the brain.  
 
Subjects within chapter 3 were injected with the radioactive isotope 11Carbon (11C) bound to 
the molecule CUMI. This radioligand is a competitive agonist that binds preferentially to 5-
HT1A receptors, but also provides a better estimate of specific receptor occupancy than other 
noncompetitive ligands which may themselves have both a lower affinity for these receptors, 
and a higher affinity for others (Milak et al, 2011). Critically, this ligand was also chosen due 
to its likelihood of being sensitive to displacement from 5-HT1A receptors by endogenous 5-
HT, in an analogous manner to 11C-raclopride’s displacement from D2/D3 receptors by 
dopamine (Montgomery et al, 2003). In other words, since CUMI can be displaced from 5-
HT1A receptors by 5-HT itself, it may provide a method of indexing serotonin release, in 
contrast to all other 5-HT receptor ligands, which are only able to asses binding. 
 
Subjects participated in two sessions, one of which included being administered 10mg 
placebo before 11C-CUMI, and the other of which included being administered 10mg an SSRI 
(citalopram) before the same ligand. The purpose of the placebo condition was to measure 
baseline 5-HT1A receptor binding values. The purpose of the citalopram condition was to 
image 5-HT release. In this condition, whilst 11C-CUMI binds to subjects’ 5-HT1A receptors, 
citalopram binds with high affinity to the 5-HTT. The latter point means that this transporter 
cannot fulfill its normal function of removing excess 5-HT from the synaptic cleft, 
theoretically resulting in increased 5-HT in the synaptic cleft relative to placebo. Increased 5-
HT availability in the synaptic cleft should result in increased binding to 5-HT receptors 
(including 5-HT1A), and in doing so results in the displacement of 11C-CUMI from the 5-
HT1A receptors. The resultant decrease in 11C-CUMI binding signal (relative to placebo) 
caused by this displacement then provides a measure of serotonin release. 
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Subjects underwent both conditions with at least 5 days between each (mean inter-scan 
interval=12.5 days). Participants underwent testing in a randomized double-blind design in 
which they received a slow 30 minute intravenous infusion of either citalopram (10mg) or 
placebo before injection of the 11C-CUMI, the latter of which was synthesized as described in 
Milak et al (2011).   
 
PET scans were acquired from a GE Discovery RX PET/CT scanner with an axial field of 
view of 15.7cm. 22 frames in total were acquired, each with 47 slices at 3mm thickness. The 
dynamic PET scans were acquired over 90 minutes. Time frames were of increasing duration: 
30 seconds pre-injection background, 1 x 15 seconds, 3 x 5 seconds, 1 x 30 seconds, 4 x 60 
seconds, 7 x 300 seconds, and 5 x 600 seconds. The dynamic scans were de-noised using a 
level 2, order 64 Battle Lemarie wavelet filter (Turkheimer et al, 1999). Head movement in 
the dynamic PET acquisition was corrected for using frame-by-frame realignment using a 
mutual information algorithm (Studholme et al, 1997).  
 
The whole-brain parametric images were acquired from the dynamic images using RPM 
(receptor parametric mapping) software using the SRTM (simplified reference tissue model; 
Lammerstma and Hume, 1996) method. Each subject’s parametric image from one condition 
was then co-registered to their parametric image from the other condition, and one image was 
subtracted from the other. The resultant difference (displacement) image was then spatially 
normalised to the PET template within SPM8 software (statistical parametric mapping 8; 
www.fil.ion.ac.uk/spm/software/spm8/), as was the image from the placebo condition. All 
images were then smoothed with an 8mm full-width at half maximum Gaussian kernel. 
Participants’ scores from each of the behavioural tasks (see 2.4.1.1, 2.4.2 and 2.4.3 above) 
were entered as second level covariates in analyses including 1) their placebo images and 2) 
their difference image to permit the calculation of correlations between their behaviour and 
baseline 5-HT1A binding, and between behaviour and the decrease in 5-HT1A binding 
(corresponding to 5-HT release) due to citalopram infusion, respectively.  
 
Due to the importance of the dorsal raphe nucleus in the 5-HT system, we also conducted a 
secondary region of interest (ROI) analysis in order to observe any potential correlations 
between 5-HT1A availability in this region with behaviour. This was done by using signal 
extracted from the bilateral dorsal raphe nucleus ROI that was manually defined as a fixed 
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sized region (648 mm3) on the summed PET images of each individual. These were each 
entered along with participants’ behavioural scores into the Statistical Package for Social 
Sciences (SPSS 19, SPSS Inc., Chicago, IL) and a Pearson’s r test of correlation was 
performed. We adopted a threshold of P<0.01 to adjust for the number of correlations 
conducted. 
 
2.6 Serotonergic Manipulation Techniques 
 
2.6.1 MDMA Administration; Chapter 4 
 
MDMA is a psychoactive drug, leading to symptoms such as euphoria and visual 
hallucinations that reach a peak at roughly 90-120 minutes, and subside roughly 2.5-3.5 hours 
later. Administration of MDMA has been shown to acutely (at the time of administration) 
increase 5-HT levels (Rudnick and Wall, 1992), and subacutely (that is, typically, after mood 
change has subsided) decrease them (Stone et al, 1986, Kish et al, 2000). It has also been 
shown both to increase, and subacutely decrease mood (Curran and Travill, 1997). As such, 
administration of MDMA was used here as a method of 5-HT depletion, by examining 
participants during the sub-acute period.  
 
Participants underwent administration of 100mg of MDMA or placebo (encapsulated 
ascorbic acid /vitamin-C) via injection into the antecubital vein, on acute day 1, and then the 
opposite on acute day 2 (at least one week later) in a within subjects, counterbalanced design. 
The same participants then returned 3 days later to participate in the behavioural testing 
session in which they performed the 3 behavioural tasks described in 2.4.1.1, 2.4.2 and 2.4.3 
above. No drug was administered on this day, so that the subacute effects of prior MDMA 
administration upon decision-making could be assessed.  
 
2.6.2 Acute Tryptophan Depletion (ATD); Chapter 5 
 
ATD is an experimental technique used in order to decrease levels of 5-HT’s precursor, the 
large neutral amino (LNAA) acid L-tryptophan (TRP). The synthesis of 5-HT within the 
brain is dependent on the availability of TRP, with the latter being firstly synthesised into 5-
hydroxy-l-tryptophan (5-HTP) by tryptophan hydroxylase (TPH), and then into 5-HT by 
aromatic-l-amino acid decarboxylase (DDC; figure 2.6). Whilst 5-HT cannot cross into the 
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brain through the blood-brain barrier (BBB), both TRP and 5-HTP can. This means that ATD 
can be achieved through administration of the other LNAAs (of which there are 5), excluding 
TRP, via either capsules, or, as in this thesis, a drink. All LNAAs compete for entry into the 
brain via the LNAA transporter at the BBB. This transporter is non–LNAA specific, and thus 
competition exists between the LNAAs for entry. Administering LNAAs without TRP 
decreases the TRP:LNAA ratio in the blood and cerebrospinal fluid (Crockett et al, 2012), 
and as such TRP’s competition increases, making ‘Acute Tryptophan Depletion’ something 
of a misnomer; this method actually increases levels of competing LNAAs, leading to a 
hypothesised decrease in levels of TRP (and thus 5-HT) in the brain (Crockett et al, 2012).  
 
Due to the fact that until recently, there has been no way in which to image 5-HT release in 
the living human brain (see Selvaraj et al, 2012), there has been no way to show ATD’s 
ability to decrease such a release. However, this method has been shown to reduce 5-HT 
levels in rodent brain tissue in vivo (Moja et al, 1989), reduces cortical 5-HT release in rats 
(Stancampiano et al, 1997), and has been shown Nishizawa et al (1997), using PET and the 
radiotracer α-11 C-methyl-tryptophan, to reduce 5-HT synthesis 5 hours after ATD. 
As such, this technique was used here in order to manipulate levels of 5-HT and examine the 
effect of this upon participants decision-making behaviours.  
 
 
	  
	  
Fig.	   2.6.	   The	   serotonin	   synthesis	   pathway.	   Tryptophan	   is	   converted	   in	   5-­‐Hydroxytrptophan	   by	  
Tryptophan	  Hydroxylase,	  which	  is	   itself	  then	  converted	  to	  Serotonin	  (5-­‐HT)	  by	  Aromatic-­‐L-­‐Amino	  
Acid	  Decarboxylase	  	  
 
The study in chapter 5 was a double-blind, within subjects design, and as such participant’s 
ingested either a tryptophan-depleted (TRP-) or sham-depletion (TRP+) mixture in week 1, 
and the converse in week 2 (for constituents, see table 2.1).  
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TRP - TRP +  
4.1g 4.1g L-alanine 
2.4g 2.4g L-glycine 
2.4g 2.4g L-histidine 
6g 6g L-isoleucine 
10.1g 10.1g L-leucine 
6.7g 6.7g L-lysine 
4.3g 4.3g L-phenylalanine 
9.2g 9.2g L-proline 
5.2g 5.2g L-serine 
4.9g 4.9g L-threonine 
5.2g 5.2g L-tyrosine 
6.7g 6.7g L-valine 
3.7g 3.7g L-arginine 
2g 2g L-cysteine 
2.3g 2.3g L-methionine 
0g 3g L-tryptophan 
  TOTAL 
  TRP- = 75.2g 
  TRP+ = 78.2g 
 
 
Table	  2.1.	  Constituents	  of	  amino	  acid	  mixtures	   ingested	  by	  participants.	  TRP	  –	   indicates	  mixture	  
without	  L-­‐tryptophan	  (intended	  to	  deplete	  volunteer’s	  tryptophan),	  whilst	  TRP	  +	  indicates	  mixture	  
with	  L-­‐tryptophan.	  These	  measurements	  were	  given	  to	  participants	  regardless	  of	  gender	  
 
The amino acid mixture was commercially mixed (Nutricia), coded according to a blinding 
protocol by another member of the laboratory who was otherwise not involved in the study 
(only unblinded after the final participant completed the study), and added to roughly 568ml 
(1 pint) of water, with either grapefruit, cherry vanilla, or lemon/lime flavouring to make the 
drink more palatable. The exact composition of amino acids was chosen based upon Roiser et 
al (2006) and Roiser et al (2007). Potential side-effects of the drink included nausea, which 
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two volunteers experienced and thus were withdrawn from the study (having completed only 
session 1).  
 
Participants also had their blood taken (6ml) before ingestion of the amino acid drink, and 5 
hours after ingestion (6ml again). Immediately after venepuncture, blood was centrifuged at 
3000rpm for 10 minutes, and then frozen at -80°C. All samples were sent to the Department 
of Biology and Biomedical Sciences at Oxford Brookes University for amino acid analysis 
for both levels of total tryptophan, and the ratio of large neutral amino acids to tryptophan. 
This analysis was performed by Dr Michael Franklin of Faculty of Life Sciences, Oxford 
Brookes University.  
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3) DECISION-MAKING AND THE 5-HT1A RECEPTOR: A POSITRON 
EMISSON TOMOGRAPHY STUDY 
 
3.1 Introduction 
 
3.1.1 The 5-HT1A receptor and decision-making 
 
The 5-HT1A receptor is an inhibitory G-coupled protein receptor found on the axon, soma and 
dendrites of serotonergic neurons. 5-HT1A receptors exist within the dorsal raphe nucleus (the 
origin of the brain’s 5-HT system) as autoreceptors, where they respond to 5-HT released by 
the neurons in whose membranes they are embedded, and in projection sites throughout the 
rest of the cortex as heteroreceptors, where they respond to 5-HT released by adjacent 
neurons. These 5-HT1A receptors are the most widespread of all 5-HT receptors, and are 
found in high numbers within the raphe nuclei, hippocampus, amygdala, basal ganglia and 
thalamus, as well as throughout the cortex (Hannon and Hoyer, 2008). In the raphe, 5-HT1A 
autoreceptors play a critical role in 5-HT transmission, dampening down the firing of 5-HT 
neurons via an inhibitory feedback loop (Blier et al, 1998). 
 
As discussed in the introduction, 5-HT is thought to influence numerous cognitive processes, 
in particular decision-making (e.g. Dayan and Huys, 2008, Seymour et al, 2012, Crocket et 
al, 2012). The 5-HT1A receptor may play an important role in this influence, with animal 
studies having also provided support for this: Miyazaki et al (2012) demonstrated that 
selective injection of the 5-HT1A receptor agonist 8-OH-DPAT into the dorsal raphe, which 
decreases 5-HT neuron firing rates, increased rats’ number of waiting errors for delayed 
rewards but not immediate rewards on a temporal discounting paradigm. Similarly Carli and 
Samanin (2000) reported that administration of 8-OHDPAT into the raphe both depleted 
forebrain 5-HT by 90% and increased rats’ discounting of future rewards based upon their 
temporal delay. Conversely, Cervantes et al (2009) reported that impulsive choice behaviours 
in adult male hamsters were reduced following systemic 5-HT1A agonist administration. The 
results of Carli and Samanin (2000) and Cervantes et al (2009) are thus complimentary due to 
the fact that the administration of 8-OH-DPAT into the raphe in the former study decreases 
transmission at the 5-HT1A autoreceptors in this region, whilst systemic agonist 
administration in the latter increases transmission at the 5-HT1A heteroreceptors throughout 
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the cortex. However, Liu et al (2004) reported that rats systemically injected with the 5-HT1A 
receptor agonist buspirone at different doses (0.5, 1 and 2mg/kg) showed different effects 
upon temporal discounting depending on the dosing schedule, with acute buspirone dose-
dependently increasing discounting, but chronic administration (over a 65 day period) 
reversing this pattern (decreasing discounting compared to baseline) at a dose of 1mg/kg. 
Further, these effects of buspirone were reversed by administration of the 5-HT1A receptor 
antagonist WAY-100635.  
 
Further, human studies of genetic polymorphisms have also provided support for an influence 
of 5-HT1A receptors upon decision-making: Schmitz et al (2009) showed that participants 
who were homozygous for the 5-HT1A C(-1019) G polymorphism, which is linked to 
increased expression of 5-HT1A receptors (Czesak et al, 2012), exhibited both increased 
reaction times to potential rewards and decreased reaction times to potential punishments. 
Further, Gu et al (2013) report that schizophrenia patients with rs6295 polymorphisms in the 
HTR1A gene (which encodes the 5-HT1A receptor) performed poorly on the ‘ambiguity’ 
trials of the IGT compared to controls, and Benko et al (2010) showed that healthy volunteers 
who were homozygous for the same polymorphism displayed significantly higher 
impulsiveness on both the  impulsive subscale of the Eysenck impulsiveness, 
venturesomeness and empathy scale and the Barratt impulsiveness scale compared to 
heterozygotes and those without the polymorphism. Finally, Chamberlain et al (2007) 
reported no effects of administration of either 20mg or 30mg of buspirone upon impulsive 
responding in healthy human volunteers. The results of this latter study are in direct 
contradiction to those of Liu et al (2004) above, yet it must be noted that the task used in 
Chamberlain et al was the stop-signal task from the CANTAB rather than a test of temporal 
discounting. As such, whilst some studies into the effect of the 5-HT1A receptor in decision-
making and impulsivity using human participants have been performed, this area remains 
largely unexplored. 
 
3.1.2 The role of the striatum and hippocampus’ in decision making 
 
Many brain regions innervated by 5-HT have been implicated in decision making, in 
particular the striatum, which has long been thought to play a central role in reward 
processing (e.g. Delgado et al, 2000, Kable and Glimcher, 2007, Pine et al, 2009; see Robbins 
and Everitt, 1996 and Everitt et al, 1999 for a review of the striatum’s role in the processing 
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of rewards, and Cardinal et al, 2004 for a review of the role of the striatum in delayed 
reinforcements and temporal discounting).  
 
Other studies highlight a specific role for 5-HT in the striatum in both reward and punishment 
processing. For example, Seymour et al (2012) used a decision-making task that permitted 
examination of the effects of rewards and punishments separately to show that 
pharmacologically decreasing levels of 5-HT through ATD altered the exchange rate by 
which rewards and punishments were compared, leading to an attenuation of the subjective 
representation of reward value, linked to an increase in haemodynamic responses in parts of 
the striatum and prefrontal cortex. Further, McCabe et al (2010) have highlighted the effect of 
SSRIs upon the neural processing of rewards and punishments within the striatum. Here, the 
authors administered citalopram for 7 days, and discovered that it reduced activation to 
appetitive stimuli (chocolate) in the ventral striatum whilst reboxetine (a selective 
norepinephrine uptake inhibitor) had no such effect. Further, Abler et al (2012) report that 
administration of the SSRI paroxetine bilaterally decreased activation within the nucleus 
accumbens during the processing of rewards (erotic videos). Finally, Tanaka et al (2007) 
administered ATD to participants who were performing a temporal discounting paradigm, 
and discovered that participants displayed activity within the ventral striatum that correlated 
with reward prediction at shorter time scales, which was stronger at low levels of 5-HT, and 
displayed activity in the dorsal striatum during the prediction of rewards at longer time 
scales, which was stronger at higher levels of 5-HT.  
 
The hippocampus has also been implicated in decision making due to its role in contextual 
punishment processing in experimental animals. For example, Fanselow and Dong (2010) 
showed that rats with hippocampal lesions have a deficit in fear processing in a tone-shock 
association paradigm, but only when the context changed. It has also been argued that 
hippocampal place cells provide spatial evaluation functions that are involved in the planning 
and representation of location with goal proximity (e.g. Viard et al, 2011) in order to provide 
a basis for appropriate choice selection. Importantly, in humans Camara et al (2008) showed 
increased coupling between the ventral striatum and regions of the amygdala and 
hippocampus during the processing of gains and losses. Work on human participants has 
argued that the hippocampus and parahippocampal gyrus play a crucial role in the formation 
of past, present and future episodic representations (Schacter and Addis, 2009); and Peters 
and Buchel (2010) suggest that decision-making within a temporal discounting paradigm 
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depends on the subjective capacity for future episodic thought, with this ‘mental time travel’ 
(self-projection into the future) involving the hippocampus.  
 
Research is beginning to highlight the involvement of 5-HT in the relationship between the 
hippocampus and decision-making. Acute tryptophan depletion (ATD) is associated with 
lower performance on hippocampal-dependent episodic memory tasks (Riedel et al, 1999), 
which is argued to be due to a resultant decreased activation of excitatory 5-HT receptors 
(Meeter et al, 2006). Further, 5-HT has also been linked with the hippocampus’ potential role 
in temporal discounting: Mobini et al (2000) reported that rats whose 5-HT systems had been 
destroyed with 5,7-dihydroxytryptamine became more impulsive and exhibited increased 
choosing of smaller, sooner rewards in a temporal discounting paradigm, which correlated 
with a decrease of 5-HT in the hippocampus. However, little work has attempted to link 5-HT 
transmission in the hippocampus to decision-making in humans.  
 
3.1.3 Present study and predictions 
 
In order to assess the hypothesis that transmission at the 5-HT1A receptor plays an important 
role in decision making, we measured individual differences in regional binding of this 
receptor by using PET and correlated this with participants’ performance on three decision-
making tasks at a separate testing session. 
 
Initially, Selvaraj et al (2012) administered 11C-CUMI-101, a partial agonist of the 5-HT1A 
receptor, before either a placebo, or citalopram. The former allowed the researchers to 
observe baseline 5-HT1A receptor binding, whilst the latter allowed the assessment of 5-HT 
release (see experimental methods chapter 2.6.1). For this first section of the study, it was 
predicted that citalopram infusion would lead to increased 5-HT within the brain and thus 
decreased binding of CUMI to the 5-HT1A receptors, due to increased binding of endogenous 
5-HT to these receptors throughout the cortex.  
 
On a separate testing session, we administered the pruning task described in 2.4.1, the 
gambling task described in 2.4.4 and the temporal discounting paradigm presented in 2.4.5. 
Participants scores were then entered as second-level covariates in an SPM analysis in order 
to observe any correlation between performance on these tasks and both baseline 5-HT1A 
availability, and the change in such availability due to citalopram infusion. 
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It is important to note that PET scans (to observe both the baseline and the change in 5-HT1A 
receptor availability due to citalopram infusion) were performed by Selvaraj et al (2012), 
whilst the separate behavioural session, in which the 3 cognitive tasks were administered, 
was carried out by me, as was the subsequent statistical analysis in which participants’s 
scores were correlated with their 5-HT1A availability. 
 
With regards to participants’ baseline PET scans, it was predicted (based on theory and 
previous findings) that participants with low levels of 5-HT1A (heteroreceptor) availability in 
projection sites would display decreased pruning (based on Dayan and Huys, 2008 and Huys 
et al, 2012), decreased sensitivity to rewards and probabilities on the gambling task (as 
elicited with acute tryptophan depletion: Rogers et al, 2003 and Rogers et al, 1999), and 
increased discounting (as elicited with acute tryptophan depletion: Schweighofer et al, 2008). 
It was also predicted that participants with low levels of 5-HT1A (autoreceptor) availability 
within the dorsal raphe nucleus would have attenuated inhibition of 5-HT firing within the 
raphe, and therefore increased release in projection sites, and thus higher levels of pruning, 
greater sensitivity to rewards and probabilities on the gambling task, and decreased 
discounting.  
 
With regards to participants’ citalopram-induced change in 5-HT1A receptor availability 
within projection sites, it was predicted that participants with low levels of 5-HT release 
would display low levels of pruning, poorer sensitivity to rewards and probabilities, and 
increased discounting.  
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3.2 Methods 
 
3.2.1 Participants 
 
Fifteen participants (13 males, mean age 50.9 years, range 35-63 years) were recruited via the 
website www.gumtree.com. Of these 15 participants, all underwent a PET scan in the placebo 
condition, and 13 underwent a scan in the citalopram condition. Scanning took place at the 
Cyclotron Unit at the Hammersmith Hospital campus of Imperial College London. All 
participants completed the behavioural session at the Institute of Cognitive Neuroscience, 
University College London. Participants were free of any psychiatric disorders, as determined 
by assessment on the MINI, HAM-D, BDI and STAI at the behavioural session. None of the 
participants had taken any psychotropic medication in the 12 months prior to participating, 
nor had they any previous history of alcohol/substance dependence. Informed written consent 
was obtained from all participants at both scan and behavioural sessions, and ethical approval 
was obtained from the Hammersmith, Queen Charlotte’s and Chelsea Hospitals Research 
Ethics committee for the PET scan and from the UCL ethics committee for the behavioural 
testing.  
 
3.2.2 Procedure 
 
Participants arrived for their PET sessions at the Hammersmith Hospital at 9am, with 
scanning commencing at 11am for all participants at all sessions. Participants were scanned 
with at least 5 days between their sessions (mean inter-scan interval = 12.5 days). Participants 
were injected with either 10mg of placebo (saline) or citalopram 45 minutes before injection 
of the radioligand. This dose of SSRI was chosen as it has been shown to produce robust and 
lasting release of anterior pituitary hormones, which is considered to be a marker of 
activation of 5-HT pathways (Hinz et al, 2008 and Attenburrow et al, 2001). For details of the 
PET analysis methods, refer to chapter 2, section 2.5. Participants were compensated £50 for 
their time and effort during these scans. Details of the scanning procedure can be seen in 
Selvaraj et al (2012). 
 
Participants arrived for their behavioural sessions (on a separate day to the PET session) at 
either 9am, or 1pm, depending on allocation. They performed the three tasks, in a counter-
balanced, randomized order. The pruning task, however, was always administered first. 
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Participants were compensated for their time and effort in this portion of the study. This 
included receiving £20 to compensate for travel and time, and up to £10 on 2 of the 3 
cognitive tasks, depending on performance, meaning each volunteer was compensated 
between £20 and £50 for this session.  
 
3.2.3 Statistical Analyses  
 
Our primary analyses were conducted using the whole-brain parametric PET images 
presented in Selvaraj et al (2012), using SPM8 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm8/) using MATLAB software 
(http://www.mathworks.co.uk/products/matlab/). Participants’ scores from each of the four 
behavioural tasks (pruning task, choice x risk, temporal discounting and the Pavlovian to 
Instrumental-Transfer (PIT) – see experimental methods, chapter 2), were entered as second 
level covariates in analyses involving both their placebo PET images, and their difference 
images (calculated as the difference between binding in the placebo and citalopram 
conditions), in order to identify correlations between performance on the tasks and both their 
baseline 5-HT1A availability, and the change in 5-HT1A binding due to citalopram infusion, 
respectively.   
 
We corrected for multiple comparisons, controlling the family-wise error rate. We were 
particularly interested in relationships between 5-HT1A availability and behaviour in the 
striatum and hippocampus, and as such created specific a striatal mask (containing the nucleus 
accumbens, putamen and pallidum only, due to very low binding values within the caudate) 
and a hippocampal mask (including the parahippocampal gyrus to make a hippocampal 
complex mask). These masks were defined using the HamNET Atlas, and applied to constrain 
the search volume to adjust the correction for multiple comparisons.  
 
Due to the importance of the dorsal raphe nucleus in the 5-HT system we also conducted a 
secondary analysis in order to observe correlations between 5-HT1A availability in this region 
and participants’ behaviour. This was done by using signal extracted from a bilateral dorsal 
raphe nucleus ROI that was manually defined as a fixed sized region (648 mm3) on the 
summed PET images of each individual. These were each entered along with participants’ 
behavioural scores into the Statistical Package for Social Sciences (SPSS 19, SPSS Inc., 
Chicago, IL) and a Pearson’s r test of correlation was performed.  
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3.3 Results 
 
3.3.1 5-HT1A receptor binding 
 
Table 3.1 and Figure 3.1 summarize the regions of citalopram-induced change in 5-HT1A 
receptor binding as shown by the whole-brain analysis. The direction of this change in 5-
HT1A receptor binding was surprising due to the fact that CUMI-binding was increased, 
implying decreased 5-HT release due to citalopram infusion, which was opposite to the 
direction predicted. The regions displaying change are consistent with those from the region 
of interest analyses reported in Selvaraj et al (2012), especially with respect to the frontal and 
temporal lobes, hippocampus bilaterally and the cingulate gyrus. Importantly, no effect was 
detected in any region at P < .001, uncorrected, for the opposite contrast (i.e. in the direction 
to that was predicted). The raphe nucleus (midbrain) did show a non-significant (P>.05, 
uncorrected) numerical decrease in CUMI binding however (dorsal raphe CUMI-binding 
mean (SD) in the placebo condition = 1.66 (0.28), and mean (SD) in the citalopram condition 
= 1.61 (0.30), t[12] = 0.57, P = 0.58).  
 
Region Cluster size Z score X Y Z 
Angular gyrus (L) 
Lateral Orbital gyrus (L) 
Isthmus cingulate gyrus (R) 
Medial frontal gyrus (R) 
Putamen (R) 
Medial frontal gyrus (R) 
Superior frontal gyrus (L) 
Cingulate gyrus (R ) 
Precentral gyrus (R) 
Hippocampus (R) 
Postcentral gyrus (R) 
Putamen (L) 
Superior temporal gyrus R 
Superior frontal gyrus (L) 
Internal capsule (L) 
347 * 
509 * 
326 * 
5187 * 
221 * 
50 
832 * 
308 * 
434 * 
517 * 
33 
291 * 
422 * 
71 
61 
5.15 * 
5.02 
4.99 
4.97 
4.44 
4.4 
4.36 
4.33 
4.25 
4.19 
4.17 
4.16 
4.12 
3.9 
3.89 
-26 
-28 
8 
48 
20 
18 
-20 
12 
54 
18 
36 
-20 
72 
-14 
-20 
-66 
40 
-52 
26 
8 
10 
30 
-42 
-10 
-12 
-44 
14 
-18 
-8 
-24 
34 
-18 
14 
32 
16 
42 
34 
30 
44 
8 
74 
2 
-8 
64 
-4 
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Supramarginal gyrus (L) 
Hippocampal commissure (L) 
Inferior temporal gyrus (R) 
Entorhinal cortex (R) 
Medial temporal gyrus (R) 
Entorhinal cortex (L) 
Inferior temporal gyrus (L) 
Occipital gyri (L) 
Medial frontal gyrus (R) 
Medial frontal gyrus (R) 
Supramarginal gyrus (R) 
Medial temporal gyrus (R) 
Postcentral gyrus (R) 
Superior frontal gyrus(R) 
Superior frontal gyrus (L) 
Medial temporal gyrus (R) 
 
66 
142 
162 
86 
33 
155 
21 
29 
29 
49 
29 
54 
22 
20 
69 
21 
 
3.87 
3.84 
3.82 
3.76 
3.7 
3.68 
3.68 
3.66 
3.61 
3.57 
3.57 
3.52 
3.51 
3.47 
3.42 
3.33 
 
-40 
-6 
52 
8 
56 
-10 
-44 
-22 
34 
44 
28 
66 
52 
10 
-18 
42 
 
-46 
-36 
6 
-8 
-32 
8 
-46 
-82 
-10 
-10 
-56 
-32 
-22 
-10 
14 
-66 
 
28 
20 
-48 
-44 
-26 
-26 
-12 
-14 
44 
62 
28 
18 
48 
80 
48 
22 
 
 
Table	   3.1.	   Table	   summarizing	   the	   whole-­‐brain	   analysis	   denoting	   regions	   of	   change	   in	   5-­‐HT1A	  
receptor	  binding	  from	  the	  contrast	  citalopram-­‐placebo,	  the	  size	  of	  clusters	  in	  voxels	  and	  the	  peak	  
co-­‐ordinates	  in	  MNI	  space.	  Asterisks	  indicate	  where	  an	  effect	  survives	  whole-­‐brain	  correction	  for	  
multiple	   comparisons	   at	   the	   cluster	   level	   (Cluster	   size	   column)	   or	   voxel	   level	   (Z	   score	   column).	  
Images	  were	  initially	  thresholded	  at	  P	  <	  .001,	  uncorrected,	  minimum	  cluster	  size	  20	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Figure	   3.1.	   Statistical	   Parametric	   Map	   indicating	   citalopram-­‐induced	   change	   in	   5-­‐HT1A	   receptor	  
binding	  within	  brain	  regions	  (citalopram	  condition	  –	  placebo	  condition	  contrast,	  thus	  indicating	  an	  
increase	   in	  CUMI	  binding).	  Whole-­‐brain	  analysis	  presented	  at	  p	  <	   .001,	  uncorrected.	  Colour	  bars	  
denote	  t-­‐values	  
 
3.3.2 Relationship between 5-HT1A receptor binding and behaviour 
 
Scores on each of the task variables were added as 2nd level covariates into SPM in order to 
identify correlations between both baseline 5-HT1A receptor availability, and the change in 
such availability due to citalopram infusion, and performance on the tasks. Results of these 
2nd level analyses can be seen in table 3.2 below.  
 
 
Task	  (Variable)	   Condition	   Direction	   Region	   Cluster	  size	   Z	  value	   X	   Y	   Z	  
Pruning	  (Specific)	  	   Change	   Positive	   Inferior	  Temporal	  Gyrus	  (L)	   10	   3.35	   -­‐40	   -­‐64	   -­‐4	  
	   	   	   Medial	  Temporal	  Gyrus	  (R)	   12	   3.28	   54	   -­‐76	   6	  
CxR	  (Win)	   Baseline	   Positive	   Occipital	  Gyrus	  (R)	   22	   3.52	   14	   -­‐58	   16	  
	   	   Negative	   Medial	  Temporal	  Gyrus	  (L)	   11	   3.91	   2	   -­‐28	   -­‐4	  
CxR	  (Loss)	   Baseline	   Positive	   Inferior	  Temporal	  Gyrus	  (R)	   15	   3.41	   42	   -­‐62	   0	  
	   	   	   Inferior	  Temporal	  Gyrus	  (L)	   32	   3.34	   -­‐54	   -­‐32	   -­‐36	  
	   	   Negative	   Inferior	  Temporal	  Gyrus	  (L)	   29	   3.92	   -­‐10	   -­‐50	   36	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CxR	  (Loss)	   Change	   Positive	   Inferior	  Temporal	  Gyrus	  (L)	   19	   4.08	   -­‐44	   -­‐12	   -­‐32	  
	   	   	   Medial	  Temporal	  Gyrus	  (L)	   56	   4.06	   -­‐30	   26	   58	  
	   	   	   Parietal	  Operculum	  (R)	   29	   4.01	   44	   -­‐36	   26	  
	   	   	   Nucleus	  Accumbens	  (R)	   23	   3.88	  *	   10	   18	   0	  
	   	   	   Medial	  Frontal	  Gyrus	  (R)	   20	   3.55	   46	   20	   56	  
	   	   	   Inferior	  Temporal	  Gyrus	  (R)	   12	   3.47	   42	   -­‐46	   -­‐12	  
	   	   	   Piriform	  cortex	  (R)	   23	   3.36	   26	   0	   -­‐10	  
CxR	  (Prob.)	   Baseline	   Positive	   Perirhinal	  Cortex	  (L)	   55	   4.06	   -­‐10	   4	   -­‐36	  
	   	   	   Perirhinal	  Cortex	  (R)	   292	  	   3.87	  *	   18	   6	   -­‐38	  
CxR	  (Prob.)	   Change	   Positive	   Brainstem	   25	   4.15	   6	   -­‐16	   -­‐40	  
Temp.	  Disc.	  (K)	   Baseline	   Negative	   Parahippocampal	  (L)	   411	  	   4.24	  *	   -­‐26	   -­‐14	   -­‐42	  
	   	   	   Paracentral	  Lobule	  (L)	   23	   4.00	   -­‐16	   -­‐42	   46	  
	   	   	   Striate	  Area	  (L)	   49	   3.54	   -­‐8	   -­‐88	   8	  
	   	   	   Inf.	  Temporal	  Gyrus	  (R)	   31	   3.29	   46	   -­‐44	   -­‐34	  
	   	   	   Occipital	  Gyrus	  (R)	   15	   3.26	   26	   -­‐88	   -­‐6	  
	   	   	   Fusiform	  Gyrus	  (R)	   16	   3.21	   40	   -­‐18	   -­‐46	  
Temp.	  Disc.	  (K)	   Change	   Positive	   Sub	  thalamic	  nucleus	  (R)	   56	   4.10	   6	   -­‐16	   -­‐12	  
	   	   	   Inferior	  frontal	  gyrus	  (R)	   28	   3.83	   56	   26	   -­‐16	  
	   	   	   Parahippocampal	  gyrus	  (L)	   13	   3.40	   -­‐12	   -­‐30	   -­‐20	  
Temp.	  Disc.	  (r)	   Baseline	   Positive	   Lateral	  Sup.Frontal	  Gyrus	  (L)	   24	   3.71	   -­‐34	   40	   50	  
Temp.	  Disc.	  (r)	   Change	   Positive	   Medial	  frontal	  gyrus	  (R)	   27	   3.65	   40	   38	   26	  
	   	   	   Superior	  Frontal	  Gyrus	  (L)	   32	   3.61	   -­‐12	   32	   40	  
	  
Table	   3.2.	   Results	   of	   the	   covariate	   analyses.	   All	   images	   were	   initially	   thresholded	   at	   P<.001,	  
uncorrected.	   Asterisks	   denote	   correlations	   that	   survived	   small	   volume	   correction	   for	   multiple	  
comparisons	  
 
3.3.2.1 Pruning  
 
3.3.2.1.1 Behavioural Analysis 
 
Eight models were applied to the data in order to explain participants’ choices, which are 
explained in 2.4.1.1. Figures 3.2 and 3.3 show the results of these models, each of which have 
been compared using the BIC method. Each of the four models with the ‘rho’ parameter (that 
examines participants’ sensitivity to each of the four transition types) was increasingly better 
at explaining the data, even after being penalized for its added complexity. Furthermore, 
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when this parameter was added to each model, it significantly increased each model’s ability 
to explain participant’s choices. Figures 3.2 and 3.3 show that the model including the 
separate pruning parameters (general and specific pruning) along with the Pavlovian and loss 
aversion components ((rho) Prun. & Pav.) was the most parsimonious, supporting the 
presence of pruning in this sample.  
 
 
	  
Figure	   3.2.	   Results	   of	   BIC	  model	   comparison.	   The	   top	   four	  models	   are	   presented	   in	   descending	  
order	  of	  complexity,	  as	  are	  the	  bottom	  four	  (bottom	  four	  without	  rho	  parameter).	  Model	  pruning	  
and	  Pavlovian	  with	   the	  rho	  parameter	  provided	  the	  most	  parsimonious	  model.	  There	   is	  decisive	  
evidence	  in	  favour	  of	  the	  most	  complex	  model	  (log10	  BIC	  difference>10)	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Figure	   3.3.	   Predictive	   probabilities	   for	   each	   of	   the	   4	   models.	   This	   table	   shows	   that	   the	   most	  
parsimonious	  model	  from	  table	  3	  (rho	  Prun.	  &	  Pav.)	  was	  best	  at	  predicting	  participants’	  choices	  
 
3.3.2.1.2 Correlation of specific pruning scores with PET data 
 
From the SPM voxel-wise analyses, no relationship between the specific pruning parameter 
(γS ) and baseline (placebo) 5-HT1A receptor availability was detected, even at a threshold of 
P < .001, uncorrected. However, the specific pruning vs citalopram-induced change in 5-
HT1A availability contrast revealed positive correlations, though these did not survive 
correction for multiple comparisons. Table 3.2 summarizes the regions evident in this 
analysis.  
 
The small volume correction applied to the data revealed no suprathreshold clusters.  
 
3.3.2.2 Choice x Risk 
 
3.3.2.2.1 Behavioural analysis 
 
Participants chose the ‘experimental’ gamble significantly more often when its probability of 
winning was higher (t[14] = 15.0, p < 0.001), when the amount they could win was higher 
(t[14] = 2.9, p = .011) and when the amount they could lose was lower (t[14] = 3.0, p = .009). 
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The mean sensitivity to wins was 0.110 (SD 0.147), the mean sensitivity to losses 0.115 (SD 
0.146) and mean sensitivity to probability was 0.694 (SD 0.180).  
 
3.3.2.2.2 Correlation of sensitivity to wins, losses and probabilities with PET data 
 
No correlations between sensitivity to win and 5-HT1A availability survived correction for 
multiple comparisons (table 3.2). 
 
The correlation of loss sensitivity with the change in 5-HT1A availability due to citalopram 
infusion produced positive correlations detected at a threshold of P < .001 (table 3.2). The 
small volume correction that was applied to the data revealed two positive correlations from 
the contrast of sensitivity to loss with the change in 5-HT1A binding due to citalopram 
infusion, although only the former survived correction for multiple comparisons; right 
nucleus accumbens ([x = 10, y = 18, z = 0], cluster size = 19, Z = 3.88, PSVC = .038; figure 
3.2), and the right putamen ([x = 26, y = 0, z = -8]), cluster size 3, Z = 3.30, PSVC = .183). 
This indicates that greater sensitivity to information pertaining to losses was linked with 
increased 5-HT1A availability (which indicates decreased citalopram-induced 5-HT release) in 
the right nucleus accumbens following citalopram infusion (figure 3.2). 
 
          
 
Figure	   3.2.	   Left:	   SPM	   image	   depicting	   the	   change	   in	   11C-­‐CUMI	   binding	   within	   the	   right	   nucleus	  
accumbens	   ROI	   that	   positively	   correlates	   with	   participants’	   sensitivity	   to	   loss	   in	   the	   change	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condition	  (10,	  18,	  0,	  small	  volume	  correction	  analysis	  presented	  at	  PSVC	  =	  .038).	  Right:	  Scatterplot	  
of	   correlation.	   This	   correlation	   shows	   that	   those	   participants	   who	   were	   more	   sensitive	   to	  
information	   pertaining	   to	   loss	   also	   displayed	   greater	   increase	   in	   5-­‐HT1A	   receptor	   availability	  
(indicative	   of	   decreased	   5-­‐HT	   release)	   within	   the	   right	   nucleus	   accumbens	   due	   to	   citalopram	  
infusion	  	  
 
The correlation of probability sensitivity with the baseline 5-HT1A availability produced only 
positive correlations; both in the perirhinal cortex detected at a threshold of P < .001 (table 
3.2). 
 
The small volume correction that was applied to the data revealed correlations between 
baseline 5-HT1A availability in these regions bilaterally, though only the correlation in the 
right survived correction for multiple comparisons; (right; [x = 20, y = 0, z = -38], cluster size 
= 45, Z = 3.63, PSVC = .028, figure 3.3, left). This indicated that greater sensitivity to 
information pertaining to the probability of winning was linked with higher baseline 5-HT1A 
receptor availability. 
 
             
 
Figure	   3.3.	   Left:	   Statistical	   Parametric	  Map	   (SPM)	   depicting	   11C-­‐CUMI	   binding	   at	   baseline	  within	  
the	   right	   hippocampal/parahippocampal	   ROI	   that	   positively	   correlates	   with	   participants’	  
sensitivity	   to	   probability	   (20,	   0,	   -­‐38,	   small	   volume	   correction	   analysis	   presented	   at	   PSVC	   =	   .028).	  
Right:	  Scatterplot	  of	  correlation	  between	  participants’	  sensitivity	  to	  probability	  and	  baseline	  11C-­‐
CUMI	   binding	   within	   this	   cluster.	   This	   correlation	   shows	   that	   those	   participants	   who	   showed	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greater	   sensitivity	   to	   information	   pertaining	   to	   probability	   had	   greater	   baseline	   5-­‐HT1A	   binding	  
within	  the	  right	  hippocampal	  complex	  	  
  
The correlation of sensitivity to probability with the change in 5-HT1A availability due to 
citalopram infusion produced only a positive correlation detected at a threshold of P < .001 
(table 3.2). 
 
3.3.2.3 Temporal Discounting 
 
3.3.2.3.1 Behavioural Analysis 
 
All participants were found to be concentrating sufficiently on the task as they all chose the 
larger-sooner reward on above 90% of the 20 catch trials (mean 19.4, SD 0.83). On average 
participants chose the sooner, smaller option over the later option (mean 119.2, SD 48.05) 
times (out of 200).  
 
Using the model of best fit from Pine et al (2009) it was shown that participants discounted 
the value of future rewards (mean k = 0.099, SD = 0.057) and also exhibited a concave utility 
function (mean r = 0.0086, SD = 0.017), comparable to results reported previously on this 
task (Pine et al, 2009).  
 
3.3.2.3.2 Correlation of k values (discount factor) with PET data 
 
The correlation of k values (discount factor) with baseline 5-HT1A availability produced 
negative correlations detected at a threshold of P < .001, (table 3.2). The small volume 
correction applied to the data revealed a significant negative correlation that survived 
correction for multiple comparisons in the left parahippocampal gyrus ([x = -26, y = -14, z = -
36], cluster size 14, Z = 3.54, PSVC = .037; figure 3.4). This indicates that a lower discounting 
(i.e. an increased choosing of the larger, later rewards) was linked to higher baseline 5-HT1A 
receptor availability. 
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Figure	   3.4.	   Left:	   SPM	   image	   depicting	   baseline	   11C-­‐CUMI	   binding	   within	   the	   left	  
hippocampal/parahippocampal	  ROI	  that	  negatively	  correlates	  with	  participants’	  discount	  factor	  (-­‐
26,	   -­‐14,	   -­‐36,	   small	   volume	   correction	   analysis	   presented	   at	   PSVC	   =	   0.037).	   Right:	   Scatterplot	   of	  
correlation	  between	  discount	   factor	   and	  baseline	  5-­‐HT1A	   receptor	   availability	  within	   this	   cluster.	  
This	  correlation	  indicates	  that	  those	  participants	  who	  displayed	  increased	  discounting	  of	  rewards	  
based	  upon	   their	   temporal	  delay	  had	  decreased	  baseline	  5-­‐HT1A	   receptor	  binding	  within	   the	   left	  
hippocampal	  complex	  
 
The correlation of k values with the change in 5-HT1A availability due to citalopram infusion 
produced only positive correlations detected at a threshold of P < .001  (table 3.2). The small 
volume correction applied to the data revealed a positive correlation in the left putamen, 
however this did not survive correction for multiple comparisons ([x = -20, y = 14, z = -6], 
cluster size 8, Z = 3.30, PSVC = .175). 
 
3.3.2.3.3 Correlation of r values (utility concavity) 
 
No correlations between participants’ utility concavity and 5-HT1A availability survived 
correction for multiple comparisons (see table 3.2).  
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3.3.3 Relationship between 5-HT1A receptor binding in the dorsal raphe nucleus and 
behaviour 
 
Due to the importance of the dorsal raphe nucleus in the 5-HT system, a secondary analysis 
was also conducted, in which signal was extracted from a manually defined fixed size region 
(648 mm3) on the summed PET image of each participant, and correlated (using a Pearson’s r 
test of correlation) with variables from each of the above behavioural tasks. No significant 
correlations were observed (all P > .2). 
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3.4 Discussion 
 
3.4.1 Citalopram challenge 
 
The results of the citalopram challenge upon 5-HT1A availability were surprising. It was 
originally hypothesized that, relative to placebo, citalopram infusion would lead to increased 
synaptic 5-HT (due to reuptake blockade) and thus decreased CUMI binding (due to 
displacement) in all brain regions. However, the inverse was found, with CUMI-5-HT1A 
receptor binding numerically (but not significantly) decreasing within the raphe, and 
increasing significantly in projection sites.  
 
One explanation for these unexpected effects relates to effects mediated at 5-HT1A 
autoreceptors: activation of the 5-HT1A receptors in the dorsal raphe has been demonstrated to 
inhibit both the firing of serotonin neurons and 5-HT release within the prefrontal cortex 
(Stockmeier et al, 1998). If citalopram increased the extracellular availability of 5-HT, and 
thus the binding to the 5-HT1A autoreceptors in the raphe, this would then lead to decreased 5-
HT firing in this region, and thus increased CUMI binding to the 5-HT1A heteroreceptors in 
the projection sites (all areas other than the raphe), due to decreased 5-HT release in those 
regions. However, whilst Giovacchini et al (2005) were able to demonstrate similar results to 
these by using an intermediate-affinity antagonist [(18)F]FPWAY in anaesthetized monkeys, 
this explanation (Blier et al, 1998) remains speculative, and it will be necessary to confirm 
CUMI’s sensitivity to 5-HT displacement using other 5-HT manipulations such as acute 
tryptophan depletion (which reduces levels of 5-HT) or methylenedioxymethamphetamine 
(MDMA, which releases 5-HT).  
 
This theory has been proposed to explain why depressed patients who are administered SSRIs 
initially report no change, or even a decrease in mood, which subsides within roughly 1-2 
weeks, by which time an improvement in mood starts to occur (Blier et al, 1998): 
desensitization of the 5-HT1A autoreceptors within the raphe is thought to occur after this 
period of time, allowing for an increase in the levels of 5-HT within projection sites, and 
consequently an increase in mood. This theory could be tested via administration of 
citalopram over a 14 day period, and a citalopram challenge (using CUMI) at baseline and 
day 14. Nevertheless, these results have implications for studying 5-HT transmission in 
neuropsychiatric disorders such as depression, as they highlight the in vivo effects of a single 
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administration of citalopram for the first time. It is interesting to note that there is evidence 
for an immediate change in 5-HT1A functioning, neuroendocrine functioning (increased 
adrenocorticotrophin hormone and prolactin release; Mondelli et al, 2006) and cognitive 
changes (Harmer and Cowen, 2013) following a single dose of citalopram, but that mood 
takes up to 2 weeks to change (e.g. Blier et al, 2003). As such, these findings could support 
the notion that neurological and behavioural changes are necessary in order to allow those 
experiencing low mood to make different decisions and interpret outcomes in a more positive 
manner, before mood can increase (Harmer and Cowen, 2013). 
 
3.4.2 Pruning task 
 
The behavioural results from the pruning task replicated previous findings (Huys et al, 2012), 
in that the model including a specific pruning and Pavlovian factor was best at explaining the 
data. However, in this study the addition of a ‘rho’ parameter (to identify participants’ 
subjective valuations of each of the 4 monetary outcomes) also improved the parsimony of 
the model, unlike in the original data (Huys et al, 2012). All participants except one had high 
specific pruning values, suggesting that they were pruning branches of the decision tree due 
to anticipated large losses, as predicted. However, no correlations between participants’ 
specific pruning scores and 5-HT1A availability in either condition survived correction for 
multiple comparisons. Whilst Dayan and Huys (2008) posit a theory by which 5-HT 
transmission could be involved in pruning, the results of this study were unable to confirm 
this hypothesis with respect to the 5-HT1A receptor. 
 
3.4.3 Choice x Risk  
 
Participants’ sensitivities to wins and losses were lower than the values from participants 
within the original study describing this task (means of 0.110 and 0.115 compared to means 
of 0.300 and 0.250 respectively; Rogers et al, 2003). Furthermore, these values are much 
lower than the values for sensitivity to probability (mean of 0.694), which is also higher than 
the original study (original mean of 0.520). Taken together, these data suggest that 
participants were not adequately using information pertaining to the magnitudes of potential 
gains and losses when making decisions, and were instead over-relying on information 
regarding the probability of outcome. As such, this may have affected the results of the 
correlations of performance with PET data, and may help to explain why Rogers et al (2003) 
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discovered a decrease in sensitivity to wins on this task after acute tryptophan depletion, but 
here a link between 5-HT transmission and win sensitivity was not identified.  
 
The involvement of the hippocampal complex in participants’ sensitivity to probability 
supports previous research that has highlighted a role for this structure in reward and 
punishment processing (i.e. Camara et al, 2008). Furthermore it supports the notion that 5-HT 
may have a role to play in this relationship, since those participants with greater 5-HT1A 
availability at baseline were more likely to use information about the probability of winning 
when making their decisions on the gambling task. This finding is consistent with studies in 
which ATD decreased participants’ choices of probable gain outcomes on the CGT (Rogers 
et al, 1999b); however, opposing results have also been reported, with Talbot et al (2006) 
reporting that ATD led to increased selection of more probable gain outcomes. Further, the 
fact that indices of participants’ baseline 5-HT1A receptor were obtained from the PET 
session, and their behavioural (sensitivity to probability) indices were obtained at a separate 
testing session may make this result difficult to interpret. 
 
The involvement of 5-HT1A receptors within the striatal ROI in participants’ sensitivity to 
losses supports previous research that has highlighted a role for the striatum in punishment 
processing (e.g. Seymour et al, 2012). However, due to the fact that participants were 
administered citalopram in the PET session (from which the index of the change in 5-HT1A 
receptor availability was obtained), but did not receive this SSRI during the behavioural 
session (from which participants’ sensitivity to losses were obtained) makes this result 
difficult to interpret. Another difficulty in interpreting these results is that the results of the 
citalopram challenge were counter-intuitive. In the present study, participants who exhibited 
higher sensitivity to information pertaining to losses demonstrated increased 5-HT1A receptor 
availability (indicative of decreased 5-HT release) in the right nucleus accumbens after 
citalopram infusion. This is supported by the work of Schmitz et al (2009), who were able to 
show a role for the 5-HT1A receptor in punishment processing by demonstrating that a 5-
HT1A C(-1019)G polymorphism-linked increase in 5-HT1A availability is correlated with a 
greater sensitivity to punishments. However, it will be important to clarify the robustness and 
direction of this effect in future work as the overall levels of CUMI binding in the striatum 
were very low. 
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3.4.4 Temporal Discounting 
 
As expected participants were found to discount future rewards, and their discount factors 
and utility concavity scores were found to be similar to that from the original study (0.099 
compared to 0.033 and 0.0086 compared to 0.0089; Pine et al, 2009).  Whilst no correlations 
between participants’ utility concavities and 5-HT1A availability survived small volume 
correction in either condition, there was a significant negative correlation between 
participants discount factors and 5-HT1A availability in the left hippocampal complex in the 
placebo condition. This supports previous research that has highlighted a role for this region 
in temporal discounting (i.e. Mobini et al, 2000 and Schacter and Addis, 2009), and previous 
work using ATD that has suggested and involvement of 5-HT in delay discounting (i.e. 
Schweighofer et al, 2008). In the present study participants with greater 5-HT1A availability 
were less likely to discount the value of rewards that were available further in the future. 
Although the hippocampus is typically associated with episodic memory processing and 
contextual learning, Peters and Buchel (2010) describe a manner in which this region may 
contribute to temporal discounting. These authors administered a standard discounting 
paradigm, but with the addition of a novel episodic condition which involved the presentation 
of relevant future episodes (i.e. vacation in Paris) that coincided with the later time point. 
They were able to show that these ‘episodic tags’ decreased participants’ discount rates, and 
through connectivity analyses, that this tag effect was associated with increased coupling 
between the ACC and the hippocampus bilaterally. As such, it could be very interesting to 
extend the current study using a similar paradigm in order to understand whether such 
episodic tags mediate this relationship between temporal discounting and hippocampal 
complex 5-HT1A receptor availability. 
 
3.4.6 Limitations 
 
Several limitations of this study merit comment. Firstly, PET scans of only 15 participants 
were used in the baseline analysis, and 13 participants in the change analysis. This means that 
only large effects could be identified reliably, and that smaller effects may have been missed. 
However, such low statistical power can also result in false positive findings (such as the 
small volume corrected significant correlations observed above, e.g. Button et al, 2013). As 
such, increased power from a larger subject population may help to find effects that this 
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number of participants could not, and would help to increase the reliability and 
generalizability of the results.  
 
Secondly, the particular subject population and testing conditions within this study could 
have contributed to some of the differences between the above and original results; 
participants here were older than typically included in cognitive neuroscience studies (mean 
50.9, range 35-63) with only one female subject. 
 
Thirdly, study-specific factors may have had an effect upon the results. The pruning task was 
always administered first, since the prediction relating to pruning formed our primary 
hypothesis. This could have meant that length of this long, complex task, and entire 
behavioural testing session (3-4 hours) may have affected participant’s motivation and 
engagement with the task, leading to a failure to identify significant PIT results and relative 
lack of win and loss sensitivities in the Choice x Risk task. 
 
Fourthly, this study has observed correlations of decision making behavior with only one 5-
HT receptor. Whilst this receptor has previously been shown to be involved in decision-
making (i.e. Schmitz et al, 2009), the fact that it exists in such small numbers in a brain 
region (striatum) known to be heavily involved in reward and punishment processing, along 
with impulsivity, does not provide us with strong sensitivity to identify correlations. In order 
to gain a more complete picture of 5-HT’s role in decision making, it will be necessary to 
measure other 5-HT receptors (e.g. the 5-HT2 receptor subtype) which are present in far 
greater numbers in the human striatum (Joyce et al, 1993).  
 
Finally, this study suggests that it is possible to observe the relationship between 5-HT and 
decision making by looking at a specific receptor subtype, rather than simply observing the 
effects of a global decrease or increase in 5-HT using, for example, acute tryptophan 
depletion or SSRI administration.  However, the fact that CUMI is a competitive agonist of 
the 5-HT1A receptor, meaning that it can be displaced from these receptors, means that both 
5-HT1A receptor density and levels of extracellular 5-HT contribute to measured 11C-CUMI-
101 signal at baseline, with more receptors increasing the signal, and more extracellular 5-HT 
decreasing it. As such, whilst this research does allow us to make predictions about the 
effects of increasing or decreasing the former or latter upon decision making, it is difficult to 
know the extent to which performance on the above tasks correlated with the amount of 
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extracellular 5-HT or receptor density at baseline. This question could be addressed using a 
non-competitive ligand such as [11C]WAY-100635 that would allow a more definitive 
conclusion to be made regarding the nature of the observed correlations. 
 
3.4.7 Conclusion 
 
In conclusion, we found that the influence of 5-HT on decision making can be observed at the 
level of the receptor. This has implications for psychiatric disorders in which 5-HT 
transmission is hypothesised to be compromised, such as depression, in which abnormalities 
in reward/punishment processing and impulsivity are also seen (Eshel and Roiser, 2010) and 
5-HT1A receptors may be reduced (Drevets et al, 1999). It would be of great interest to use the 
individual differences approach we adopted in the present study to investigate whether the 5-
HT1A receptor is linked to poor decision making in depression and other neuropsychiatric 
disorders. 
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4) DECISION-MAKING 3 DAYS AFTER ADMINISISTRATION OF 3,4 – 
METHYLENEDIOXYMETHAMPTHETAMINE (MDMA) 
 
4.1 Introduction 
 
MDMA is a psychoactive stimulant of the amphetamine family that has been shown to target 
the serotonergic system (Fitzgerald and Reid, 1990). Effects of administration include 
euphoria, increased extroversion, heightened sensual awareness, mild perceptual alterations 
and increased physical energy (Curran and Travill, 1997), which typically last for around 2-4 
hours (Gamma et al, 2000). MDMA is a recreational drug typically taken at clubs or raves in 
pill form, with each dose containing anywhere between 0-150mg of MDMA (Cole et al, 
2002). However, many pills taken in social settings may also contain other psychoactive 
substances, and many users will also knowingly ingest other drugs and alcohol, meaning that 
much human MDMA research may be better characterised as MDMA-polydrug 
investigations (Cowan, 2007).  
 
4.11 Pharmacology and action of MDMA  
 
MDMA has been shown in vitro to increase levels of 5-HT by entering neurons and binding 
to the 5-HT transporter (5-HTT), reversing its normal function. Due to this rather than being 
able to re-uptake 5-HT from outside the cell and transport it back inside, the 5-HTT actively 
increases levels of 5-HT within the extracellular space (Fleckenstein et al, 2007, Rudnick and 
Wall, 1992). Stone et al (1986) demonstrated the subacute effects of MDMA administration 
(i.e. the effects of the drug once the cognitive and perceptual effects have subsided), reporting 
that MDMA decreases both TPH and 5-HTP, the latter of which is then itself synthesized into 
5-HT by aromatic-L-amino acid decarboxylase) and 5-HT within the rat hippocampus, 
striatum and cortex 3 hours after a single sub-cutaneous injection of MDMA. Furthermore, 
the authors discovered that repeated sub-cutaneous injection of MDMA (5 injections at 6 
hour intervals) led to a 75% decrease in TPH and a 30% decrease in 5-HT within the same 
brain regions. It is important to note here that metabolism in rats is much faster than that of 
humans, and that any effects of MDMA 3 hours after administration should be considered 
subacute effects equivalent to those occurring over a longer time period (days) in humans 
(Stone et al, 1986). O’Shea et al (2006) report that repeated MDMA administration produces 
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long term damage to the axons of serotonergic neurons, without a compensatory increase in 
5-HT synthesis. Studies in humans have reported decreases in 5-HTT binding throughout the 
cortex (Kish et al, 2010) (which has also been shown to be inversely correlated to the number 
of previous MDMA exposures; Mcann et al, 1998) and (Ricaurte et al, 1990) report reduced 
cerebrospinal fluid 5-HT metabolite levels in chronic MDMA users. Finally, Kish et al 
(2000) report that MDMA exposure leads to decreased levels of 5-HT within the striatum. 
 
4.1.2 Cognitive effects of MDMA administration 
 
A number of studies have reported on the effects of MDMA on cognition, yet results are 
mixed. The most consistent cognitive effects of MDMA use are memory deficits (Kalechstein 
et al, 2007). However, some studies report no differences between MDMA users and 
controls, especially when groups are well matched for cannabis use (Croft et al, 2001, Dafters 
et al, 2003). For example, Raj et al (2010) observed no difference in MDMA users and 
controls who were well matched for cannabis use on a semantic verbal recognition task. 
However, the review by Kalechstein et al (2007) concludes that chronic MDMA users display 
deficits in attention, nonverbal learning and memory, motor/psychomotor speed and 
executive functions. However, none of the studies discussed above could exclude the 
possibility that any differences observed were pre-existing, since they all adopted cross-
sectional designs. 
 
The evidence for deficits in decision-making processes in ecstasy users is, however, less well 
understood. Quednow et al (2007) examined the decision-making and impulsivity behaviours 
of chronic but recently-abstinent MDMA users by comparing them with chronic but recently-
abstinent cannabis users and controls on three decision making tasks: the Matching Familiar 
Figures Test (MFFT; Kagan et al, 1966 – Information processing in the child:), a Go/No-Go 
task (Newman et al, 1990 – Passive avoidance in psychopaths) and the Iowa Gambling Task 
(IGT; Bechara et al, 1994). MDMA users exhibited higher impulsivity on the MFFT and 
poorer performance on the IGT (but did not make more errors on the Go/No-Go task) when 
compared to both groups. These findings are supported by results of other studies that show 
regular ecstasy users to display increased impulsive responding compared to both poly-drug 
users and drug-naïve controls on the MFFT (e.g. Morgan et al, 2002 – see Clark et al, 2009) 
and the Stroop task (i.e. Halpern et al, 2004 – see Clark et al, 2009) and tests of delay 
discounting (e.g. Bickel and Marsch, 2001 – see Clark et al, 2009). However, Clark et al 
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(2009) reported that a cohort of previous ecstasy users and current ecstasy users did not 
display disrupted reflection impulsivity (the tendency to make decisions before gathering 
sufficient information to make a well-judged decision) compared to drug-naïve controls on an 
information sampling task. These results occurred despite the previous and current ecstasy 
users scoring significantly higher on the impulsivity subscale of the self-report Eysenck 
Impulsivness-Venturesomeness-Empathy questionnaire (interestingly the previous users 
scored (numerically) higher on this subscale than current users). As such, research findings 
on decision-making deficits in ecstasy users are mixed.  
 
Many studies have examined the effect of MDMA use on scores on depression scales, 
comparing MDMA users with both polydrug users (e.g. Gamma et al, 2000, Parrott et al, 
2000) and drug-naïve controls (i.e. Morgan et al, 2002, Gerra, et al, 1998). For example, 
Curran and Verheyden (2003) reported that ecstasy users scored nearly 3 points more on the 
BDI than poly-drug users. However, it must be noted that neither MDMA-users nor poly-
drug users scored within the clinical range for depression in this study. Finally, Gerra et al 
1998 report that MDMA-users score significantly higher on the Hamilton Rating Scale for 
Depression than non-drug users. 
 
The above studies typically required an abstinence period of several weeks in order to assess 
medium-to-long term effects. However, Curran and Travill (1997) examined recreational 
users’ mood levels both acutely and sub-acutely, and reported that users rated their mood as 
elevated immediately after MDMA administration, but that this became progressively lower 
over the next 4 days, with some recording mood within the range for clinical depression. The 
authors attribute this subsequent low mood to reflect MDMA-dependent 5-HT depletion that 
may occur days after administration. Few studies, however, have examined changes in 
cognition during this sub-acute period, and even fewer studies have been able to control for 
non-ecstasy drug use and sleep deprivation. This latter fact is due to the data being collected 
from drug users who self-administered a range of drugs in a naturalistic setting. As such, the 
present study, which examined the subacute effect of MDMA administration on cognition in 
a controlled design, should be more straightforward to interpret.  
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4.1.3 Study design and experimental hypotheses 
 
The aim of the present study was to test the hypothesis from Dayan and Huys (2008) that 
pruning decision trees is dependent upon 5-HT transmission. Healthy volunteers were 
administered administered either MDMA or a placebo in a within subjects, counter-balanced, 
randomised design, as part of a larger study involving the administration of tasks inside an 
MRI scanner on the acute administration day, and the administration of a large battery of 
tasks on the subacute day (not inside such a scanner). The only data presented in this chapter 
are the data obtained from the pruning paradigm explained in chapter 2 (2.4.1.2), which was 
administered 3 days after they had been administered either MDMA or a placebo. 
Participants were administered pure MDMA in a clinical setting, meaning that this should not 
be considered to be an MDMA-polydrug investigation (Cowan, 2007). It was predicted that 
participants would display both decreased pruning and decreased mood 3 days after MDMA 
administration compared to 3 days after administration of a placebo, which would be due to 
the subacute 5-HT-depleting effects of MDMA. It was also predicted that the MDMA-
induced decrease in mood would be associated with the MDMA-induced decrease in pruning, 
based upon Dayan and Huys (2008) hypothesis that low levels of serotonin cause lower mood 
by decreasing pruning. 
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4.2. Methods 
 
4.2.1 Participants 
 
Nineteen participants (12 males, mean age 31.2 years, range 21-46 years) were included in 
the study. One subject (female) was subsequently excluded from the analyses due to a failure 
to follow task instructions, leaving data from 18 participants. The within subjects design of 
this task, with an N of 18 gives this study 79% power to detect an effect size of 0.80 or above 
(which is classified as a ‘large’ effect size; Cohen, 1988), and 52% power to detect an effect 
size of .50 or above (which is classified as a ‘medium’ effect size). Subjects were free of 
psychiatric disorders as determined by the MINI (Sheehan et al, 1998) at acute visit 1. 
Although past exposure to MDMA was an inclusion criterion for the study, participants had 
also taken no MDMA for at least 7 days prior to the study and no other drugs for at least 48 
hours prior to the acute visits, confirmed by a urine screen. A breathalyser test confirmed that 
no participants had consumed alcohol prior to the acute visit. Participants had used MDMA 
an average 35 times (range 1-200) before entering the study, and the median time since last 
usage was 260 days (range 7 to 7300 days). Informed written consent was obtained at the 
beginning of both acute visit 1 and subacute visit 1, and ethical approval was provided by the 
West London Research Ethics Committee, Imperial College Healthcare NHS Trust and 
Imperial College London’s Faculty of Medicine, and the study was conducted in accordance 
with Good Clinical Practice guidelines. A Home Office Licence was obtained for the storage 
and handling of a Schedule 1 drug. Ethical approval was gained from the UCL ethics 
committee for the subacute visits.  
 
4.2.2 Procedure 
 
All participants underwent administration of either 100mg of placebo (encapsulated ascorbic 
acid/vitamin-C) or 100mg of MDMA at session one (acute visit 1), and then the alternative at 
session two (acute visit 2), at the Hammersmith Hospital campus of Imperial College 
London, in a within-subjects, counterbalanced, double-blind, placebo-controlled design. This 
part of the study was conducted by Prof. Val Curran (University College London) and Prof. 
David Nutt (Imperial College London). Participants completed the two acute sessions at least 
a week apart. All participants then participated in the behavioural session at The 
Psychopharmacology Unit, University College London 3 days after both acute visit 1 and 2 
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(subacute visit 1 and 2, respectively; one participant completed their first subacute visit 4 
days after acute visit 1 due to illness). This behavioural session was completed by myself.  
 
Participants began the subacute visit by completing the BDI and Visual Analogue Mood 
scales, and then began behavioural testing. This involved administration of 4 cognitive tasks: 
a self-referential encoding task, a self-referential recognition task, an angry stories task and 
the pruning paradigm. Only data from the latter task were analysed as part of this study, with 
the data from the other tasks being analysed by the research group of Prof. Val Curran 
(University College London). The pruning task was administered either first or last in the task 
sequence, in a counter-balanced manner.  
 
The pruning task was administered as reported in chapter 2 (experimental methods), with the 
transition matrix training being first, followed by the reward matrix training and then the 
main task. As described in the methods section 2.4.1.2, this version of the pruning task 
contained large punishing transitions that cost the participants 70p (-70 transitions), and was 
timed. The transition matrix training was omitted in week 2 (subacute visit 2). Participants 
were compensated up to £20, depending on performance on this task.  
 
4.2.3 Statistical Analyses 
 
The variables of interest for this task were the measures of ‘proportion best remaining’ 
(defined in the methods section as the proportion of LLO trials in which participants did not 
take the optimal sequence of transitions due to the fact that it contained a large negative, and 
instead took the next best sequence that did not contain a large negative), and the ‘difference 
estimate’ (defined in the methods section as difference between the proportion of trials in 
which the optimal sequence of moves was made on NLLO compared to LLO trials. Other 
variables of interest include the proportion of optimal choices made on each trial type 
calculated for 3, 4 and 5 move problems. The reaction times on each trial type were also 
analysed. For a more complete description of task variables, see page 50. Due to certain 
variables suffering from deviations from parametric assumptions, a set of transformations 
was applied to the data: an arcsine (square root) transformation was applied to proportion 
optimal scores on both NLLO and LLO trials from each treatment condition, a log transform 
was applied to all reaction time data, and a square root transform was applied to all data 
concerning the number of missed trials in each condition. 
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Repeated measures ANOVAs were run on the data. Firstly, in order to assess the effect of 
prior MDMA administration on proportion optimal scores on both NLLO and LLO trials, and 
therefore the difference estimate, a 2x2x3 factor ANOVA was conducted, with prior 
treatment (MDMA or placebo), trial type (NLLO or LLO), and depth (3, 4 or 5 moves) as 
factors. Secondly, in order to assess the effect of MDMA on proportion best remaining 
scores, a 2x3 ANOVA was calculated, with prior treatment (MDMA or placebo), and depth 
(3, 4 or 5 moves) as factors. Thirdly, in order to assess the effect of MDMA on reaction times 
on each of the two trial types (without difficulty factor), a 2x2 ANOVA was performed, with 
treatment (MDMA or placebo) and trial type (NLLO or LLO) as factors The order of 
treatment administration (i.e. MDMA in week 1 or week 2) was added as a between-subjects 
factor in all ANOVAs so as to examine any possible practice effects.  
 
In order to analyse the mood data, a series of analyses was performed. Firstly, paired t-tests 
were performed in order to examine any differences between conditions in mood scores on 
the BDI and subscales 2 (Discontented-Contented), 3 (Amicable-Antagonistic), 4 (Annoyed-
Composed), 5 (Happy-Sad), 6 (Calm-Anxious), 10 (No Euphoria-Extreme Euphoria), 11 
(Lethargic-Energetic), 20 (Compassionate-Indifferent), 24 (Shy-Self Confident) and 27 (Not 
at all high-Extremely High) on the VAS. Secondly, Pearson’s correlation analyses were run 
on both the data from the MDMA, and the difference between the placebo and MDMA 
conditions in order to observe any relationships between the above psychometric mood scores 
and both the proportion best remaining and difference estimate scores from the pruning task. 
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4.3 Results  
 
4.3.1 Practice Effects 
 
Participants performed more optimally on both NLLO and LLO trials in week 2 compared to 
week 1: main effect of order (F(1,16)=11.644, P=.004). There was also a trend towards a 
practice effect (increase) on participants proportion best remaining scores: main effect of 
order (F(1,13)=3.737, P=.075), but no significant practice effect on participants’ difference 
estimate scores (trial type*order interaction (F(1,16)=.079, P=.783). Finally, participants’ 
reaction times were significantly shorter in week 2 compared to week 1: main effect of order 
(F(1,16)=8.057, P=.012). There was however no significant trial type*order interaction, 
indicating that these practice effects did not affect reaction times on each trial type differently 
(F(1,16)=.184, P=.674). For a full summary of these practice effects, see table 4.1. 
 
Variable Week 1 Week 2 
Proportion Optimal (NLLO) 0.71 (.23) * 0.84 (.19) * 
Proportion Optimal (LLO) 0.39 (.14) * 0.52 (.15) * 
Proportion Best Remaining .42 (.23) .51 (.26) 
Difference Estimate .32 (.22) .32 (.23) 
Reaction Times (NLLO) 490ms (104) * 428ms (110) * 
Reaction Times (LLO) 501ms (134) * 438ms (93) * 
 
Table	  4.1.	  Summary	  of	  means	  and	  standard	  deviations	  (in	  brackets)	  of	  each	  variable	  in	  week	  1	  and	  
2.	  Red	  asterisks	  denote	  a	  statistically	  significant	  difference	  between	  week	  1	  and	  week	  2	  
 
4.3.2 Treatment Effects 
 
4.3.2.1 Difference Estimate 
 
Participants performed significantly better (attaining a higher proportion of optimal choices) 
on NLLO relative to LLO trials (F(1, 17)=39.256, P=<.001), confirming the presence of a 
significant difference estimate. This difference estimate was significantly more marked at 
higher depths, as shown by a significant trial type*depth interaction (F(2,34)=5.127, P=.012). 
However, prior MDMA exposure did not affect participants’ overall proportion optimal 
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scores (F(1, 17)=.001, P=.978), confirming that participants were not simply worse at 
planning overall. There was a trend towards MDMA reducing the difference estimate (see 
figures 4.1 and 4.2), as indicated by the treatment*trial type interaction (F(1,17)=3.305, 
P=.088). Prior MDMA exposure however did not affect the difference estimate differently at 
each depth, (treatment*trial type*depth interaction F(2,34)=1.434, P=.253). For a summary 
of difference estimate scores see table 4.2. 
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Figure	  4.1.	  Proportion	  optimal	  scores	  on	  NLLO	  and	  LLO	  trials	  within	  the	  placebo	  (top)	  and	  MDMA	  
conditions	   (bottom).	   Note	   that	   the	   difference	   between	   proportion	   optimal	   scores	   on	   each	   trial	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type	  at	   all	   depths	   is	   smaller	   in	   the	  MDMA	  plot,	   signifying	  a	  decrease	   in	   the	  difference	  estimate	  
after	  MDMA	  administration	  
 
Difference estimates
   Depth 3           Depth 4            Depth 5
D
iff
er
en
ce
 e
st
im
at
e 
sc
or
es
0.0
0.2
0.4
0.6
0.8
1.0
Placebo
MDMA
 
 
Figure	  4.2.	  Difference	  estimates	  between	  proportion	  optimal	  scores	  on	  each	  trial	  at	  each	  depth	  
 
4.3.2.2 Proportion Best Remaining 
 
Prior MDMA exposure was found to reduce proportion best remaining scores (see figure 4.3; 
F(1,17)=7.478, P=.017). However, MDMA had a similar effect upon proportion best 
remaining scores at each depth, as shown by no treatment*depth interaction (F(2,12)=.819, 
P=.464). For a summary of proportion optimal data see table 4.2, and figure 4.3.  
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Figure	  4.3.	  Proportion	  best	  remaining	  scores	  in	  each	  condition	  at	  each	  depth	  
 
The MDMA-induced change in proportion best remaining scores (i.e. post-MDMA scores 
minus post-placebo scores) and the MDMA-induced change in difference estimate scores 
were significantly positively correlated (r =.486, P=.048). 
 
4.3.2.3 Reaction Times 
 
There was no main effect of trial type (NLLO vs LLO; (F(1,16)=.842, P=.372).  
 
Furthermore, there was no significant effect of treatment on reaction times overall 
(F(1,16)=.097, P=.760). Further, there was no significant effect of prior MDMA 
administration upon reaction times on either trial type (F(1, 17)=.007, P=.936). For a 
summary of reaction time data see table 4.2. 
 
Variable Placebo MDMA 
Proportion Optimal (NLLO) 0.81 (.14) 0.74 (.27) 
Proportion Optimal (LLO) 0.43 (.13) 0.48 (.19) 
Proportion Best Remaining .55 (.23)* .38 (.24)* 
Difference Estimate .38 (.18) .26 (.25) 
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Reaction Time (NLLO) 457ms (108) 461ms (116) 
Reaction Time (LLO) 469ms (100) 470ms (138) 
 
Table	  4.2.	  Summary	  of	  means	  and	  standard	  deviations	  (in	  brackets)	  of	  each	  variable	  in	  the	  placebo	  
and	   MDMA	   conditions.	   Red	   asterisk	   denotes	   a	   statistically	   significant	   difference	   between	  
conditions	  
 
4.3.2.4 Mood data 
 
Analysis of mood scores from the BDI and VAS scales with repeated measures ANOVA 
(including drug order as a between subjects factor) revealed no order effects (all P>.116), and 
no effects of prior MDMA exposure (all P>.149) upon participants mood scores. For a 
summary of the psychometric data, see table 4.3 below.  
 
Variable Placebo MDMA 
BDI 1.53(2.50) 1.29(2.26) 
Discontented-Contented 8.17(1.67) 8.53(1.17) 
Amicable-Antagonistic 2.00(2.45) 1.59(1.23) 
Annoyed-Composed 8.47(1.55) 9.12(1.05) 
Happy-Sad 2.06(2.08) 2.12(1.45) 
Calm-Anxious 1.77(1.82) 1.88(1.36) 
No Euphoria-Extreme Euphoria 0.76(1.75) 1.00(1.90) 
Lethargic-Energetic 6.88(1.87) 6.76(2.05) 
Compassionate-Indifferent 2.81(1.83) 3.59(2.43) 
Shy-Self Confident 7.06(1.91) 7.06(2.30) 
Not at all high-Extremely high 0.13(0.34) 0.24(0.56) 
 
Table	  4.3.	  Summary	  of	  means	  and	  standard	  deviations	  (in	  brackets)	  of	  each	  psychometric	  variable	  
in	  the	  placebo	  and	  MDMA	  conditions.	  For	  all	  variables	  except	  BDI,	  a	  low	  score	  denotes	  being	  more	  
of	   the	   first	   descriptive	   of	   the	   variable	   (e.g.	   Discontented),	   and	   a	   higher	   scores	   denotes	   the	  
opposite	  (e.g.	  Contented). 
 
Correlational analyses were performed with mood scores from the BDI and VAS and both 
proportion best remaining scores and the differences estimate scores from the MDMA 
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condition. There was a significant negative correlation between proportion best remaining 
scores and the scale ‘Annoyed-Composed’ (i.e. higher annoyance correlated with higher 
proportion best remaining scores: r=-.510, P=.037), a trend positive correlation between the 
scale ‘Amicable-Antagonistic’ and the difference estimate (i.e. higher antagonism correlated 
with higher difference estimate scores: r=.472, P=.056), and a trend negative correlation 
between the scale ‘Annoyed-Composed’ and the difference estimate (i.e. higher annoyance 
correlated with higher difference estimate scores: r=-.478, P=.052).  
 
Further, correlational analyses were performed in order to examine the relationship between 
MDMA-induced change (i.e. the differences between treatment conditions) in the proportion 
best remaining, difference estimate, and MDMA-induced change in BDI and VAS scores. 
Trend positive correlations were found between the scale ‘Amicable-Antagonistic’ and the 
difference estimate (i.e. higher MDMA-induced antagonism correlated with higher difference 
estimate scores: r=.452, P=.068) and the scale ‘Happy-Sad’ and the difference estimate (i.e. 
higher MDMA-induced sadness correlated with higher difference estimate scores: r=.470, 
P=.057). The direction of these correlations is counter to that which was hypothesised: 
increased negative mood is positively correlated with increased pruning (see figure 4.4). No 
correlations were found between the difference in proportion best remaining scores and any 
variables on the BDI or VAS.  
 
 
Figure	   4.4.	   Positive	   correlation	   between	   negative	   affect	   and	   pruning:	   increased	   negative	   mood	  
(antagonism)	  following	  MDMA	  is	  related	  (at	  trend	  level)	  to	  increased	  pruning	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4.4 Discussion 
 
This study used a within subjects, randomised, placebo-controlled design in order to 
investigate the impact of prior MDMA administration, thought to depleted levels of 5-HT, 
upon pruning. Healthy volunteers were administered either a placebo or a dose of MDMA 3 
days before they were administered the pruning task described in the methods section 2.4.1.2, 
with the hypothesis that participants would have depleted levels of 5-HT 3 days after MDMA 
administration, and as such would exhibit decreased pruning. The results indicated that 
MDMA administration 3 days prior to performance on the pruning task did weaken 
participants’ pruning compared to placebo. However, participants’ mood was not decreased 3 
days after MDMA administration. There was a trend correlation between participants’ 
negative mood and their pruning as shown by the difference estimate, yet this was in the 
opposite direction to that which was hypothesized. This study will be discussed and 
considered in light of previous work by Huys et al (2012) and Dayan and Huys (2008).  
 
4.4.1 Pruning Data 
 
As expected participants displayed greater proportion optimal scores on NLLO trials 
compared to LLO trials (which is consistent with pruning) and made more optimal choices at 
lower depths, indicating that they found these depths easier to compute. Assessment of the 
treatment effects showed that MDMA decreased both participants’ proportion best remaining 
scores and difference estimate scores (although the latter was only decreased at the trend 
level), which could be interpreted as being due to the expected low levels of 5-HT 
experienced by participants 3 days after administration of MDMA, and thus providing 
support for the theory that pruning is dependent upon normal 5-HT functioning (Dayan and 
Huys, 2008). Neither the proportion best remaining or difference estimate scores were 
affected differently at each depth. Further, prior MDMA treatment did not affect reaction 
times on any trial type. Finally, whilst participants did display improved performance on both 
NLLO and LLO trials in week 2, they displayed only a trend effect upon their difference 
estimate, and no such effect on their proportion best remaining scores, indicating that practice 
did not significantly influence pruning.   
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4.4.2 Mood Data 
 
Examination of participants’ mood scores revealed no significant differences between the 
conditions, indicating that MDMA did not reduce mood 3 days after administration. A 
number of correlations between pruning and mood data were identified. Firstly, in the 
MDMA condition annoyance correlated positively with both proportion best remaining and 
difference estimate scores, and antagonism correlated positively with the difference estimate. 
Secondly, MDMA-induced increase in antagonism correlated positively with MDMA-
induced increase in the difference estimate. Dayan and Huys (2008) and Huys et al (2012) 
propose a theory that links low mood with abnormal 5-HT functioning (e.g. Everett and 
Toman, 1959, Coppen 1967) and 5-HT functioning with pruning. However, no correlation 
between BDI scores and pruning was seen in the current sample, possibly due to the facts that 
the range of BDI scores was relatively low, and that BDI scores did not differ between each 
condition. The above correlations with annoyance and antagonism are in direct opposition to 
the original theory (posited by Dayan and Huys, 2008) which states that negative affect is 
linked to decreased pruning. However, Huys et al (2012) reported a significant positive 
correlation between scores on the BDI and pruning scores, again indicating that the more 
participants displayed negative affect, the more they pruned. However, it is important to note 
that these correlations (both significant and at trend level) were not corrected for multiple 
comparisons and should thus be considered as uncorrected. As such, the mood data of this 
study not only fail to provide evidence for Dayan and Huys (2008) theory, but also provide a 
little support the mood data from Huys et al (2012) which opposes it. 
 
4.4.3 Limitations and further work 
 
Several limitations of this study merit comment. Firstly, the number of participants included 
in this within subjects design was low compared to other behavioural studies, especially those 
using a between subjects design (i.e. studies of MDMA users). However, whilst simply 
increasing the number of participants in a study can often lead to an increase in significance 
levels (Wagenmakers et al, 2011), the fact that MDMA was found to affect pruning with such 
a low number of participants increases confidence in this effect.  
 
Secondly, the participants included in the study all had a history of abusing drugs such as 
heroin, marijuana, cocaine, nicotine and even MDMA (the latter of which was taken by some 
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participants over 2000 times in their lifetime). These drugs have been shown to affect the 5-
HT, DA, norepinephrine and cholinergic systems, meaning that these participants may have 
damage of an unknown nature to these systems, which could affect their pruning abilities due 
to alterations in cognitions such as reward and punishment processing. As such, one direction 
for future study could be to administer the pruning paradigm to participants who have been 
administered MDMA 3 days prior, but who have never taken any illicit drugs. One caveat of 
this however is that such a study may raise ethical problems; participants in this study were 
only accepted if they had prior experience with MDMA without any adverse experiences in 
order to decrease the chances of such experiences occurring during testing. This would be 
impossible to ensure in those who have never taken any form of illicit drug before.  
 
Thirdly, it was expected that participants would display decreased subacute mood due to a 
putative decrease in 5-HT; however, this was not observed. This prediction was made based 
on work by Curran and Travill (1997), which showed that participants who recreationally 
administered MDMA at the weekend reported low mood in midweek. However, this prior 
study may be confounded by the possible multitude of drugs/alcoholic beverages that may 
have also been ingested by the participants, along with the fact that these participants may 
have had disturbed sleep patterns. Furthermore, the concentration of MDMA ingested by 
these participants was not measured, and could have been much lower than expected, and 
even mixed with other drugs/substances. All of this could have affected both 5-HT and mood 
levels in these participants 3 days after their Saturday night self-administration. The mood 
data from the present study reflect the mood of participants who have not taken MDMA or 
any other drug/alcohol for at least 7 days, and had taken no other drugs or alcohol at the same 
time, unlike the users in the Curran and Travill (1997) study above. Furthermore, the 
participants in the current study were not sleep deprived as many of the users in the above 
study would have been; participants in this study were administered MDMA at roughly 9-
11am in the morning, and returned home at roughly 5-6pm, meaning that they had ample rest 
on the day of administration, which could affect subacute mood levels. The fact that subacute 
effects of MDMA on pruning were observed indicates that these effects occurred over and 
above mood effects, and that 5-HT transmission may not have recovered on day 3.  
 
Fourthly, whilst this study does provide some support for Dayan and Huys (2008) theory that 
pruning is dependent upon normal 5-HT function, the data within the study fail to support the 
notion that low mood is related to decreased pruning. Indeed, the opposite was observed; 
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negative affect was positively correlated with pruning, which is interestingly in the same 
direction as the correlation between negative affect (depression scores) and pruning observed 
in Huys et al (2012). 
 
Finally, exploring the role of genetic influences upon the cognitive effects of MDMA may be 
useful in better understanding the effect of this drug upon pruning behaviours. It has been 
shown, for example, that regular users of MDMA who carry a COMT val/val polymorphism 
or the ‘short’ allele of the serotonin transporter (SERT s/s) displayed poorer performance on 
tasks of visuospatial attention and memory (Cuyas et al, 2011), and Roiser et al (2006) report 
that the increase in attention to differences in the probability of winning on a risky decision-
making task that occurred in healthy controls carrying the short allele of SERT was 
attenuated in ecstasy users who carried this same allele. Studies such as these highlight a role 
for individual variability in the effects of drug use upon cognition, and as such examining 
certain polymorphisms may help improve our understanding of the subacute (and even acute) 
effects of MDMA upon decision-making behaviours. However, this would require testing a 
much larger sample than was included in the current study.  
 
4.4.4 Conclusion 
 
In conclusion, the results of this study suggest some evidence for an effect of MDMA 
administration on pruning 3 days later. However, no subacute effect of MDMA on mood was 
observed. These results are hypothesized to be due to a decrease in 5-HT, which lowered 
participants’ abilities to prune efficiently without decreasing mood 3 days after 
administration. Surprisingly, pruning was positively correlated with negative mood. The 
results of this study provide some evidence to support Dayan and Huys (2008) and Huys et al 
(2012) hypothesis that pruning is dependent on normal 5-HT functioning, though they 
contradict the notion that this leads to negative mood. 
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5) THE INFLUENCE OF ACUTE TRYPTOPHAN DEPLETION ON THE 
DECISION-MAKING ABILITIES OF HEALTHY VOLUNTEERS 
 
5.1 Introduction 
 
5.1.1 Acute Tryptophan Depletion 
 
Acute tryptophan depletion (ATD) is a dietary technique used experimentally in order to 
attempt to decrease levels of 5-HT within the brain. It is thought to do this by decreasing 
levels of 5-HT’s precursor, the large neutral amino acid (LNAA) L-tryptophan (TRP). 
Synthesis of 5-HT in the human brain is dependent upon availability of TRP, which is firstly 
synthesised into 5-Hydroxy-L-Tryptophan (5-HTP) by Tryptophan Hydroxylase (TPH), and 
then into 5-HT by Aromatic-L-amino acid decarboxylase (DDC) in the brain (van Donkelaar, 
2011). Whilst 5-HT cannot cross the blood brain barrier (BBB), TRP can, meaning that 
decreased levels of 5-HT in the brain can be achieved by increasing levels of the remaining 5 
LNAAs in the blood. These LNAAs then act as ‘competition’ to TRP, with all 7 LNAAs 
(leucine, isoleucine, valine, methionine, tyrosine and phenylalanine) competing for entry into 
the brain via the LNAA transporter at the BBB. Administering LNAAs without TRP 
decreases the TRP:LNAA ratio in the blood leading to a hypothesised decrease in levels of 
TRP (and thus 5-HT) in the brain (Crockett et al, 2012).  
 
5.1.2 Mood and cognitive effects of Acute Tryptophan Depletion 
 
Administration of ATD has been shown to reinstate depressive symptoms in patients who 
have recovered from depression (Delgado et al, 1990, Smith et al, 1999).  Patients with a 
more severe form of depression (i.e. those who required administration of SSRIs, or those 
who experienced many episodes) are at increased risk of mood change following ATD 
treatment (Booij et al, 2002, Delgado et al, 1990), as are those who are vulnerable to 
depression but have never been depressed themselves (i.e. those with a family history: 
Ellenbogen et al, 1999, Stewart et al, 2002). Furthermore, ATD has also been shown to affect 
neural metabolism and responsivity in similar regions to those implicated in depression. For 
example, Morris et al (1999) examined the neural correlates of such transient depressive 
symptom increases caused by ATD treatment using PET, and identified decreased perfusion 
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within the orbitofrontal cortex (OFC) and increased co-variation between the habenula and 
the dorsal raphe nucleus (DRN), with this coupling correlating negatively with plasma 
tryptophan levels, and positively with mood scores on the Hamilton Rating Scale for 
Depression (HAM-D). However, O’Reardon et al (2004) were able to show that ATD only 
produces this transient recurrence in symptoms in roughly 50-60% of patients who have 
recovered using SSRI treatment, and that those patients who have recovered by other means 
(e.g. cognitive-behavioural therapy) rarely experience such symptoms due to ATD treatment. 
 
Much research has also been conducted into the cognitive effects of ATD treatment. For 
example, ATD treatment has been shown to affect the processing of emotional stimuli (e.g. 
Klaassen et al, 2002, Murphy et al, 2002), and performance on tasks of verbal learning tasks 
of episodic memory (e.g. Riedel et al, 1999, Schmitt et al, 2000). Mendelsohn et al (2009) 
argue that ATD treatment does not affect spatial memory, and studies have argued ATD to 
have no effect on tasks of declarative memory (e.g. Park et al, 1994, Porter et al, 2000, 2005) 
or semantic memory (Allen et al, 2006, Amin et al, 2006, Gallagher et al, 2003). Further, 
tasks that tap executive functions such as working memory, attention, response inhibition, 
planning and cognitive flexibility show either no detrimental effect of ATD upon 
performance, or in some cases improved performance (e.g. Talbot et al, 2006, Luciana et al, 
2001, Schmitt et al, 2000, Clark et al, 2005, Cools et al, 2005a: see Mendelsohn et al (2009) 
for a review).  
 
5.1.2 Effects of Acute Tryptophan Depletion upon decision-making 
 
Whilst ATD has been found to have little effect on the performance of various cognitive tasks 
(excluding emotional processing and episodic memory) this dietary technique has been 
shown to influence decision-making in healthy volunteers. For instance, Schweighofer et al 
(2008) reported that participants who had undergone ATD displayed increased discounting of 
future rewards relative to those who had undergone acute tryptophan loading (to increase 
levels of 5-HT). However, whilst the results of this study are supported by those of Tanaka et 
al (2007), Crean et al (2002) reported a lack of ATD effects upon temporal discounting in 
both males with and without a family history of alcoholism.  
 
Further, ATD has also been shown to influence decision making by altering the manner in 
which participants respond to information pertaining to both rewards and punishments; 
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Rogers et al (2003) reported that participants made more decisions based on rewarding 
information than sham-treated controls on a gambling task, whilst Cools et al (2008) claim 
that ATD affects punishment (but not reward) prediction. Cools et al (2005) also report that 
ATD induced faster but less accurate responses to cues that were predictive of high 
reinforcement certainty compared to cues that were predictive of lower reinforcement 
sensitivity on the cued-reinforcement reaction time task (CRRT), thus modulating the 
coupling between motivation and action. Further, Roiser et al (2006) administered ATD to 
both ll and ss homozygotes of the 5-HTT gene before they performed the CRRT. The authors 
report that ATD abolished reinforcement-related speeding on trials with a higher probability 
of reinforcement compared to trials with a low probability of reinforcement in the ss 
genotypes (similar to the result reported by Cools et al, 2005), whereas this reinforcement-
related speeding was still present following ATD in the ll genotypes. The results of this study 
thus demonstrate that the cognitive effects of ATD may only be observed in specific subtypes 
of individuals.  
 
Whilst results do not completely agree on whether ATD affects solely reward or punishments 
(or both), Seymour et al (2012) administered a decision-making task that allowed the authors 
to examine both rewards and punishments separately, and discovered that ATD altered the 
exchange rate by which rewards and punishments were compared, leading to an attenuation 
of the subjective representation of reward values. Finally, Crockett et al (2012) administered 
an information sampling task in which participants could sample as much information as they 
wanted, at a small local cost for each piece of information, in order to avoid making an 
incorrect decision which incurred a larger global cost, and discovered that ATD reflexively 
removed the suppressive effect of smaller local costs on information sampling behaviours. 
The authors explained this finding in terms of work by Dayan and Huys (2008) and Huys et 
al (2012) that characterises 5-HT as promoting reflexive avoidance of negative outcomes.  
 
5.1.3 Study design and experimental hypotheses 
 
The aim of the present study was to examine the role of 5-HT in decision-making by 
administering a battery of tasks to participants who had undergone ATD or sham-depletion in 
a within subjects, counter-balanced, randomised design.  
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Participants’ total TRP and LNAA levels were measured in order to observe the effectiveness 
of the ATD procedure, and related to performance on the three decision-making tasks below 
between conditions.  
 
Firstly, the pruning task described in the methods section 2.4.1.2 was administered. Based 
upon theoretical work by Dayan and Huys (2008), which proposes that 5-HT provides a 
Pavlovian inhibitory signal in the face of punishment, and the experimental work by Huys et 
al (2012), it was predicted that participants would display decreased pruning behaviours after 
ATD compared to sham.  
 
Secondly, the gambling task described in the methods section 2.4.2 was administered. Based 
on previous work (Rogers et al, 2003) it was predicted that participants would display altered 
processing of information pertaining to both rewards and punishments after ATD compared 
to sham.  
 
Finally, the temporal discounting task described in the methods section 2.4.3 was 
administered. Based on previous work it was predicted that participants would display a more 
impulsive decision-making style, choosing the smaller, sooner option when administered 
ATD compared to sham.  
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5.2. Methods 
 
5.2.1 Participants 
 
Thirty-one healthy volunteers (13 male, mean (SD) age 30.82 (7.45) years, range 22-51 
years) were included in the study. Four participants (all female) withdrew from the study, 
failing to return for the second session (1 no-show, 1 due to having already completed the 
pruning task in another study, and 2 due to experiencing adverse effects of the drink), 
meaning that analyses were performed on 27 volunteers. A within subjects design with an N 
of 27 gives this study 97% power to detect an effect size of .80 (which is defined as a ‘large 
effect size’; Cohen et al, 1988), and 71% power to detect an effect size of .50 (a ‘medium’ 
effect size). Participants were free of psychiatric disorders as determined by administration of 
the MINI (Sheehan et al, 1998). Inclusion criteria included no past or present psychiatric 
disorders or alcohol/substance dependence (alcohol/substance abuse was allowed if not 
within the past 6 months) as assessed by MINI and HAM-D (Hamilton, 1960). Participants 
were also free of any medication at the time of participating. Informed written consent was 
obtained from all subjects at the beginning of the session, and ethical approval was obtained 
from the UCL ethics committee. Participants were compensated for their time, which 
included being paid £35 for their time and inconvenience plus up to £20 (depending on 
performance) on the pruning task per session, meaning that participants could leave with 
between £70 and £110 for the entire study.  
 
5.2.2 Procedure 
 
All participants underwent administration of either ATD or sham depletion (both described in 
methods section 2.6.2) at session one, and the opposite at session two at the Wellcome Trust 
Centre for Neuroimaging, University College London in a within subjects, counterbalanced, 
double-blind, placebo-controlled design. Participants completed the two sessions at least a 
week apart. Participants were initially asked questions from the MINI over the phone, in 
order to identify their potential suitability for participation. At the testing session, participants 
firstly answered questions from the entire MINI interview, along with questions from the 
HAM-D, Beck Depression Inventory (BDI; Beck, 1961), Profile of Mood States (POMS) the 
personality scale Neuroticism, Extraversion, Openness (NEO; Costa and McCrae, 1985), the 
State/Trait Anxiety Inventory (STAI; Speilberger et al, 1983) and the verbal section of the 
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Weschler Test for Adult Reading (WTAR; Weschler, 2001), as described in the methods 
sections 2.2 – 2.3. Once these were complete, suitable participants then had 5ml of their 
blood taken at time 1 by medically qualified members of staff so that baseline levels of the 
LNAAs could be identified. Once this was complete, the relevant LNAA mixture (see 
5.2.2.1) was mixed with 5g of flavouring (Grapefruit, Lemon-Lime or Cherry-Vanilla, 
depending on the participants’ preference) and 450ml of water, which was then ingested. 
Participants were told that they could take as long as they wanted to drink this unpalatable 
drink, but that they needed to finish the entire drink. Of the participants who did not 
withdraw, only 2 (both female) did not drink the entire drink (one ingested ~75%, and the 
other ~66%). Of these two participants, only one ingested less drink than the other 
participants (~66% total) in the TRP- condition, but was one of the five participants from 
whom a blood sample could not be obtained at each of the four time points, meaning that they 
were excluded from the amino acid analyses and thus did not affect results (see 5.3.1 below). 
Task data from these two participants were not excluded from the below analyses.  
 
Once this was complete, testing began 5 hours later in order to ensure that the levels of 
LNAAs would be altered maximally. As such, participants were trained on the pruning task 
immediately after drink ingestion, and then allowed to rest in the waiting area of the imaging 
department until 4 hours 45 minutes had passed since ingestion. Participants then answered 
the state anxiety section of the STAI, a second blood sample was taken, (in order to examine 
levels of the LNAAs again; time 2), and then began the battery of tests. All participants 
completed the battery of tests (the pruning paradigm, gambling task and temporal discounting 
paradigm described in the methods section 2.4) within 100 minutes.  
 
5.2.2.1 Amino acid mixtures 
 
The quantities of amino acids in each drink were based on those used in (Roiser et al, 2006), 
in which robust reductions in plasma tryptophan levels were observed. Amino acid mixtures 
were: 
 
TRP+ : L-alanine, 4.1g; L-glycine, 2.4g; L-histidine, 2.4g; L-isoluecine, 6g; L-leucine, 10.1g; 
L-lysine, 6.7g; L-phenylalaine, 4.3g; L-proline, 9.2g; L-serine, 5.2g; L-threonine, 4.9g, L-
tryosine, 5.2g; L-valine, 6.7g, L-arginine 3.7g, L-cysteine, 2.0g;, L-methionine, 2.3g; L-
tryptophan, 3g – total: 78.2g   
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 TRP- : L-alanine, 4.1g; L-glycine, 2.4g; L-histidine, 2.4g; L-isoluecine, 6g; L-leucine, 10.1g; 
L-lysine, 6.7g; L-phenylalaine, 4.3g; L-proline, 9.2g; L-serine, 5.2g; L-threonine, 4.9g, L-
tryosine, 5.2g; L-valine, 6.7g, L-arginine 3.7g, L-cysteine, 2.0g;, L-methionine, 2.3g – total: 
75.2g   
 
The same amino acid levels were administered to all participants, regardless of gender or 
height/weight. 
 
5.2.2.2 Analysis of plasma amino acid levels 
 
Following blood draws using the BD Vacutainer system ® using EDTA tubes 
(http://www.hdft.nhs.uk/EasysiteWeb/getresource.axd?AssetID=4865&), the plasma was 
separated by centrifugation and stored at -20oC. Concentrations of total LNAA levels 
(tyrosine, leucine, isoleucine, valine, phenylalanine, methionine and tryptophan, from which 
the LNAA:TRP ratio was also calculated) were measured by means of HLPC using 
fluorescence end-point detection and pre-column sample derivatisation adapted from the 
methods used by Furst et al (1990). The limit of detection used 5nmol/ml using a 10µl 
volume sample. The inter-assay and intra-assay coefficients of variation were <15% and 
<10% respectively. These analyses were carried out by Dr Michael Franklin of Faculty of 
Life Sciences, Oxford Brookes University. 
 
5.3.3 Statistical analyses 
 
All data were analysed in the Statistical Package for Social Sciences (SPSS 19, SPSS Inc., 
Chicago, IL). The main outcomes for the pruning task were the same as in chapter 4 
(proportion best remaining, the difference estimate, proportion optimal scores and reaction 
times on each trial type). The main outcomes for the gambling task include sensitivity to 
probabilities, sensitivity to wins and sensitivity to losses, and for the temporal discounting 
task were participants’ discount factor (k), utility concavity (r) and the number of sooner 
choices made.  
 
Due to certain variables not meeting normality criteria some of them were transformed: an 
arcsine (square root) transformation was applied to proportion optimal scores from each trial 
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type, and a log transform was applied to reaction time data from the pruning task. Further, an 
arcsine transform was applied to the variables from the gambling task. No variables from the 
temporal discounting were transformed. 
 
The statistics performed on the pruning task data mirror those in chapter 4 exactly. Briefly, 
they include a 2x2x3 ANOVA to observe treatment effects, with treatment (ATD or sham), 
trial type (NLLO and LLO) and depth (3, 4 or 5 moves) as factors, a 2x3 ANOVA to assess 
the effect of treatment upon proportion best remaining scores, with treatment as two levels 
and depth as three, and a 2x2 ANOVA to assess reaction times on each of the two trial types, 
with both treatment and trial type constituting two levels. Regarding the gambling task, a 
2x2x2x2 ANOVA was computed, with treatment constituting two levels (ATD and sham), 
and each of probability, win and loss constituting two (high and low). With regards to the 
temporal discounting task, ANOVAs were computed including participants’ discount factors, 
utility concavities and the number of sooner, smaller choices made, with treatment (ATD of 
sham) as the only within-subjects factor. The order of treatment administration (i.e. sham in 
week 1 or week 2) was added as a between-subjects factor into all ANOVAs in order to 
assess any order effects. Finally, in order to further assess the relationship between decreased 
tryptophan levels and performance on the above decision-making tasks, the difference 
between the LNAA:TRP ratio at time 1 and time 2 in the TRP- session was added as a 
covariate in exploratory analyses.  
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5.3 Results 
 
5.3.1 Plasma amino acid concentrations 
 
Due to difficulties in taking blood, plasma samples were not available at all four time points 
for five subjects (2nd time point TRP- x2, 2nd time point sham x2, and 1st time point sham x1). 
As such, the below analyses pertain to the remaining 22 participants (14 males, mean (SD) 
age = 31.24 (8.12) years, range = 22-51 years). 
 
Total tryptophan concentration (nmol/ml) in the plasma was lower overall on the depletion 
day (mean = 38.26, SD = 9.19) than the sham day (mean = 91.70, SD = 21.45, F(1, 20) = 
161.889, P < .001) and was lower overall at time point 2 than time point 1 (F(1, 20) = 9.650, 
P = .006). As expected treatment had a different effect upon total tryptophan concentration at 
the 2nd time point in the sham session and TRP- session (F(1, 20) = 130.700, P < .001). Post-
hoc analyses indicated that tryptophan concentration in the plasma increased 126.5% from 
time 1 to time 2 on the sham day (mean time 1 = 56.16, SD = 12.50, mean time 2 = 127.24, 
SD = 40.42, t[21] = 7.994, P < .001), and decreased 73.3% from time 1 to time 2 on the 
depletion day (mean time 1 = 60.39, SD = 13.97, mean time 2 = 16.12, SD = 5.66, t[21] = 
19.239, P < .001). Importantly, there was no difference between mean tryptophan 
concentrations between sham and depletion days at time 1 (t[21] = 1.343, P = .194). 
Furthermore, there was no effect of order of drink administration (F(1, 20) = .782, P = .388) 
or gender (F(1, 20) = .685, P = .419) on tryptophan levels. It should be noted that all 
interactions with gender were non-significant (all P>0.1). 
 
The tryptophan:LNAA ratio was also lower overall on the depletion day (mean = 0.096, SD = 
0.031) than the sham day (mean = 0.172, SD = 0.043, F(1, 20) = 94.823, P < .001) and was 
lower overall at time point 2 than time point 1 (F(1, 20) = 27.105, P = < .001). There was a 
significant treatment x time interaction (F (1, 20) = 105.583, P < .001), and post-hoc analyses 
indicated that there was a 17.2% increase in the tryptophan:LNAA ratio from time 1 to time 
on the sham day, which showed a trend towards being significant (mean time 1 = .1560, SD = 
.046, mean time 2 = .1885, SD = .015, t[21] = 1.931, P = .067), and a significant 85.1% 
decrease in this ratio from time 1 to time 2 on the depletion day (mean time 1 = .1661, SD = 
.054, mean time 2 = .0247, SD = .012, t[21] = 13.860, P < .001). Importantly, there was again 
no difference between this ratio between days at time 1 (t[21] = .937, P = .359). Finally, 
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again there was no effect of order of drink administration (F(1, 20) = 1.319, P = .266) or 
gender (F(1, 20) = 1.042, P = .321) on the TRP:LNAA ratio.  It should again be noted that all 
interactions with gender were non-significant (all P>0.1). 
 
5.3.3 Pruning task 
 
Five participants obtained proportion correct scores of less than 40% on the NLLO trials in 
both weeks, indicating either that they were not concentrating, or that they could not perform 
the task adequately. As such, these 5 were excluded from the analyses, meaning that the 
below analyses were performed on the remaining 22 participants (13 males, mean (SD) age = 
30.59 (6.71) years, range = 22-46 years). 
 
5.3.3.1 Practice effects 
 
Participants performed more optimally on both NLLO and LLO trials in the second week 
compared to the first, (F(1, 20) = 28.419, P<.001). There was also a practice effect on 
participants’ proportion best remaining scores (F(1, 19)=10.104, P=.005), but no significant 
practice effect upon participants’ difference estimate scores, (F(1, 20)=.003, P=.958). Finally, 
participants’ reaction times were not significantly shorter in week 2 compared to week 1: F(1, 
20)=.342, P=.565. For a summary of these data see table 5.1.  
  
Variable Week 1 Week 2 
Proportion Optimal (NLLO) 0.75 (.17) * 0.84 (.15) * 
Proportion Optimal (LLO) 0.33 (.15) * 0.45 (.17) * 
Proportion Best Remaining .43 (.22) * .62 (.27) * 
Difference Estimate .42 (.22) .39 (.21) 
Reaction Times (ms: NLLO) 450 (104)  422 (75)  
Reaction Times (ms: LLO) 440 (137)  447 (81)  
 
Table	  5.1.	  Summary	  of	  means	  and	  standard	  deviations	  (in	  brackets)	  of	  each	  variable	  in	  week	  1	  and	  
2.	  Red	  asterisks	  denote	  a	  statistically	  significant	  difference	  between	  week	  1	  and	  week	  2	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5.3.3.2 Treatment effects 
 
5.3.3.2.1 Difference estimate 
 
When examining proportion optimal scores, participants made significantly more optimal 
decisions on NLLO trials than LLO trials, consistent with pruning (F(1, 20)=78.437, 
P=<.001). Participants also performed more accurately at lower depths, as shown by a 
significant main effect of depth (F(2, 19)=80.860, P<.001).  The difference estimate was 
however no more marked at higher depths, as shown by a lack of a significant trial 
type*depth interaction (F(2, 19)=1.309, P=.281).  
 
ATD treatment had no effect upon participants’ proportion correct scores (F(1, 20)=1.718, 
P=.205). Treatment also had no effect on the difference estimate as shown by a lack of a 
significant treatment*trial type interaction (F(1, 20)=1.136, P=.299; see figures 5.1 and 5.2). 
Further, treatment did not have a significantly different effect at different depths as shown by 
the lack of a significant treatment*depth interaction (F(2, 19)=.548, P=.582). Finally, 
treatment did not affect the difference estimate differently at each depth, shown by the lack of 
a significant treatment*trial type*depth interaction (F(2, 19)=.552, P=.580). For a summary 
of participants’ proportion optimal scores on each trial type in each condition see table 5.2. 
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Fig.	   5.1.	   Proportion	   optimal	   scores	   on	   NLLO	   and	   LLO	   trials	   within	   the	   sham	   (top)	   and	   TRP-­‐	  
conditions	  (bottom)	  
 
 
Fig.	  5.2.	  Difference	  estimates	  between	  proportion	  optimal	  scores	  on	  each	  trial	  at	  each	  depth	  
 
5.3.3.2.2 Proportion best remaining 
 
ATD treatment was found to have no effect upon participants’ proportion best remaining 
scores (F(1, 19)=. 302, P=.589), (figure 5.3). Furthermore, ATD treatment was found to not 
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have a significantly different effect at each depth (F(2, 18)=.164, P=.850). For a summary of 
proportion best remaining scores see table 5.2.  
 
 
Figure	  5.3.	  Proportion	  best	  remaining	  scores	  in	  each	  condition	  at	  each	  depth	  
 
5.3.3.2.3 Reaction times 
 
There was no significant effect of treatment upon participants’ reaction times across NLLO 
and LLO trial types (F(1, 20)=.317, P=.579). However, there was a trend towards a 
difference in the effect of treatment upon participants’ reaction times on each trial type (F(1, 
20)=2.414, P=.051), with ATD treatment numerically decreasing participants’ reaction times 
on NLLO trials and numerically increasing reaction times on LLO trials (see figure 5.2 
below). However, neither change in reaction times was significant in post-hoc analyses (both 
P>.176). For a summary of participants’ reaction times, see table 5.2. 
 
Variable Sham TRP- 
Proportion Optimal (NLLO) 0.76 (.18) 0.82 (.14) 
Proportion Optimal (LLO) 0.39 (.18) 0.38 (.17) 
Proportion Best Remaining .53 (.28) .52 (.25) 
Difference Estimate .37 (.25) .44 (.16) 
Reaction Time (ms: NLLO) 443 (105) 428 (76) 
114	  
	  
Reaction Time (ms: LLO) 426 (130) 461 (88) 
 
Table	  5.2.	  Summary	  of	  means	  and	  standard	  deviations	  (in	  brackets)	  of	  each	  variable	  in	  the	  sham	  
and	   TRP-­‐	   conditions.	   There	   were	   no	   statistically	   significant	   differences	   between	   treatment	  
conditions	  
 
5.3.4 Gambling task  
 
For a summary of participants’ sensitivities to probability, wins and losses across both 
conditions, see table 5.3. 
 
Variable Both Conditions 
Sensitivity to Probability .1510 (.141) 
Sensitivity to Wins .1777 (.168) 
Sensitivity to Losses .6267 (.276) 
 
Table	   5.3.	   Summary	   of	   participants’	  mean	   (SD)	   sensitivity	   to	   probability,	  wins	   and	   losses	   across	  
both	  conditions	  
 
5.3.4.2 Practice effects 
 
Participants displayed no practice effects (meaning that they did not display a significantly 
increased choosing of high or low probability (F(1, 25)=.188, P=.668) win (F(1, 25)=.112, 
P=.741) or loss (F(1, 25)=2.126, P=.157) gambles in week 1 or week 2). Further, there were 
no practice effects upon participants’ reaction times to probabilities, wins and losses, as 
shown by the lack of main effects of order upon each of these variables (F(1, 25)=.107, 
P=.747, F(1, 25)=.312, P=.582, F(1, 25)=893, P=.354, respectively). For a summary of these 
data, see table 5.4. 
 
Variable Week 1 Week 2 
Sensitivity to Probability .6123 (.221) .6412 (.326) 
Sensitivity to Wins .1586 (.151) .1412 (.132) 
Sensitivity to Losses .2001 (.193) .1551 (.140) 
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RT high probability (ms) 2176 (1067) 1576 (774) 
RT low probability (ms) 2379 (1022) 1846 (821) 
RT high win (ms) 2271 (1000) 1713 (813) 
RT low win (ms)  2284 (1070) 1709 (729) 
RT high loss (ms) 2376 (1112) 2179 (961) 
RT low loss (ms) 1777 (752) 1645 (775) 
	  
Table	  5.4.	  Summary	  of	  means	  and	  standard	  deviations	  (in	  brackets)	  of	  each	  variable	  during	  week	  1	  
and	  week	  2	  
 
5.3.4.3 Treatment effects 
 
As expected, participants chose the experimental gamble significantly more often when its 
probability of winning was higher (F(1, 25)=165.261, P<.001), when the amount that could 
be won was higher (F(1, 25)=31.986, P<.001) and the amount that could be lost was lower 
(F(1, 25)=40.929, P<.001). 
 
Following ATD participants showed a trend towards choosing the experimental gamble less 
often overall than following sham ((F(1, 25)=3.542, P=.072). For participants’ sensitivity to 
high and low probabilities, wins and losses in each treatment session, see figure 5.4. 
Examining each sensitivity separately, there was no effect of treatment upon sensitivity to 
win or loss, as shown by the treatment*win and treatment*loss interactions (F(1, 25)=.047, 
P=.830 and F(1, 25)=.043, P=.838, respectively). However, there was a trend towards an 
effect of treatment upon participants’ sensitivity to probability (F(1, 25)=3.099, P=.091), 
with participants’ sensitivity to probability decreasing after ATD treatment (mean (SD) sham 
= .666 (.226), TRP- = .588 (.318)). For these treatments effects see figure 5.4. 
 
Post-hoc analyses revealed that ATD treatment reduced participants’ sensitivity to high 
probabilities (mean (SD) sham = 3.365 (.579), TRP- = 3.065 (.728), t[26]=2.061, P=.049), 
reduced participants’ sensitivity to small wins (mean (SD) sham = 1.741 (.461), TRP- = 
1.574 (.497), t[26]=2.360, P=.026), and produced a trend towards a reduction in participants’ 
sensitivity to small losses (mean (SD) sham = 2.380 (.361), TRP- = 2.245 (.407), 
t[26]=1.815, P=.081; see figure 5.5).  
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Figure	  5.4.	  Mean	  sensitivities	  to	  probabilities,	  wins	  and	  losses	  in	  each	  condition	  
 
 
 
Figure	  5.5.	  Mean	  choice	  of	  the	  experimental	  gamble	  at	  high	  and	  low	  probabilities,	  wins	  and	  losses	  
in	   each	   condition.	   ATD	   treatment	   produced	   a	   significant	   reduction	   in	   participants’	   sensitivity	   to	  
high	  probabilities	  and	  low	  wins,	  and	  a	  trend	  towards	  a	  reduction	  in	  sensitivity	  to	  low	  losses	  
 
Finally, treatment did not affect participants’ choosing of the experimental gamble differently 
between weeks, as shown by non-significant treatment*order interactions with regards to 
117	  
	  
their sensitivity to probabilities (F(1, 25)=.014, P=.907), wins (F(1, 25)=1.135, P=.297) or 
losses (F(1, 25)=1.163, P=.291). 
  
5.3.4.4 Reaction times 
 
For a summary of participants’ reaction times to high and low probabilities, wins and losses, 
see table 5.5 below. 
 
There was a main effect of probability (F(1, 25)=8.742, P=.007), with participants reacting 
quicker to information pertaining to high probability, and a main effect of loss (F(1, 
25)=11.770, P=.002), with participants reacting quicker to information pertaining to a smaller 
loss. There was however no main effect of win (F(1, 25)=.007, P=.932). 
 
ATD treatment did not have an effect upon participants’ reaction times (F(1, 25)= 882, 
P=.357 ), and specifically there were no effects of treatment upon participants reaction times 
to probability, win or loss as shown by a lack of significant treatment*RT_probability, 
treatment*RT_win and treatment*RT_loss interactions (F(1, 25)=.087, P=.771, F(1, 
25)=.473, P=.498 and F(1, 25)=1.339, P=.258, respectively).  
 
Reaction Times Sham TRP- 
Probability (ms)   
High 1789 (980) 1963 (973) 
Low 2040 (946) 2184 (979) 
Wins (ms)   
High 1895 (957) 2089 (941) 
Low 1934 (948) 2058 (969) 
Loss (ms)   
High 2019 (983) 2134 (1007) 
Low 1810 (918) 2013 (898) 
 
Table	   5.5.	   Participants’	   mean	   (SD)	   reaction	   times	   to	   information	   pertaining	   to	   high	   and	   low	  
probabilities,	  wins	  and	  losses	  on	  the	  gambling	  task	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5.3.5 Temporal Discounting  
 
Data for this task were lost for the first two participants, and two participants were found to 
be not concentrating sufficiently on the task, choosing the larger, sooner option on a mean of 
14 (SD = 2.83) trials in the sham condition, and on a mean of 14.5 (SD = 0.71) trials in the 
TRP- condition. As such, these participants were excluded from the analyses, meaning that 
the below analyses were conducted on 23 participants (13 males, mean (SD) age = 30.38 
(7.28) years, range = 22-51 years). 
 
5.3.5.1 Practice effects 
 
For a summary of the means for each variable in each week, see table 5.5. 
 
Participants were found to be concentrating sufficiently on the task in both weeks, choosing 
the larger sooner option on over 97% of the 20 catch trials in both weeks 1 and 2. There was 
no significant difference between performance on these catch trials between weeks as shown 
by a lack of a treatment*order interaction (F(1, 23)=.112, P=.741).  
 
There were significant order effects upon participants’ discount factors (F(1, 23)=6.638, 
P=.017), with participants discounting future rewards more in the second week (mean (SD) 
week 1 = .068 (.038), week 2 = .103 (.071)). There were however no significant order effects 
upon participants utility concavities (F(1, 23)=1.909, P=.180) or the number of sooner 
choices made (excluding catch trials; F(1, 23)=.436 , P=.516). For a summary of participants’ 
performance on this task in both weeks see table 5.6. 
 
Variable Week 1 Week 2 
Catch trials (/20) 19.52 (0.73) 19.48 (0.59) 
Sooner, smaller choices 
(/200) 
121.09 (47.17) 119.22 (52.85) 
K .0687 (.038) * .104 (.071) * 
R .027 (.033) .019 (.037) 
 
Table	  5.6.	  Summary	  of	  means	  and	  standard	  deviations	  (in	  brackets)	  of	  each	  variable	  during	  week	  1	  
and	  week	  2.	  Red	  asterisk	  denotes	  a	  statistically	  significant	  difference	  between	  weeks	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5.3.5.2 Treatment effects 
 
For a summary of participants’ scores on each of the task variables in each session, see table 
5.6 below. 
 
Participants were found to be concentrating sufficiently on the task in both conditions, 
choosing the larger, sooner option on over 97% of the 20 catch trials in the both the sham and 
TRP- conditions, and treatment had no effect upon participants’ performance on these catch 
trials (F(1, 23)=.112, P=.741). 
 
Using the model of best fit from Pine et al (2009), it was discovered that participants 
discounted the value of future rewards in both conditions: however, ATD treatment had no 
effect upon participants’ discount factors, meaning that participants did not discount the value 
of a future reward any differently after ATD than after sham (F(1, 23)=.030, P=.864). Using 
the same model it was discovered that participants also displayed a concave utility function. 
However, treatment had no significant effect upon participants’ utility concavities (F(1, 
23)=.898, P=.353). Finally, ATD treatment had no effect upon the number of sooner, smaller 
choices made by participants (F(1, 23)=1.086, P=.308). For a summary of participants 
performance on this task in each condition, see table 5.7. 
 
Variable sham TRP- 
Catch trials (/20) 19.52 (0.59) 19.48 (0.73) 
Sooner, smaller choices 
(/200) 
116.92 (48.91) 119.72 (49.38) 
k .084 (.059)  .081 (.061)  
r .027 (.051) .034 (.047) 
 
Table	  5.7.	  Summary	  of	  means	  (SDs)	  of	  each	  variable	  during	  sham	  and	  TRP-­‐	  depletion	  
 
5.3.2 Mood data  
 
Participants’ scores on the BDI and on each subscale of the POMS were analysed in separate 
ANOVAs. Firstly, there was no effect of treatment upon participants’ BDI scores (F(1, 
24)=.041, P=.842). 
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Secondly, there was no effect of treatment upon participants’ state anxiety scores on the 
STAI (F(1, 24)=.002, P=.965). There was however a trend towards a significant difference 
between participants’ state anxiety scores between each time point (F(1, 24)=3.757, P=.064). 
There was also a trend towards a significant difference between the different time points in 
each treatment session, as shown by the treatment*time interaction (F(1, 24)=3.119, P=.090). 
Post-hoc analyses revealed that whilst these scores were very similar between time points in 
the sham condition (mean(SD) time 1 = 10.35(8.65), time 2 = 10.62(7.71)), participants’ state 
anxiety scores increased significantly from time point 1 to time point 2 in the TRP- condition 
(mean (SD) TRP- time 1 = 9.42, time 2 = 11.54, t[25]=2.948, P=.007). 
 
Thirdly, there was no effect of treatment upon participants’ scores on the depression, 
tension/anxiety or anger/hostility subscales of the POMS (all P>.144). There were no 
differences between participants’ scores on the subscales between each time point (all 
P>.259). Finally, there was no difference between these scores at different time points in each 
treatment session (all P>.163).  
 
Finally, there were found to be no significant order effects on any mood scores (all P>.412). 
For a summary of participants’ mood data at each time point within each session see table 5.8 
below. 
 
Variable Sham (time 
1) 
Sham (time 
2) 
TRP- (time 1) TRP- (time 2) 
 
LNAA:TRP ratio 
 
.1462 (.053) 
 
.1779 (.077)  
 
.1688 (.055) 
 
.0352 (.035)  
BDI 1.88 (2.57) - 1.96 (2.39) - 
STAI (state) 10.35 (8.65) 10.62 (7.71) 9.42 (6.34) * 11.54 (6.42) * 
POMS (tension-
anxiety) 
10.36 (3.88) 10.57 (3.89) 10.16 (2.72) 9.57 (2.79)  
POMS (depression) 17.28 (6.59) 17.17 (6.40) 16.84 (3.80) 16.35 (3.69) 
POMS (anger-hostility) 14.24 (4.68) 13.96 (4.09) 14.17 (4.75) 13.83 (4.12) 
POMS (vigour-activity) 24.32 (6.34) 23.32 (5.87) 21.44 (5.19) 21.09 (4.63) 
POMS (fatigue) 9.76 (3.06) 9.92 (3.00) 10.87 (3.51) 11.78 (3.77) 
121	  
	  
POMS (confusion) 8.04 (2.21) 8.48 (1.92) 8.39 (2.17) 9.00 (2.17) 
 
Table	  5.8.	  Summary	  of	  LNAA	  :TRP	  ratio	  and	  mood	  data	  at	  each	  time	  point.	  Data	  are	  displayed	  as	  a	  
means	  (SDs).	  Red	  asterisks	  denote	  a	  significant	  difference	  
 
Due to the fact that the only observed significant difference was between participants’ STAI 
state scores at time point 1 and 2 in the TRP- condition, the difference between STAI state 
scores at each time point was calculated and correlated with performance on the above 
decision-making tasks. However, these correlations were all non-significant (all P>.141). 
 
5.3.3 LNAA:TRP ratio covariate 
 
5.3.3.1 Pruning task 
 
There was no significant correlation between participants’ difference estimate and the 
difference between the LNAA:TRP ratio at time point 1and 2 on the TRP- session (F(1, 
19)=.109, P=.745). Further, there was no significant correlation between this ratio and 
participants’ proportion best remaining scores (F(1, 18)=.933, P=.347), and finally there was 
no correlation between this ratio and participants’ reaction times (F(1, 19)=1.078, P=.312). 
 
5.3.3.2 Gambling task 
 
There was no significant correlation between participants’ sensitivity to probability, win or 
loss and the difference between the LNAA:TRP ratio at time point 1 and 2 on the TRP- 
session (F(1, 19)=1.706, P=.207). Further, there was no correlation between this ratio and 
participants’ reaction times to information pertaining to probability, win or loss (F(1, 
19)=.070, P=.795). 
 
5.3.3.3 Temporal discounting task 
 
There was no significant correlation between participants’ discount factor on the TRP- 
session and the difference between the LNAA:TRP ratio at time point 1 and 2 in this session 
(r=-.137, P=.564). Further, there were no significant correlations between this ratio and 
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participants’ utility concavity (r=.145, P=.541) or the number of sooner, smaller choices 
made on the task (r=.088, P=.711).  
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5.4 Discussion 
 
This study used a within subjects, randomised placebo-controlled design in order to 
investigate the impact of depleted levels of 5-HT on decision-making. Healthy volunteers 
were administered either acute tryptophan depletion (ATD) or a sham depletion 5 hours 
before they were administered the pruning task described in the methods section 2.4.1.2, the 
gambling task described in 2.4.2 and the temporal discounting task described in 2.4.3. The 
hypotheses were that participants would exhibit decreased pruning on the pruning task, 
altered processing of information pertaining to both rewards and punishments on the gamble 
task, and an increased choosing of the smaller, sooner option after being administered ATD 
compared to the sham depletion. The results indicated that, contrary to both the hypotheses 
and previous work, ATD administration had no significant effect on participants’ 
performance on any of the behavioural tasks administered, although a trend towards 
treatment both decreasing participants’ sensitivity to information pertaining to probabilities 
and decreasing their overall inclination to gamble was observed on the gambling task. The 
results of this study will be discussed in light of previous studies that have argued that 5-HT 
may modulate performance on these decision-making processes.  
 
5.4.1 Pruning data 
 
Participants displayed improved performance on both NLLO and LLO trials in week 2 
compared to week 1. Further, these practice effects increased their proportion best remaining 
scores, indicating that whilst there were no such effects upon the difference estimate, practice 
increased participants’ pruning behaviours. Furthermore, as expected participants displayed 
greater proportion optimal scores on NLLO trials compared to LLO trials (which is consistent 
with pruning) and made more optimal choices at lower depths, indicating that they found 
these depths easier to compute. Assessment of the treatment effects showed that ATD did not 
affect either the difference estimate or the proportion best remaining scores, indicating that 
decreased 5-HT did not decrease pruning behaviours, and the addition of the LNAA:TRP 
ratio as a covariate in the ANOVA revealed that these variables did not correlate with 
participants’ tryptophan levels. As such, these results provide no support for the theory that 
pruning is dependent upon 5-HT functioning (Dayan and Huys, 2008). Finally, prior ATD 
treatment did not affect reaction times on any trial type.  
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5.4.2 Gambling task data 
 
Participants chose the experimental gamble more often when the probability of winning was 
high, the amount that could be won was high, and the amount that could be won was low, 
supporting the results of Rogers et al (2003). As expected there were no practice effects upon 
participants’ choices on this task, but contrary to expectations there was also no effect of 
treatment, nor were there any correlations between task variables and the LNAA:TRP ratio. 
However, ATD showed a trend towards decreasing participants’ sensitivities to probability, 
specifically reducing proportionate choice of high probability gambles.  
 
Whilst this trend result is supported by Rogers et al (1999b) who also observed a reduction in 
high probability choices after ATD on the CGT, they conflict those of Talbot (2006) who 
report an increase in high probability choices after ATD on the same task. Further, the fact 
that no significant effects were observed on sensitivity to wins on this task is in direct 
contradiction to the results of the original study using this task (Rogers et al, 2003). The 
authors of this original study used a between subjects design but used more participants (18 
per group) than the current study, and observed an effect of ATD decreasing sensitivity to 
wins with an effect size of 0.76. The current study, using 27 participants in a within subjects 
design had 96.7% power to detect such an effect size and thus had adequate power to detect 
effects observed in Rogers et al (2003). However, whilst these results were not replicated in 
the current study, this chapter did provide some evidence of a role of 5-HT in decision-
making.  
 
5.4.3 Temporal discounting task 
 
Participants discounted future rewards based upon their temporal delay somewhat more than 
the original study (.084 in the sham condition and .081 in the TRP- condition compared to 
.033 in Pine et al, 2009), and also displayed increased utility concavities (.027 in the sham 
condition and .034 in the TRP- condition compared to .0089 in Pine et al, 2009). However 
surprisingly there was no effect of treatment upon participants’ discount factors, utility 
concavities, or the number of sooner, smaller choices made, which was contrary to 
expectations based upon the results of previous studies (i.e. Tanaka et al, 2007, Schweighofer 
et al, 2008). However, it must be noted that these two previous studies did not use the same 
model to analyse the data as the used here, which was taken from Pine et al (2009); 
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specifically this form of analysis included examination of participant’s utility concavities. As 
such, this form of analysis has never been tested in participants who have undergone ATD 
treatment, and so these results present the first evidence of a lack of an effect of this dietary 
technique upon participants’ discount factors and utility concavities as defined by this model. 
However, the fact that ATD had no effect upon the number of sooner, smaller choices made 
(which is a ‘raw’ score of impulsivity on this task) does not support the two previous studies, 
or indeed research in the animal literature (e.g. Soubrie et al, 1986). Further, practice effects 
are not typically observed on this task (e.g. Tanaka et al, 2007, Schweighofer et al, 2008). 
However, the fact that this task is hypothetical (which could have been avoided if participants 
were actually awarded the money stated on each trial), means that in the second session 
participants gain a greater sense that this is hypothetical, perhaps magnifying the observed 
difference in discount rates that has sometimes been shown to occur between real vs 
hypothetical intertemporal choice in humans (Bickel et al, 2009).  
 
5.4.4 Mood data 
 
Participants did not display differences between scores on the BDI or POMS, which supports 
previous findings in this area (e.g. Carpenter et al, 1998, Nishizawa et al, 1997, Riedel et al, 
1999, Rogers et al, 1999a). However, surprisingly differences were seen in participants’ state 
anxiety scores as shown by the STAI, with such scores increasing on the TRP- day after 
ingestion of the drink. This is in direct contradiction to previous research, which have shown 
there to be no effect of ATD upon STAI state measures (e.g. Hood et al, 2010). Further, 
Altman et al (2010) report no effect of ATD upon (non STAI) anxiety questionnaires, even in 
participants vulnerable to depression. However, there is much research indicating that 5-HT 
is involved in anxiety disorders (e.g. Mosienko et al, 2012), and it may be that in the current 
study ATD led participants to be more prone to increased anxiety due to their knowledge of 
an upcoming stressful situation (a 2 hour testing battery including a complex pruning 
paradigm in which financial compensation could be received). However, as no effects of 
ATD upon state anxiety scores on the STAI have been observed in prior studies, this 
interpretation is purely speculative and more research would provide a better understanding 
of these results.  
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5.4.5 Limitations and further work 
 
Several limitations of this study merit comment. For example, the fact that no significant 
effects of ATD upon performance on the pruning and temporal discounting paradigms could 
be due to the decreasing of statistical power due to the need to exclude certain participants 
during the analysis stage. For instance, 5 participants were excluded from the analyses of the 
pruning data due to an inability to perform the task. This meant that the power to discover a 
‘medium’ effect size of .50 (Cohen et al, 1988), or even a ‘small’ effect size of .30 dropped 
70% and 32% to 61% and 26% respectively. Four participants also had to be excluded from 
the temporal discounting analysis (2 due to lost data, and 2 due to poor performance on the 
‘catch’ trials). This reduced the power to 63% and 28% for a ‘medium’ and ‘small’ effect 
size. With regards to the temporal discounting paradigm, the results of Schweighofer et al 
(2008), who reported a decrease in temporal discounting after ATD treatment, observed such 
an effect at a size of .87 (large; Cohen et al, 1988). The current study had 99.1% power to 
detect an effect size of this magnitude, and as such a decrease in power due to the exclusion 
of the 4 and 5 participants (for the temporal discounting and pruning tasks) cannot be the sole 
reason for the failure to find any treatment effects on these two tasks. Further, no subjects 
were excluded from the analysis of the gambling task data, and as described above the results 
of the original study, in which ATD decreased sensitivity to wins, were not replicated, despite 
the current study having sufficient power to do so. However, increasing the sample size here 
would increase the statistical power and improve the chances of observing an effect of ATD 
upon participants’ performance on these decision-making tasks.  
 
Further, the fact that a within subjects design was utilised here is important. Whilst this 
design was used in order to increase the statistical power (as an increased N is required in a 
between subjects design in order to obtain the same power as would be achieved with a 
smaller sample size in a within subjects design; Wagenmakers et al, 2012), studies using this 
design have been shown to discover treatments effects in week 1, but nothing in week 2 (see 
McCabe et al, 2010 for a discussion). If this was the case here, the repeated measures may 
have masked the ability of this study to uncover treatments effects. However, this was not the 
case, as treatment was found to have no effect in both week 1 and week 2.  
 
Finally, whilst participants’ LNAA:TRP and tryptophan concentration nmol/ml were 
significantly reduced following ATD treatment, the fact that participants were allowed no 
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food from midnight the night before testing until the end of the session at roughly 5:30pm (in 
order to ensure that participants ingested no tryptophan) may have affected task performance. 
This fasting (including no tea or coffee) will have increased the effects of fatigue upon 
participants’ performance. However, whilst this rigorous approach to fasting has been used in 
many studies that have found effects of ATD (e.g. Robinson et al, 2012), others have allowed 
a small tryptophan-free diet at lunchtime in order to reduce the effects of fatigue upon 
performance (i.e. Robinson et al, 2013), and this study may have been improved by the 
introduction of such a diet.   
 
5.4.6 Conclusion 
 
In conclusion, this study administered 3 decision-making tasks to healthy volunteers who had 
undergone ATD: one which allowed for the observation of pruning, one of which allowed for 
the examination of participants’ gambling behaviours (taken from Rogers et al, 2003), and 
the final one of which examined the amount to which participants discount the value of a 
reward based upon its temporal delay. The results of this chapter revealed no effect of ATD 
upon participants’ pruning behaviours or their temporal discounting behaviours. However, 
the results did reveal a trend towards ATD decreasing participants’ sensitivity to different 
probabilities on the Rogers’ (2003) gambling task. As such, the results of this study failed to 
support the hypotheses from Dayan and Huys (2008) that 5-HT depletion would result in 
decreased pruning behaviours, and further failed to replicate previous results from Rogers et 
al (2003) and Schweighofer et al (2008), the former of which showed ATD to decrease 
sensitivity to different magnitudes of wins, and the latter of which showed ATD to increase 
the discounting of rewards based upon their temporal delay. Finally, whilst ATD increased 
participants state anxiety scores, no other effects upon mood were observed, and no 
significant correlations between performance on any of the above decision-making tasks and 
mood were observed.  
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6) PRUNING ABILITIES OF PATIENTS DIAGNOSED WITH MAJOR 
DEPRESSIVE DISORDER 
 
6.1 Introduction 
 
6.1.1 Evidence for dysfunction of the 5-HT system in depression  
 
MDD is a neuropsychiatric disorder hypothesized to be linked to disruptions in 5-HT 
transmission primarily to the fact that certain drugs that alleviate depressive symptoms act 
upon the 5-HT system, such as selective serotonin reuptake inhibitors (SSRIs) e.g. fluoxetine 
and citalopram (Everett and Toman, 1959,  Coppen, 1967,  Blier, 2003). Petty et al (1994) 
were able to show that the classic animal model of depression, learned helplessness, leads to 
a reduction in 5-HT within the prefrontal cortex, whilst Petty et al (1996) reported that this 
can be inhibited by pre-treatment of SSRIs. Furthermore, depleting levels of 5-HT via acute 
tryptophan depletion (ATD) has been shown to cause a transient reappearance of depressive 
symptomatology in medicated depressed patients in remission (Delgado et al, 1990) with 
those who have experienced multiple depressive episodes being at increased risk (Booij et al, 
2002).  Furthermore, Ruhe et al (2007) report that ATD lowers mood in healthy volunteers 
with a familial risk for depression and MDD patients in remission.  
 
Owens and Nemeroff (1994) report data of post-mortem examinations of depressed patients 
and suicide victims, which includes reduced cerebrospinal fluid (CSF) concentrations of the 
main metabolite of 5-HT, 5-HIAA, decreased concentrations of 5-HT and 5-HIAA 
throughout the cortex, decreased plasma tryptophan (the precursor to 5-HT), increases in 5-
HT2  receptor density and reductions in 5-HTT throughout the cortex. Whilst there have been 
some contradictory results with regards to post mortem data (e.g. Hrdina et al, 1993), 
Stockmeier (2003) argues that this may be due in part to flaws such as poor characterisation 
of medication histories, substance abuse histories, specific psychiatric diagnoses, disorder 
remission and specific cytoarchitechtonic region co-ordinates, and that on balance the post-
mortem literature does support the existence of 5-HT dysfunction in depression. Furthermore, 
neuroimaging studies have also provided support for the notion that 5-HT dysfunction is 
involved in depression: Malison (1998) compared levels of the 5-HT transporter (5-HTT) in 
depressed patients and controls by measuring binding with the radioligand 123I-β-CIT, and 
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discovered a reduced binding potential in patients, however Dahlstrom et al (2000) report an 
increase in binding potential in unmedicated depressed children and adolescents. Drevets et al 
(2007) also report a 26% and 43% decrease in levels of the inhibitory 5-HT1A receptor in the 
mesiotemporal cortex and raphe nucleus, respectively. 
 
6.1.2 Decision-making abilities of depressed patients 
 
Decision-making depends on the ability to evaluate potential rewarding and punishing 
consequences of actions in order to select the most appropriate behavioural response (Dayan 
and Huys, 2008, Huys et al, 2011). Many studies have shown that the 5-HT system may be 
involved in reward (e.g. Rogers et al, 2003) and punishment processing (Soubriẽ et al, 1986, 
Cools et al, 2008, Crockett et al, 2009), and it has also been shown that patients diagnosed 
with depression exhibit maladaptive responses to both rewards and punishments (Eshel and 
Roiser, 2010). For example, McFarland and Klein (2009) found that depressed participants 
were significantly less happy than controls when anticipating rewards, despite no differences 
in mood when anticipating punishments. Furthermore, Pizzagalli (2005) demonstrated that 
when participants performed a task in which correct responses to one target were three times 
more likely to be rewarded than those to another target, those with higher scores on the Beck 
Depression Inventory (BDI) and those with MDD developed a weaker preference for the 
former target when compared to controls, demonstrating an inability to modulate behaviour 
according to prior reinforcements. Furthermore, Huys et al (2013) report that this is due to a 
specific reduction in reward sensitivity, rather than a reduction in sensitivity to prediction 
errors for reward that determines reward-related learning. With regards to the processing of 
punishments, Beats et al (1996) demonstrated that on a variety of tasks, depressed patients 
performed poorly on trials which followed an error (and thus negative feedback) on the 
previous trial, suggesting a hyper-sensitivity to perceived failure. This tendency also 
correlates with the severity of depression (Elliott et al, 1996), and Holmes and Pizzagalli 
(2007) showed that healthy volunteers with high scores on the BDI adjusted their responses 
significantly less after errors than those with low scores on the Simon (Simon, 1969) and 
Stroop tasks (Stroop, 1935).  
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6.1.3 Theory of altered pruning in depression 
 
Dayan and Huys (2008) posit a theory by which serotonin leads to low mood. Here the 
authors observe that serotonin has been shown to be involved in both the prediction of 
aversive events (e.g. Deakin, 1983) and behavioural inhibition (Soubrie, 1986), preventing 
ongoing actions or behaviours in light of these aversive events. As such, the authors argue 
that serotonin is involved in pruning a tree of potential decisions (specifically, in curtailing 
the search of such a tree in light of potentially aversive events), and that a decrease in levels 
of serotonin could result in decreased behavioural inhibition, leading to both decreased 
pruning and large negative prediction errors. This, in turn, would lead to an increase in 
negative prediction errors which would occur due to an occurrence of aversive events and 
more negative consequences, contributing to a pessimistic evaluation of the world, and a 
consequent decrease in mood. However, Huys et al (2012) found that, contrary to this 
hypothesis, pruning was associated with increased depression scores in a non-clinical sample, 
and a similar finding was identified in chapter 4 following MDMA administration. Therefore 
it is important to test the pruning hypothesis of depression in a clinical sample. 
 
6.1.4 Study design and experimental hypotheses 
 
The present study administered the pruning paradigm explained in the methods section 
(2.4.1), to both control subjects and MDD subjects in order to test Dayan and Huys (2008) 
hypothesis that the pruning of decision trees is dependent upon normal 5-HT functioning. It 
was predicted that due to the putative decrease in 5-HT transmission in depression, depressed 
subjects would exhibit decreased pruning of sub-trees in response to large punishment.  
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6.2 Methods 
 
6.2.1 Participants  
 
Thirty-one control subjects (15 males, mean age 30.4 (10.80) years, range 19-61 years) were 
recruited via the website advertisements and the University College London Psychology 
Subject Pool, and thirty MDD patients (15 males, mean age 33.8 (10.44) years, range 19-55 
years) were recruited either via the Camden and Islington National Health Service 
Foundation Trust, Psychological Treatment Services, or via advertisement. This number of 
participants was chosen due to the fact that a between subjects design with an N of 31 
controls and 30 patients would give this study 85% to detect a ‘large’ effect size of 0.8 
(Cohen et al, 1988) and 61% power to detect a ‘medium effect size (0.5). Patients were 
initially screened for the below inclusion criteria by telephone, and then in person at the 
Institute of Cognitive Neuroscience, University College London. The testing session took 
place at the same location. Inclusion criteria for the control subjects were: no past or present 
psychiatric disorders (save for a remote (> 6 months) history of substance or alcohol abuse) 
as assessed by the Mini International Neuropsychiatric Inventory (MINI; Sheehan et al, 1998) 
and Hamilton Rating Scale for Depression (HAM-D; Hamilton 1960). Inclusion criteria for 
the depressed participants were: current major depressive episode (assessed as above), no 
antidepressants within the past month (2 months for fluoxetine), bipolar disorder or 
psychosis. However, generalized anxiety disorder was allowed, with more than almost two 
thirds of patients presenting symptoms of anxiety, and the patient group showing 
significantly increased levels of state and trait anxiety compared to controls (see results 
section, below). Further, patients were not allowed to have been administered antidepressant 
medication within the past 6 months, but were permitted to be undertaking a course of 
behavioural treatment (Cognitive Behavioural Therapy), as was common in those who were 
recruited via the Camden and Islington Psychological Services. Informed written consent was 
obtained from all subjects at the beginning of the session, and ethical approval was obtained 
from the UCL ethics committee. Participants were compensated for their time, which 
included £10 for participating and up to £20 depending on performance on the task.  
 
 
 
 
132	  
	  
6.2.2 Procedure 
 
Participants initially answered questions from the MINI, in order to identify suitability as 
described above, and then answered questions from the HAM-D, BDI, NEO, STAI and the 
WTAR Beck Depression Inventory as described in the methods sections 2.1-2.3. Participants 
were then trained on the behavioural task described in 2.4.1.1 before playing the task for real. 
The task involved completing 48 episodes of varying length (2-8 moves). Once this was 
complete, participants were debriefed and paid according to their earnings on the task. 
 
6.2.3 Statistical Analyses and Computational Modelling 
 
As described in the methods section 2.4.1, a set of increasingly complex models was fit to the 
data using Bayesian model comparison (Huys et al, 2012). After the best fitting model was 
identified, the parameter estimates from it were extracted for each participant and subjected 
to classical statistical analyses. 
 
These data were then analysed using Statistical Package for the Social Sciences (SPSS 19, 
SPSS Inc., Chicago, IL). The main outcome measures of this task were participants’ general 
(γG) and specific (γS) pruning parameters from the winning model (see methods chapter 
2.4.1.1). Both are represented on a scale between 0 and 1, with the former denoting the 
chance that a participant would continue to search through the tree in general and the latter 
denoting the chance that a participant would continue to search through the tree specifically 
when encountering a large punishment. Sensitivities (rhos) to the +140, +20, -20 and -140 
transitions were also estimated and compared between the groups (see 2.4.1.1). Independent t 
tests were performed in order to determine the existence of any differences between the two 
experimental groups on the task variables, and a set of correlations was conducted in order to 
determine the existence of any relationship between parameter values and symptoms and 
personality measures. Due to the large number of correlations there was a need to control for 
the increased risk of a type 1 error occurring, therefore a threshold of P<.01 was adopted.  
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6.3 Results 
 
Demographic, clinical and mood ratings appear in table 6.1 below. 
 
 Control 
Subjects 
MDD Patients t value P value 
N (Male) 31 (15) 30 (15) - - 
Age (SD) 30.2 (10.7) 
years 
33.3 (10.1) years 1.227 .225 
IQ (SD) 108.4 (14.7) 112.2 (10.3) 1.809 .078 
BDI 
HAM-D 
STAI state 
STAI trait 
NEO Neuroticism 
NEO Extraversion 
NEO Openness 
NEO Agreeableness 
NEO Conscientiousness 
Number of depressive 
episodes (SD) 
Current episode length 
(months; SD) 
Age of first episode (years; 
SD)  
N of participants attempted 
suicide 
3.00 (4.61) 
1.78 (1.80) 
10.19 (7.53) 
14.71 (8.16) 
17.06 (6.39) 
29.81 (6.33) 
29.65 (8.04) 
32.32 (4.99) 
33.03 (6.77) 
- 
- 
- 
0 
25.44 (7.48) 
20.28 (4.43) 
23.44 (11.39) 
32.88 (9.74) 
34.80 (7.99) 
19.44 (5.72) 
29.63 (5.94) 
29.57 (6.40) 
26.68 (7.33) 
8.1 (3.82)  
3.64 (4.9)  
20.1 (6.3) years 
7 
13.779 
16.708 
5.219 
7.601 
9.232 
6.357 
.119 
1.524 
3.365 
- 
- 
- 
- 
< .001*  
< .001* 
< .001* 
< .001* 
< .001* 
< .001* 
.906 
.133 
.001* 
- 
- 
- 
- 
Table	  6.1.	  Demographic,	  clinical	  and	  mood	  data.	  Asterisk	  denotes	  significantly	  different	  scores	  
 
6.3.1 Computational modeling of decision making task 
 
Eight models were applied to the data in order to explain participants’ choices. Figures 6.1 
and 6.2 depict the results of these models, each of which were compared using the BIC 
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method. There was greater evidence (lower BIC) for each of the four models incorporating 
reward sensitivities to each of the four transitions types (+140, +20, -20, -140) than the 
corresponding models without such sensitivities. Within these four models the best fitting 
model (red star in Figure 6.1) included both γS and γG parameters, suggesting that loss-
specific pruning had a robust influence on behaviour. However, including the immediate 
Pavlovian (state attraction) component decreased the model evidence despite providing a 
slightly better fit to the data, due to increased model complexity. Therefore parameters were 
estimated from the “Loss and Pruning” model.  
 
 
 
Figure	   6.1.	   Results	   of	   BIC	  model	   comparison.	   The	   top	   four	  models	   are	   presented	   in	   descending	  
order	  of	  complexity,	  as	  are	  the	  bottom	  four	  (bottom	  four	  without	  loss	  aversion	  (rho)	  parameters).	  
Model	  pruning	  with	  loss	  aversion	  component	  provided	  the	  best	  fit	  to	  the	  data.	  Note	  the	  decisive	  
evidence	  in	  favour	  of	  the	  second	  most	  complex	  model	  (log10	  BIC	  difference>10)	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Figure	  6.2.	  Predictive	  probabilities	   for	  all	  models.	  All	   Loss	  models	  provide	  a	  better	  prediction	  of	  
choices	   than	   the	   corresponding	   models	   without	   loss	   aversion	   parameters.	   Although	   the	   Loss,	  
Pruning	  &	  Pavlovian	  model	  has	  the	  best	  predictive	  probability,	  the	  addition	  of	  an	  extra	  parameter	  
(immediate	  Pavlovian)	  is	  penalized,	  resulting	  in	  a	  lower	  BIC	  	  
 
This winning model provided a good fit to the data. Figure 6.3 shows its ability to predict 
participants’ decisions when their next move was the 1st-8th in a sequence. The model 
performed at a high level across all choices, never predicting less than 80% of choices 
correctly.  
 
Figure	   6.3.	   Proportion	   of	   choices	   correctly	   predicted	   by	   the	   winning	   model	   ‘loss	   and	   pruning’	  
across	   different	   depths	   (blue	   bars).	   The	   grey	   line	   depicts	   the	   simple	   ‘optimal’	  model	   (assuming	  
perfect	   planning),	   and	   the	   blue	   dashed	   line	   denotes	   chance	   (50%).	   Left:	   patients	   and	   controls	  
combined.	  Middle:	  controls.	  Right:	  patients	  
 
Parameters for the winning model are shown in Figure 6.4. It is notable that the reward 
sensitivity parameters do not provide evidence for loss aversion: the mean (SD) reward 
136	  
	  
sensitivity across the two groups for the -140 transitions = -2.49 (1.04), the -20 transitions 
mean = -.008 (.05), the +20 transitions mean = 1.51 (.78) and the +140 transitions mean = 
7.31 (3.25), indicating that the +140 transition is more appetitive than the -140 transition is 
aversive (see Figure 6.4, left). This is also evident in Figure 6.4, middle: participants’ 
estimated valuation of gains vs losses from the parameters of the winning model are depicted. 
Figure 6.4, right depicts the general and specific pruning for both groups (represented as 
continuing probabilities). This shows that both groups prune very strongly, as the winning 
model suggests, with a greater probability of curtailing a tree search in the face of a large 
negative outcome (γS) relative to other outcomes (γG).  
 
 
Figure	   6.4.	   Left:	   Reinforcement	   sensitivity	   parameters.	   Middle:	   Absolute	   ratio	   of	   large	   reward	  
(+140)	  to	  large	  loss	  (-­‐140).	  Right:	  Splitting	  of	  pruning	  parameter	  into	  general	  (γG)	  and	  specific	  (γS)	  
pruning.	  MDD	  patients	  are	  in	  red,	  controls	  in	  green.	  Results	  here	  show	  that	  both	  groups	  prune	  (as	  
shown	  by	  γS	  	  scores),	  but	  that	  there	  is	  no	  difference	  between	  the	  γS	  scores	  of	  each	  group	  
 
6.3.2 Group comparisons  
 
There were no significant differences between groups on either specific (t[59] = 1.123, P 
=.266) or general pruning (t[59] = .322, P = .749). There were also no significant differences 
between groups on reward sensitivities to any of the four transition types: reward sensitivity 
to -140 transitions- t[59] = .831, P = .409; reward sensitivity to -20 transitions - t[59] = .459, 
P = .349; reward sensitivity to +20 transitions - t[59] = -.073, P = .942; reward sensitivity to 
+140 transitions -  t[59] = -.105, P = .917. 
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Variable Control MDD 
γS .1227 (.042) .1357 (.049) 
γG  .631(.135) .617(.189) 
Reward Sensitivity (-140) -2.601 (1.115) -2.378 (.969) 
Reward Sensitivity (-20) -.006 (.047) -.011 (.046) 
Reward Sensitivity (+20) 1.505 (.782)  1.520 (.792) 
Reward Sensitivity (+140) 7.252 (3.481) 7.339 (3.046) 
	  
Table	  6.2.	  Summary	  of	  task	  variable	  means	  and	  standard	  deviations	  in	  each	  group.	  There	  were	  no	  
significant	  differences	  between	  groups	  	  
 
6.3.3 Psychometric correlates  
 
MDD patients’ pruning parameters (γ ‘G’ and ‘S’) and reward sensitivities as defined by the 
winning model were correlated with their mood and personality scores, as indexed by the 
NEO, BDI, HAM-D and STAI questionnaires. Results revealed no significant correlations 
between patients’ specific pruning parameter and BDI scores (r=-.083, P=.693), HAM-D 
scores (r=-.036, P=.853), Neuroticism scores (r=.082, P=.666), Extraversion scores (r=-.066, 
P=.730), Openness scores (r= .024, P=.902), Agreeableness scores (r=.202, P=.284), 
Conscientiousness scores (r=-.111, P=.559), state anxiety scores (r=-.120, P=.528) or trait 
anxiety scores (r=.164, P=.368).  
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6.4 Discussion 
 
This study used a between subjects design in order to investigate the impact of depression on 
pruning. Two groups were included in the study: 31 controls and 30 depressed patients, who 
were all tested on the pruning paradigm described in the methods section 2.4.1.1. The results 
revealed that the model ‘Loss and Pruning’ was a good fit to the data, explaining more than 
80% of participants’ choices. However, there were no significant differences between groups 
in terms of performance on the pruning task, and no significant correlations between mood or 
personality scores and pruning. These results will be discussed and considered in light of both 
previous work by Huys et al (2012) and Dayan and Huys (2008).  
 
6.4.1 Pruning task 
 
Results of the Bayesian model comparison revealed that the model ‘Loss and Pruning’ best 
explained participants’ choices on the task, which suggested that loss-specific pruning had a 
robust influence on behaviour. Furthermore, examining general and specific pruning scores 
from this winning model did not provide evidence for a difference between groups in either 
their general planning abilities or their pruning behaviours due to a large loss, respectively. 
Furthermore, patients and controls did not differ in their reward sensitivities to any of the four 
transition types, with both groups finding the rewarding transitions more appetitive than they 
found the punishing transitions aversive, meaning that loss aversion was not observed. The 
fact that no differences were observed in sensitivities to both rewards and punishments was 
surprising, as many previous studies have shown the opposite effect (see Eshel and Roiser, 
2010 for a review). As expected, participants did differ on personality and mood scores, and 
the results of the NEO are in line with previous reports of increased neuroticism, decreased 
extraversion and decreased conscientiousness in depression (Klein et al, 2011).  
 
A number of studies have examined decision-making in depressed patients (e.g. Beats et al, 
1996, Elliot et al, 1996). However, these studies did not examine patients’ performances in 
multi-step decisions, and this is the first study to test the pruning abilities of a depressed 
population. Huys et al (2012) demonstrated that when faced with a series of actions, healthy 
volunteers prune away potential actions as soon as they encountered a large loss. The current 
study was able to replicate these results and provides clear evidence of pruning. However, the 
winning model from Huys et al (2012) included a ‘Pavlovian’ parameter, indicating that 
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participants had a reflexive attraction to certain states (as opposed to transitions), and 
aversion to others. The Pavlovian parameter did not improve model parsimony in this study 
however, meaning that considering participants’ valuation of states (boxes) rather than 
considering just their sensitivity to the four transition types did not make for a better model 
fit. Furthermore, Huys et al (2012) also reported a correlation between sub-clinical mood 
disturbances and pruning behaviours in their healthy volunteers. The authors explain this 
latter result in a framework that links mood disturbances with abnormalities in 5-HT 
functioning (i.e. Everett and Toman, 1959, Coppen 1967) and 5-HT functioning with pruning 
(based on Dayan and Huys (2008) theoretical work), such that depressed patients (with 
putative serotonergic abnormalities) should display decreases in the curtailment of potential 
decision trees in response to a large loss. The present study provided no evidence for this 
hypothesis.  
 
There are a number of possible explanations as to our failure to observe the existence of 
differences in the pruning behaviours between healthy volunteers and depressed participants. 
For example, it may be that whilst 5-HT is involved in the pruning of decision trees, the 
depressed patients in this study suffer from abnormalities in a range of neurotransmitter 
systems, rather than just serotonin (Di Chiara et al, 1999). These transmitter systems, such as 
dopamine, have been shown to influence sensitivity to rewards and punishments (e.g. Cools, 
Nakamura and Daw, 2011), which may exert an influence upon loss-specific pruning in these 
subjects. Further, the failure to find effects may simply be due to a lack of suitable power: 
with only 31% power to detect a ‘small’ effect size of 0.3 (Cohen et al, 1998) such small 
group effects may have been missed, resulting in a type 2 error.  
 
6.4.2 Limitations 
 
Due to difficulties with recruitment, only two-thirds of these patients were recruited via the 
Camden and Islington National Health Service Foundation Trust, Psychological Therapy 
Services. The remaining patients were recruited via website advertisements, meaning that 
their psychiatric profile had not been examined by a professional within the National Health 
Service. However, considering this, all depressed participants included in the study did 
satisfy criteria for a current major depressive episode, yet without documented anti-
depressant use histories for these subjects it is difficult to make conclusions regarding the link 
between 5-HT and pruning in these subjects.   
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6.4.3 Further work 
 
In order to assess the evidence for the hypothesis set out in Dayan and Huys (2008) and Huys 
et al (2012), this pruning task could be administered to (as well as the serotonin-depleted 
individuals reported in this thesis) participants who have increased levels of serotonin 
(through acute tryptophan loading and SSRI administration). This would hopefully allow for 
a better understanding of serotonin’s role in pruning. Further, whilst much work indicates that 
5-HT may be involved in pruning decision-trees (i.e. Deakin et al, 1983, Soubrie et al, 1986, 
Dayan and Huys, 2008), other monoamine systems have been shown to be involved in reward 
and punishment processing (e.g. van der Schaaf, 2012), and observing the role of other 
neurotransmitter systems may shed light on the neurochemical basis of pruning behaviours. 
Further, depressed patients have been shown to have altered levels of various receptor 
subtypes linked to various neurotransmitter systems (i.e. increased 5-HT2 receptors in the 
PFC; McKeith et al, 1987 and increased D2/D3 receptors in the amygdaloid complex; Klimek 
et al, 2002). As such, it may prove fruitful to examine the expression of certain genes linked 
to various neurotransmitter systems (i.e. HTR1A, HTR2C, DRD2 genes which code for the 
5-HT1A, 5-HT2C and dopamine-D2 receptors, respectively) in these groups in order to shed 
further light on the link between MDD, pruning and neurotransmitter systems. Finally, 
examination of pruning in different psychiatric groups, such as patients with anxiety, may 
provide useful insights into whether decision-making is altered in different psychiatric 
disorders. 
 
6.4.3 Conclusion 
 
We observed no differences between depressed patients and healthy controls on general 
pruning, specific pruning and reward sensitivities to both small and large rewards and 
punishments. Therefore, this study failed to provide support for Dayan and Huys (2008) 
theory that depressed patients would display poorer pruning abilities due to aberrant 5-HT 
functioning.  
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7) GENERAL DISCUSSION  
 
This discussion will provide an integrative summary of the experiments presented in chapters 
3-6. A brief overview of the main results of each study will be given first, after which a 
comparison of the effects of 5-HT1A binding, acute tryptophan depletion and subacute 
MDMA administration upon reward and punishment processing will be presented, along with 
how these effects relate to those observed in the depressed sample from chapter 6. The results 
of these studies will be considered in light of how much they may help improve our 
understanding of the relationship between serotonin, decision-making and mood. Finally, the 
limitations of these studies and possible directions for future research will be outlined, with 
the aim of improving further our understanding of the pathophysiology and potential 
treatments of MDD.  
 
7.1 Summary of experimental investigations 
 
7.1.1 Study 1: Decision-making and the 5-HT1A receptor: a positron emission tomography 
study 
 
The aim of this study was to build upon studies that have shown a role for general 5-HT 
transmission in reward and punishment processing (i.e. Rogers et al, 2003, Schweighofer et 
al, 2008, Tanaka et al, 2007) by observing the relationship between 5-HT1A binding and 
decision-making behaviour in a group of healthy volunteers. This was done by initially 
administering the novel ligand CUMI before a placebo in order to observe baseline 5-HT1A 
availability, and before intravenous administration of 10mg citalopram in order to observe the 
change in 5-HT1A receptor availability (from which an index of 5-HT release is inferred). The 
results of the citalopram challenge were surprising in that administration of this SSRI led to 
an apparent decrease in 5-HT release throughout the cortex. In order to test the relationship 
between the 5-HT1A receptor and decision-making, performance on 3 behavioural tasks was 
correlated with the above indices of 5-HT1A receptor availability. Consistent with prior 
results, participants exhibited robust aversive-based pruning, as indicated by a substantial 
increase in evidence for the computational models in which the pruning parameter was 
incorporated. Whilst no significant correlations between 5-HT1A binding or 5-HT release and 
the pruning parameter were observed, there were significant correlations between sensitivity 
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to losses and the change in 5-HT1A availability (due to citalopram infusion) in the right 
nucleus accumbens and between sensitivity to probability and baseline 5-HT1A availability in 
the right hippocampal complex. Further, a significant correlation between participants’ 
discount factor on the temporal discounting task and baseline 5-HT1A receptor availability in 
the left hippocampal complex was also observed. The results of this study suggest that a 
relationship exists between both sensitivity to the probability of winning when gambling and 
temporal discounting, and baseline 5-HT1A receptor availability in the hippocampus. Further, 
these results also suggest that there exists a relationship between sensitivity to losses and the 
change in 5-HT1A receptor availability in the striatum following administration of an SSRI.   
 
7.1.2 Study 2: Decision-making 3 days after administration of 3, 4- 
methylenedioxymethamphetamine (MDMA) 
 
The aim of this study was to test the theory of Dayan and Huys (2008) that 5-HT is involved 
in the pruning of decision trees. This was done by administering MDMA on day 1 to a group 
of healthy volunteers, and then testing them on the pruning paradigm 3 days later in order to 
assess the effect of putatively decreased levels of 5-HT and low mood upon pruning 
behaviours. The results suggested that participants’ displayed decreased pruning (as shown 
by significantly decreased scores on the pruning variable of the proportion best remaining 
and a trend towards a significant difference in the difference estimate) after MDMA 
compared to after placebo. This MDMA-induced decrease in pruning behaviours was 
specific, rather than the result of a more general cognitive impairment, as shown by the fact 
that participants did not significantly differ on their performance on the NLLO trials, from 
which an index of planning is obtained, between treatments. 
 
Despite the results of Curran and Travill (1997) suggesting that MDMA self-administration 
leads to decreased mood 3-5 days later, no differences in mood in this study were observed. 
However, the results did reveal a negative correlation between mood and pruning: those who 
displayed increased scores on the BDI and the antagonism scale of the POMS (increased 
negative affect) following MDMA also displayed increased proportion best remaining scores 
(denoting increased pruning). However, the direction of this relationship is in direct 
opposition to that predicted by Dayan and Huys (2008), who proposed that decreased 5-HT 
causes decreased mood by decreasing pruning. Nonetheless, the fact that MDMA still 
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decreased participants’ pruning behaviours provided some support for Dayan and Huys’ 
theory.  
 
7.1.3 Study 3: The influence of acute tryptophan depletion on the decision-making abilities 
of healthy volunteers 
 
There were 3 main aims of this study. The main aim was to assess the role of 5-HT in pruning 
by depleting 5-HT by the dietary method of ATD. Secondly, this study aimed to replicate the 
results of ATD upon win sensitivity during gambling observed in Rogers et al (2003). 
Thirdly, it aimed to replicate the results of Schweighofer et al (2008) and Tanaka et al (2007), 
in which it was found that ATD increased discounting of rewards based upon their temporal 
delay, by administering both the temporal discounting paradigm and model from Pine et al 
(2009) which permitted the examination of participants’ discount factors and utility 
concavities. Mood and psychometric data were also collected in order to observe any 
relationships between task performance and mood. Whilst ATD was shown to successfully 
deplete participants’ plasma tryptophan levels, treatment had no effect on the main pruning 
variables (although there was a trend towards treatment reducing reaction times on NLLO 
trials and increasing them on LLO trials). Further, on the gambling task there was a trend 
towards ATD decreasing participants’ choosing of the experimental gamble overall, whilst 
also affecting participants’ sensitivity to probability also at trend level. This latter result was 
driven by a reduction in choices of high probability gambles. The results also revealed no 
effect of ATD treatment on participants’ performance on the temporal discounting paradigm. 
Finally, ATD was found to increase participants’ STAI state anxiety scores, though no 
relationships between mood change and decision-making behaviour were detected. The 
results of this study do not support the theory of Dayan and Huys (2008), and nor did they 
replicate prior reports of decreased win sensitivity and increase delay discounting following 
ATD (Rogers et al, 2003, Schweighofer et al, 2008). However, they are consistent with one 
previous report that ATD decreases choices of high probability gambles (Rogers et al, 1999), 
indicating that 5-HT may indeed play a role in participants’ use of information pertaining to 
probabilities when making choices on a gambling paradigm. 
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7.1.4 Study 4: Pruning abilities of patients diagnosed with major depressive disorder 
 
Whilst it is important to understand the importance of 5-HT in pruning and decision-making 
as a whole, Dayan and Huys’ original theory attempted to explain how altered decision-
making can lead to low mood and ultimately depression. As such, the main aim of this final 
study was to examine the performance of patients diagnosed with MDD on the pruning 
paradigm. Using a Bayesian model comparison approach, a set of computational models was 
applied to the data, and it was found that both groups displayed aversive-based pruning as 
predicted. Surprisingly, it was also found that participants found the rewarding transitions 
more appetitive than they found the punishing transitions aversive. However, when 
comparing the two groups, there was no difference between MDD patients and controls in 
pruning behaviours. Further, no significant correlations were found between participants’ 
pruning (specific pruning parameter from the most parsimonious computational model) and 
scores from any of the psychometric questionnaires. As such, these results fail to support the 
theory of Dayan and Huys (2008) that low mood is driven by low pruning. This may be due 
to inaccuracies in the theory, or may simply be due to an inability of the task to elucidate 
differences between groups in pruning behaviours. For example, there may have been 
discrepancies in the ability of financial rewards and losses to motivate behaviour to the same 
extent in both groups. If this latter case were to be true, then examining performance on this 
task with rewards and losses that are not financial in nature could help our understanding of 
pruning in depression. 
 
7.2 Comparison of the effects of 5-HT1A receptor binding, subacute MDMA 
administration, acute tryptophan depletion, and major depressive disorder upon 
decision-making and mood 
 
Each of the four studies in this thesis used a different method in order to assess the effect of 
altered 5-HT functioning upon decision-making and mood. The below discussion will 
compare and contrast the results of these studies, considering how they compare to both the 
previous findings in the depression literature and the final experimental chapter in this thesis 
which tested pruning in MDD patients. In doing so, it will also consider any similarities or 
differences between the effects of these 5-HT manipulation techniques and the depressed 
state.  
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7.2.1 Pruning  
 
It must be first noted that both the pruning paradigm and the statistical analysis used in 
chapters 4 and 5 differed from the task and analysis employed in chapters 3 and 6; the task 
administered in chapters 4 and 5 contained a trials in which participants only had 9 seconds to 
look at the matrix, and 2.5 seconds to enter their moves (as opposed to the task in chapters in 
3 and 6 in which there was no timing element), contained large loss transitions of -70p (as 
opposed to the -140p in the task in chapters 3 and 6), and was analysed by frequentist 
statistics only (unlike the task of chapters 3 and 6 which was analysed using Bayesian 
computational modelling). As such, the former will be considered separately before the latter. 
 
7.2.1.1 Pruning; Chapters 4 and 5 (timed task, without modelling) 
 
The results of chapter 4 were particularly striking: administration of MDMA 3 days prior to 
performance of the task significantly reduced the proportion best remaining index of pruning. 
Further, a trend towards a significant decrease in the other index of pruning, the difference 
estimate, was also observed 3 days following MDMA administration. In contrast, there was 
no effect of ATD treatment upon either pruning variable in chapter 5 (although there was a 
trend towards a decrease in reaction times on NLLO trials and an increase in reaction times 
on LLO trials). One potential explanation for the discrepancy between results on this task in 
chapters 4 and 5 could be the potency of each method of 5-HT depletion: MDMA has been 
shown to target the 5-HT system both in vitro (e.g. Rudnick and Wall, 1992) and in vivo (e.g. 
Kish et al, 2010), and has been shown to cause long term damage to the axons of 5-HT 
neurons after repeated exposure (O’Shea et al, 2006). Further, it has been shown in vivo to 
have both acute and subacute effects, increasing 5-HT acutely and decreasing 5-HT 
subacutely by up to 30%, whilst also reducing tryptophan hydroxylase by up to 75% in the rat 
brain (e.g. Stone et al, 1986). In contrast, whilst ATD has been shown in humans to decrease 
plasma tryptophan and levels of 5-HIAA in the CSF (e.g. Carpenter et al, 1998, Moore et al, 
2000), these effects last roughly only a few hours (e.g. Robinson et al, 2013, Crockett et al, 
2012, Roiser et al, 2006). Further, the potency of these two contrasting techniques can be 
inferred by their respective effects upon mood: MDMA has been to shown to increase mood 
at the time of administration but decrease it 3-5 days later (Curran and Travill, 1997), whilst 
ATD has been shown to neither decrease nor increase mood in healthy volunteers (e.g. 
Carpenter et al, 1998, Nishizawa et al, 1997, Riedel et al, 1999, Rogers et al, 1999a), 
146	  
	  
although it has been shown to temporarily reinstate depressive symptoms in those who have 
recovered from depression via the use of SSRIs (O’Reardon et al, 2004). As such, it may be 
that the subacute effects of MDMA administration upon pruning are due to the potency of 
this technique upon the 5-HT system.  
 
The mood effects of both of these studies were also notable: MDMA exposure did not lower 
mood significantly, which is in direct contradiction to the findings of Curran and Travill 
(1997) above, whilst ATD did increase participants’ state anxiety scores, which is in direct 
contradiction to the results of previous studies using this technique (e.g. Riedel, 2004). The 
reason for this former result may be due to the fact that MDMA was both synthesized and 
administered in a clinical setting, without the participants ingesting any other drug (illicit or 
otherwise) or being sleep-deprived, unlike the participants from the Curran and Travill (1997) 
study. Further, a positive correlation between negative affect (increased antagonism and BDI 
scores) and pruning (as shown by the difference estimate) 3 days after MDMA administration 
was observed in chapter 4, such that those who displayed increased negative affect also 
displayed increased pruning. Whilst this result contradicts the original theory put forward by 
Dayan and Huys (2008) that low mood is associated with decreased pruning, it does replicate 
the results of Huys et al (2012) in which a positive correlation between greater negative affect 
(as shown by the BDI) and high pruning was observed. However, no such correlation was 
observed after ATD, which may be due to the fact that ATD failed to affect pruning 
behaviours, meaning that analysis of the mood data in chapter 5 cannot be said to support 
either Dayan and Huys (2008) or Huys et al (2012). 
 
7.2.1.2 Pruning: chapters 3 and 6 (untimed task, incorporating computational modelling 
 
The results of the computational modelling were relatively consistent between these two 
chapters: modelling participants’ choices revealed a reliable influence of loss-specific 
pruning. However, participants in chapter 3 displayed a further immediate Pavlovian 
attraction to the state from which a large rewarding transition could be completed (even 
though simply reaching this state did not lead to said large reward), whereas participants in 
chapter 6 did not display this behaviour. 
 
Analysis of the pruning parameters in these two chapters however provided little support for 
Dayan and Huys’ (2008) theory for a link between 5-HT, pruning and mood. The results of 
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chapter 3 did not support a relationship between either baseline 5-HT1A availability or the 
change in 5-HT1A availability due to citalopram infusion and pruning. Previous research has 
indicated the 5-HT1A receptor to be an important receptor in both cognition and the aetiology 
of depression: Deakin and Graeff (1991) for example proposed that one of the two main 5-
HT systems in the brain projects from the median raphe nucleus (MRN) to the hippocampus, 
and mediates responses to life events in which loss is experienced via the 5-HT1A receptor. 
Further, rodent studies have shown dose-dependent effects of 5-HT1A receptor agonists upon 
the rewarding effects of drug-self administration (i.e. Parsons et al, 1998, Peltier and Schenk, 
1993), indicating that this receptor may be involved in the rewarding consequences 
experienced during the performance of decision-making tasks. However, whilst the results of 
this study do not prove that there is no link between pruning and 5-HT in general (especially 
since the study included only a modest number of participants), they do not support the 
hypothesis that pruning is related to transmission at the 5-HT1A receptor. Due to the fact that 
Deakin and Graeff (1991) argue that the 2nd main 5-HT system in the brain projects from the 
dorsal raphe nucleus to the amygdala, and mediates adaptive responses to potentially 
dangerous stimuli via the 5-HT2C receptor, examining the availability of 5-HT2 receptors (and 
indeed other subtypes) may shed light on the molecular basis of pruning (Shelton et al, 2009). 
 
The results of chapter 6 also failed to support the Dayan and Huys hypothesis, finding no 
significant differences between depressed and non-depressed in terms of performance on the 
pruning task. Whilst the results of studies examining reward and punishment processing in 
depression have found differences between patients and controls (i.e. Eshel and Roiser, 
2010), this study was not able to find any differences on our multi-step decision-making task. 
In fact, no relationships between participants’ pruning parameters and mood were found at 
all. This was unexpected due to the results of Huys et al (2012) who reported a correlation 
between mood and pruning such that those who displayed increased negative affect also 
displayed increased pruning. The authors here note that this is contrary to the hypothesis 
outlined by Dayan and Huys (2008), and explain this relationship was observed because 
depressed individuals exhibit decision-making that is more dependent upon the 5-HT system, 
and that those with slightly increased sub-clinical depression scores would also display 
excessive pruning due to a risk for depression, whilst those who were experiencing a current 
depressive episode would exhibit decrease pruning. However, the present study, by reporting 
no effect of depression upon pruning, fails to support this hypothesis.  
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7.2.2 Gambling task (chapters 3 and 5) 
 
Analysis of the gambling task in chapter 3 produced some interesting results. These results 
indicate the existence of a relationship between decision-making and 5-HT transmission. 
These results are consistent with the results of Rogers et al (1999b) that suggest a role for 5-
HT in sensitivity to the probability of winning; here the authors showed that participants 
made more choices of less probable gain outcomes on the CGT after ATD. However, the 
results of that study were contradicted by those of Talbot et al (2006) who reported, using the 
same task, an increased choosing of more probable gain outcomes after ATD. The authors in 
the latter study speculate that these conflicting results may be due to factors such as 
unmeasured intrinsic trait characteristics such as aggression, which Bjork et al (2000) argue 
can lead to directionally opposite affects after ATD treatment. However, this interpretation 
remains speculative. Whilst the results of chapter 3 indicate a role for 5-HT1A transmission in 
reward processing, the task administered here was different to that administered in the above 
two studies, and more research is needed in order to fully understand the relationship between 
5-HT and the processing of rewards and punishments during decision-making.  
 
The results of chapter 3 are also interesting as they indicate the existence of a relationship 
between the processing of rewards and punishments on a gambling task and activity at a 
specific 5-HT receptor subtype, with baseline 5-HT1A receptor availability within the right 
hippocampus correlating with participants’ sensitivity to probability, and the change in 5-
HT1A receptor availability in the right nucleus accumbens correlating with participants’ 
sensitivity to loss. This supports previous research that has highlighted a role for these 
structures in reward and punishment processing. For example, Klein et al (2007) report 
dynamically changing functional connectivity patterns between the hippocampus and ventral 
striatum on a positive and negative feedback-based learning task, and Cohen et al (2008) 
showed that the microstructural properties of white matter tracts connecting the amygdala, 
hippocampus and ventral striatum predicted functional connectivity patterns observed 
following both positive and negative feedback on a reversal learning task. Whilst the results 
of these two studies indicate a link between the hippocampus and reward processing, the 
tasks used in these studies were feedback-based learning tasks, rather than a gambling task 
that included known probabilities of financial gains and losses, as employed in chapter 3. 
However, Camara et al (2008) did examine hippocampal responses and performance on such 
a task. Here, the authors administered a gambling task (designed by Gehring and Willoughby, 
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2002) in which participants were faced with unexpectedly high gains and losses whilst inside 
an MRI scanner. The results of the categorical analyses revealed that monetary gains and 
losses resulted in activation bilaterally in the ventral striatum, while functional connectivity 
analyses with the seed region in the ventral striatum showed enhanced connectivity with the 
striatum during the processing of similar responses to gains in the hippocampus bilaterally. 
Taken together, these prior studies and the results of chapter 3 indicate a potentially 
important role for 5-HT transmission in the hippocampus in decision-making, and warrant 
further investigation. 
 
However, it must be noted that due to the results of the citalopram challenge being in the 
opposite direction to that hypothesised, the relationship between sensitivity to loss and the 
change in 5-HT1A availability due to citalopram infusion is difficult to interpret. Nevertheless, 
the positive correlation does support the findings of Schmitz et al (2009) which revealed a 
role for the 5-HT1A receptor in punishment processing by demonstrating that a 5-HT1A C(-
1019)G polymorphism-linked increase in 5-HT1A availability is correlated with a greater 
sensitivity to punishments.  
 
The results of chapter 5 revealed no significant effect of ATD upon sensitivity to wins or 
losses, although a trend effect was observed upon sensitivity to probability, which in part 
supports the results of Rogers et al (1999b) (though not Talbot et al,2006) who showed an 
effect of ATD upon the choosing of probabilistic gain outcomes. Further, the fact that ATD 
reduced participant’s sensitivity to high probabilities further supports the results of studies 
showing ATD to have an effect upon reward and punishment processing (e.g. Crocket et al, 
2012, Robinson et al, 2012).  
 
However, these results do fail to replicate those of Rogers et al (2003) in which ATD was 
found to reduce healthy volunteers’ sensitivity to wins, although this is to our knowledge the 
first attempt to replicate the results of Rogers et al (2003). One suggestion to improve this 
study could be to increase the statistical power to detect smaller effect sizes by increasing the 
number of participants. However, the effect size of ATD upon sensitivity to wins observed in 
Rogers et al (2003) was 0.74 (in the region of a ‘large’ effect size as defined by Cohen et al, 
1988), and the current study had 99.9% power to detect such an effect size due to the 
utilisation of a within subjects design. As such, the failure to replicate the findings of this 
study is unlikely to lie with the statistical power of the study in chapter 5. 
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7.2.3 Temporal discounting task (chapters 3 and 5) 
 
The results of the temporal discounting paradigm in chapter 3 were very interesting, with 
participants’ discount factor correlating negatively with their 5-HT1A availability in the left 
hippocampal complex. These results further suggest that 5-HT is involved in the discounting 
of future rewards based upon their temporal delay, which supports Schweighofer et al (2008) 
who reported an increase in participants’ discounting after ATD.  
 
These findings support the results of previous research which show a role for the 
hippocampus in temporal discounting. For example, Mobini et al (2000) reported that rats 
whose 5-HT systems had been destroyed with 5,7-dihydroxytryptamine became more 
impulsive and exhibited increased choosing of smaller, sooner rewards in a temporal 
discounting paradigm, which correlated with a decrease of 5-HT in the hippocampus. Further, 
studies are beginning to show a role for an involvement of the hippocampus in episodic 
representations which can affect temporal discounting. For example, Schacter and Addis 
(2009) have shown that the hippocampus and parahippocampal gyrus play a crucial role in 
the formation of past, present and future episodic representations, and Peters and Buchel 
(2010) were able to show that the addition of episodic ‘tags’ that involved the presentation of 
relevant future episodes (i.e. vacation in Paris) to a temporal discounting paradigm, led to 
both a decrease in participants’ discount rates and a coupling between the ACC and 
hippocampus bilaterally. As such the results of chapter 3 further support a role for the 
hippocampal complex in temporal discounting, indicating that this relationship may be 
mediated in part by 5-HT1A transmission. 
 
However, the results of this chapter do not support the results of Tanaka et al (2007) who 
reported a role for the striatum in this relationship. Here the authors administered a temporal 
discounting paradigm to participants inside an MRI scanner. The results of this study 
revealed that BOLD responses in the ventral striatum were related to reward prediction at 
shorter time scales which was stronger after ATD, and that such responses within the dorsal 
striatum were related to reward prediction at longer time scales, which was stronger after 
acute tryptophan loading. Whilst the results of chapter 3 do not support a role for 5-HT1A 
receptor availability within the striatum in temporal discounting, this may be due in part to 
the very low binding values within the caudate nucleus (which is why the striatal mask 
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applied to correct for multiple comparisons in chapter 3 did not contain the caudate; for 
binding values see Selvaraj et al, 2012).  
 
Contrary to chapter 3, the results of the temporal discounting paradigm in chapter 5 do not 
support a role for 5-HT in temporal discounting, thus failing to support studies in the animal 
literature (e.g. Soubrie, 1986) and the results of Schweighofer et al (2008) and Tanaka et al 
(2007). Once again one suggestion to improve this study could be to increase the statistical 
power by increasing the number of participants. The effect size seen in Schweighofer et al 
(2008) was 0.73, and the present study had 92% power to detect such an effect size. As such, 
there is a small possibility that the failure to replicate the results seen in Schweighofer et al 
(2008) here represents a false negative.  
 
It should be noted that the results of this task are supported by those of Crean et al (2002) 
who reported no effect of ATD upon temporal discounting in both males with and without a 
family history of alcoholism. Further, this study is the first examination of the role of 5-HT in 
temporal discounting using the model of Pine et al (2009), which includes the discount factor 
from Schweighofer et al, in addition to an extra parameter, ‘utility concavity’. This latter 
parameter examines the extent to which participants differ on how much value they place 
upon an amount (i.e. £1) in a total (i.e. £100), with the concavity meaning £1 is worth more 
in a £2 total than it is in a £100 total. Including this parameter could have led this model to 
capture participants’ choices differently compared to that of Schweighofer et al (2008), Crean 
et al (2002) and Tanaka et al (2007), all of which used models that included discount factors 
without the addition of a utility concavity parameter in order to examine participants’ 
discounting behaviours.   
 
Further, whilst there are many animal studies that have examined the variable of the number 
of sooner choices chosen in a temporal discounting paradigm (e.g. Soubrie et al, 1986), there 
are no reported results of an examination of this measure in humans who have undergone 
ATD treatment. Whilst it could be argued that this measure is a ‘rawer’ measurement of 
impulsivity, unconfounded by model deficiencies, no treatment effects were observed, once 
again failing to support a role for 5-HT in this form of decision-making. This is supported by 
human work performed by Rogers et al (1999b) and Talbot et al (2006) who failed to observe 
an effect of ATD upon impulsive responding (assessed by the difference between the 
‘ascending’ and ‘descending conditions’ on the CGT. As such, whilst the results of this task 
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in chapter 5 do not provide support for those of chapter 3 and other published studies, 
perhaps more consistent models of impulsive responding on this task need to be developed in 
order to better understand the role of 5-HT in this form of decision-making.  
 
7.3 Limitations of the studies within this thesis and directions for future research 
 
Whilst the above studies suggest that there may be some role for 5-HT in disrupted reward 
and punishment processing in depression, there exist certain limitations with respect to the 
conclusions that may be drawn. These limitations will be discussed below, as will directions 
for future research that aim to answer the questions arising from these studies. 
 
7.3.1 Chapter 3 limitations and aims for future research 
 
This study used a novel ligand (11C-CUMI-101) in order to assess the relationship between 5-
HT release and reward and punishment processing. However, a particular difficulty in 
interpreting the meaning of these data exists due to the fact that whilst CUMI is a competitive 
agonist of the 5-HT1A receptor (thus allowing for the observing of 5-HT release), both 
receptor density and levels of extracellular 5-HT contribute to the measured CUMI signal, 
with more receptors increasing the signal, and more extracellular 5-HT decreasing it. As 
such, whilst this research does allow us to make predictions about the effects of increasing or 
decreasing the former or the latter upon decision making, it is difficult to know the extent to 
which sensitivity to probability and participants’ discount factors were correlated with 
receptor density per se or levels of extracellular 5-HT at baseline. This question could be 
addressed using a non-competitive ligand such as [11C]WAY-100635 which would allow for 
a more definitive conclusion to be made regarding the nature of the PET signal.  
 
An obvious extension to this study would be to have participants perform the above decision-
making tasks whilst under the influence of citalopram. This would allow for an observation 
of the effects of baseline, and in particular, the change in 5-HT1A receptor availability upon 
task performance following 5-HT manipulation. The autoreceptor hypothesis argues that 
SSRIs exert their antidepressant effects by initially inhibiting the 5-HT system via agonism of 
the 5-HT1A autoreceptors in the dorsal raphe nucleus, with these autoreceptors in turn 
becoming desensitized over a number of weeks until they cease their inhibiting effects upon 
downstream 5-HT release, which allows for an increase in cortical 5-HT and decrease in 
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depressive symptoms (Blier, 2003). Further, due to the fact that it is difficult to confirm that 
such correlations are causative, it would be informative to test this theory using the CUMI 
ligand again whilst both depressed patients and healthy volunteers performed the above 
decision-making tasks in the PET scanner so that any changes in performance of these tasks 
could be linked to changes in 5-HT1A availability due to SSRI treatment. Such an approach 
might help shed light on the decision-making differences in depression and the effects SSRI 
treatment. 
 
Further, perhaps correcting the number of correlations for multiple comparisons may improve 
confidence in the significance of such results. However, such corrections were not performed 
due to the exploratory nature of this study in order to ensure that any significant correlations 
with 5-HT1A availability were observed. 
 
Finally, in the study in chapter 3 participants with greater 5-HT1A availability in the 
hippocampus were less likely to discount the value of rewards that were available further in 
the future. Although the hippocampus is typically associated with episodic memory 
processing and contextual learning, as described above Peters and Buchel (2010) were able to 
show that the addition of episodic tags to a temporal discounting paradigm decreased 
participants’ discount rates which was associated with increased coupling between the ACC 
and the hippocampus bilaterally. As such, it could be very interesting to extend the current 
study using a similar paradigm in order to understand whether such episodic tags mediate this 
relationship between temporal discounting and the 5-HT1A receptor availability. 
 
7.3.2 Chapter 4 limitations and directions for future research  
 
Whilst the results of chapter 4 were interesting in that they indicated that MDMA 
administration affected participants’ pruning of decision trees, there are also some limitations 
to this study. For example, the interpretation of these results is that participants who were 
administered MDMA 3 days prior to testing had depleted levels of 5-HT, which affected their 
performance on the task. Whilst this assumption is based upon previous research in both 
animals (i.e. Stone et al, 1986) and humans (i.e. Kish et al, 2000, 2010), there was no index of 
5-HT functioning in the present sample. As such, obtaining markers of 5-HT function, such 
as cerebrospinal fluid 5-HT metabolite levels, or indeed levels of extracellular 5-HT in the 
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brain (as shown by CUMI) would increase confidence in the interpretation that these results 
reflect a link between 5-HT and pruning.  
 
A further limitation to this study is that it only examined the subacute effects of MDMA 
administration, and an examination of the effect of acute MDMA-induced increase in 5-HT 
transmission upon pruning behaviours would be informative. However, this would bring with 
it its own difficulties, including the fact that participants may find it difficult to concentrate 
on and adequately perform the complex pruning paradigm while under the influence of 
MDMA; in all the experiments presented in this thesis there have been participants who have 
failed to adhere to task demands and have simply found this paradigm too complex to 
successfully complete even when not under the influence of such a powerful psychoactive 
stimulant.  
 
Furthermore, the reason the subacute effects of MDMA were examined precisely 3 days after 
administration was based upon the findings of Curran and Travill (1997), who reported 
progressively decreasing mood 2-5 days after MDMA self-administration. However, the 
results of chapter 4 revealed no difference in mood post MDMA compared to post-placebo. 
As mentioned above, this could be due to a variety of reasons, including a lack of multi-drug 
ingestion and sleep deprivation in the current study. Further, it may be that the time of 
administration of MDMA (9am) affected participants’ subacute mood in this study: 
participants may have experienced low subacute mood, but at an earlier time point than the 
actual subacute session due to the earlier time point on the administration day compared to 
Curran and Travill (1997), in which participants self-administered on a Saturday night. As 
such, it would be interesting to test participants on each of the 3 subacute days, as was done 
in the above naturalistic study. However, this may also be problematic, as one of the 
measures of pruning, the proportion best remaining, exhibited practice effects, which would 
presumably be exacerbated over 3 consecutive testing sessions so close together.  
 
Whilst the results of the chapter 4 indicate a role for 5-HT in pruning, which supports Dayan 
and Huys (2008) theory of altered pruning in depression, it must be noted that activation of 
certain 5-HT receptors has been shown to affect the transmission of other neurotransmitter 
systems that have been implicated in reward and punishment processing. For example, Daw 
et al (2002) discuss the opponency between 5-HT and dopamine, and Di Matteo et al, 2008 
show that agonism of 5-HT2C receptors decreases the output of dopamine neurons in vitro, 
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whilst other 5-HT receptor subtypes have facilitative effects upon the dopamine system. 
Whilst no results exist examining the subacute effects upon the dopamine system due to 
MDMA-induced increased binding at any 5-HT sub-receptors, it is possible that dopamine 
function was also disrupted in these participants during the subacute period, which led to the 
observed differences in pruning behaviours. Further, the fact that dopamine has also been 
hypothesised to be dysfunctional in depression (e.g. Di Chiara et al, 1999) and the link 
between mood and pruning discovered in chapter 4, along with that reported in Huys et al 
(2012) further indicates that it may be fruitful to examine the role of dopamine in the pruning 
of decision trees.   
 
Finally, it will prove useful to better understand participants’ pruning behaviours by 
computationally modelling their choices on the pruning paradigm: doing so in chapters 3 and 
6 provided evidence that participants’ displayed aversive-based pruning behaviours very 
reliably. Whilst such computational models were built in order to better understand 
participants’ choices in chapters 4 and 5, these models did not adequately capture such 
choices or performance on the task, particularly the effect of MDMA upon pruning 
behaviours. In part this reflects the difficulty in modelling within-subjects data using 
computational approaches. As such, further models are currently being developed, but could 
not be included in this thesis due to time constraints. 
 
7.3.3 Chapter 5 limitations and directions for future research 
 
The results of chapter 5 were intriguing, in that whilst they did provide some support for a 
role of 5-HT in decision-making, they did not support the theory of Dayan and Huys (2008) 
or replicate the findings of Rogers et al (2003) and Schweighofer et al (2008). The fact that 
administration of this dietary technique has led to conflicting results may indicate a lack of 
consistency in the study design. However, participants within this study were of a similar age 
(mean of 30.82 years) compared to other studies using this technique (i.e. Crockett et al, 
2012) which had a mean age of 25.6 years. Further, participants were tested 5 hours after 
ingestion of the drink and had also not eaten throughout the testing session as in the above 
studies (although Crockett et al (2012) administered their behavioural tasks 5.5 hours after 
participants had ingested the amino acid mixture). However, Robinson et al (2013) allowed 
participants a small, tryptophan-free meal at lunchtime and detected ATD effects on a forced-
choice emotion identification task. As such, it may be interesting to replicate this study whilst 
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allowing participants such small amounts of food midway through the testing day in order to 
reduce possible fatigue effects. 
 
One explanation for why ATD produced no effect in the current sample, but MDMA did in 
chapter 4, is that there may be several alternative underlying mechanisms of this dietary 
technique that were not considered in this study. For instance, a recent review by Van 
Donkelaar et al (2011) argues that direct evidence that ATD decreases extracellular 5-HT 
concentrations is lacking. They posit possible alternative mechanisms by which ATD could 
affect performance on various tasks, some of them working indirectly via the 5-HT system. 
For instance, they argue that decreasing 5-HT (which is a powerful vasoconstrictor; Earley et 
al, 2013) may lead to decreased vasoconstrictor tone, which may contribute to the ATD-
induced behavioural effects observed in other studies. Furthermore, they argue that 
decreasing 5-HT may decrease nitric oxide synthase (NOS) activity (Blokland et al, 1998) as 
well as decreasing both brain-derived neurotrophic factor (BDNF) and kynurenine (KYN) 
metabolites such as tryptophan 2, 3-dioxygenase, the latter of which converts the majority of 
the body’s tryptophan into KYN, leading to a decrease in the availability of tryptophan in 
organs such as the liver. As such, the authors here argue that changes in neuronal 5-HT 
functioning may not be the sole, or even main contributor to ATD-induced behavioural 
effects observed in other studies. If this were to be the case, this may help explain why ATD 
had little effect upon pruning behaviours while large effects of subacute MDMA 
administration were observed in chapter 4: pruning is hypothesized to be affected solely by 
levels of 5-HT. However, it must be noted that a counter-argument to Van Donkelaar’s was 
put forward by Crockett et al (2012), who show that there is strong evidence that ATD 
reduces brain 5-HT and disrupts stimulated 5-HT release in rats (Stancampiano et al, 1997, 
Moja et al, 1989), and that converging translational findings support a central role for brain 5-
HT in ATD’s effects upon performance on various cognitive tasks (e.g. Cools et al, 2008, 
Bari et al, 2010). However, no research findings exist that show the extent to which ATD 
leads to a decrease in 5-HT release in the human brain, and further research using the PET 
ligand used in chapter 3 (11C-CUMI-101) could be performed in order to shed light on the 
ability of ATD to affect 5-HT release in the brain.  
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7.3.4 Chapter 6 limitations and directions for future research 
 
The results of chapter 6 were counter to the hypothesis of Dayan and Huys (2008), revealing 
no differences between groups in terms of pruning behaviour. These results are interesting 
due to the fact that there have been no published results to date comparing the multi-step 
decisions made by a depressed and non-depressed population, and this study was the first to 
test Dayan and Huys’ theory of altered pruning in depression. However, whilst it did not find 
any support for this theory, there are some limitations to this study.  
 
Firstly, not every depressed patient in this study was recruited via a health care professional, 
with the remaining patients being recruited via advertisement. This means that the 
antidepressant histories of the latter patients could not be verified by the health care 
professional. If any of these patients were not forthcoming about their current use of 
antidepressants in order to be recruited for this study, it would make drawing conclusions as 
to a link between 5-HT and pruning difficult due to the fact that most antidepressants (e.g. the 
SSRIs) affect the 5-HT system (e.g. Anderson, 2000).  
 
Secondly, the fact that those patients recruited from psychological services were undergoing 
cognitive behavioural therapy (CBT), and those recruited via advertisement were not, may 
have affected the results: for example CBT includes behavioural sessions that improve 
patients’ ability to plan, which is an aspect of general pruning, as defined by the above 
computational models. As such, repeating this study including groups who both were and 
were not undergoing such therapy may improve the ability of this study to understand 
pruning in depression. 
 
Thirdly, in order to better understand participants’ pruning behaviours, developing further, 
more complex computational models of participants’ choices could be fruitful. Whilst this 
would be more important for the studies included in chapters 4 and 5 (as no such models have 
yet been successfully applied to the data), adding further parameters to the model that attempt 
to understand participants’ choices based upon their previous choices (indicating the 
formation of habits), for example, may help model parsimony. Whilst these are planned for 
future analyses, new and more complex computational models were unfortunately not formed 
in time for this thesis. Future research should examine this avenue of analysis. 
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Finally, testing both depressed patients who are, and who are not undergoing treatment with a 
range of antidepressants against control subjects would allow for a more complete 
understanding of how 5-HT, and potentially other neurotransmitter systems, are linked to 
pruning and mood. Further, this would also allow for the observation of how improvements 
in mood due to antidepressant treatment may be linked to improvements in decision-making.  
 
7.4 Conclusion 
 
This thesis has examined the relationship between 5-HT, decision-making and mood. It has 
provided an overview of the literature on the cognitive and monoamine deficits in depression, 
before describing the results of studies examining the relationship between 5-HT and reward 
and punishment processing. It then explained the experimental techniques used in each of the 
four studies presented, before presenting the results of these four experiments.  
The first experiment utilised PET in order to examine a relationship between the availability 
of the 5-HT1A receptor and performance on 3 decision-making tasks. The results of this study 
showed positive correlations between both 5-HT1A availability in the hippocampus and the 
amount participants use information pertaining to probability on a gambling task; and 
between 5-HT1A availability after citalopram infusion in the nucleus accumbens and the 
amount participants use information pertaining to losses on the same gambling task; and a 
negative relationship between 5-HT1A availability and temporal discounting. The second 
study tested Dayan and Huys’ (2008) of altered 5-HT transmission and pruning by examining 
the subacute effects of MDMA administration upon pruning. The results of this study 
revealed that MDMA subacutely decreased pruning behaviours but not mood. However, a 
negative correlation between negative affect and pruning was observed, such that those 
participants who displayed increased negative affect also displayed increased pruning, which 
contradicts that hypothesised by Dayan and Huys (2008). The third experiment examined the 
effect of ATD upon decision-making. The results of this study showed no effect of ATD 
upon participants’ pruning behaviours (thus providing no support for Dayan and Huys’ 
theory), but reduced participants’ choices to high probability gambles, supporting previous 
research. No effect of ATD treatment upon the rate at which participants discount the value 
of a future reward were observed. Finally, the fourth study tested Dayan and Huys’ (2008) 
theory that low levels of 5-HT leads to low mood by decreasing pruning. Using Bayesian 
model comparison, it was revealed that both groups displayed aversive-based pruning, but 
that there were no significant differences between groups in the performance on this task. As 
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such, the results of this study failed to provide support for Dayan and Huys (2008) above 
theory.  
 
In conclusion, this thesis has provided some evidence of a relationship between 5-HT, 
decision-making and mood. For example a relationship between reward and punishment 
processing during gambling behaviours and temporal discounting with the availability of a 
specific 5-HT receptor subtype was observed, as was a relationship between pruning 
behaviours and a putative decrease in 5-HT following MDMA administration. However, with 
the focus of this thesis being on the relationship between 5-HT, pruning and mood, this thesis 
has largely failed to provide support for the theory of Dayan and Huys (2008); no relationship 
between pruning and low levels of tryptophan after ATD or depression were observed, and 
the only correlation between pruning behaviours and mood (from chapter 4) was in the 
opposite direction to that predicted by the above theory. As such, the experiments presented 
in this thesis have yielded some potentially important results, consistent with a role for 5-HT 
in reward and punishment processing, particularly in the pruning of decision trees and 
probabilistic choice. However, whilst depression has been associated with dysfunctional 5-
HT transmission, the results of this chapter have indicated that attempting to understand 
depressed patients’ pruning behaviours in order to improve treatments for the disorder may 
not be the most fruitful avenue of research. 
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